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SUMMARY 
In the last years, nanotechnology has caught the interest of research communities all 
around the world. Among the nanomaterials, of great interest are iron oxide 
nanoparticles (IONPs), which possess unique magnetic properties, low toxicity and 
high biocompatibility. Furthermore, IONPs can be easily produced and coated with 
various molecules in order to introduce reactive groups that can be used for the 
conjugation of biomolecules. Considering their characteristics, IONPs are widely 
used in industrial and biomedical field.  
Here, IONPs were synthetized via co-precipitation method and characterized 
using different techniques, i.e. TEM, DLS, ζ-potential and SQUID magnetometry. 
The particles synthetized were reproducible in shape and size distribution, moreover, 
they were chemically stable at the conditions considered. 
In the first part of the project, IONPs were used as a platform for the 
conjugation of two thermophilic enzymes, L-aspartate oxidase from Solfolobus 
tokidaii and amylase from B. lichieniformis to obtain an effective biocatalyst. To this 
aim, they were conjugated with different binding strategies obtaining NP-enzyme 
systems with different activities. These differences in enzymatic activity were due to 
the different orientations of the enzymes respect to NP surface and to the different 
stretching of the proteins. Considering their superparamagnetism, IONPs can be 
accessed by remote stimuli and this can be exploited to activate other molecules that 
are not remotely actuable, such as enzymes. Thermophilic L-aspartate oxidase and 
amylase were activated in a “wireless” fashion by an external alternate magnetic field 
(AMF) without increasing the “overall” temperature of the solution where the reaction 
occurred. Remarkably, the nano-systems were successfully reused for at least three 
consecutive cycles of AMF activation with the loss of only the 40% of the initial 
activity. Nanoactuation of thermophilic enzymes by AMF has potential applications 
in different fields. Indeed, multi-enzymatic processes with enzymes with different 
temperature optima could be carried in the same reaction pot and thermolable products 
could be efficiently produced by thermophilic enzymes without suffering for the high 
temperatures.  
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The second part of the project was focused on the development of a nano-
antibiotic system, using IONPs as a platform for the conjugation of the glycopeptide 
antibiotic teicoplanin. It is known that  IONPs have been investigated as potential 
nanocarriers for antibiotics to be magnetically directed and recovered from infection 
sites. The antimicrobial efficacy of NP-TEICO, compared to IONPs and amino-
modified NPs (NP-APTES), was assessed through classical microbiological methods 
(i.e. growth kinetic analysis, minimal bacteriostatic and bactericidal concentrations 
and agar diffusion assay) and through morphological studies. Results clearly indicate 
that teicoplanin conjugation confers high and prolonged antimicrobial activity to 
IONPs toward Gram-positive bacteria, while no antimicrobial activity was detectable 
towards the Gram-negative Escherichia coli. Although IONPs and NP-APTES 
showed an insignificant antimicrobial activity in comparison to NP-TEICO, data 
indicate that they established diverse interaction patterns at the bacterial surface. 
Sensitivity of bacteria to NPs varied according to the surface provided by the bacteria 
and it was species specific. Positively charged NP-APTES tend to establish 
electrostatic interactions with negatively charged bacteria. Furthermore, NP-TEICO 
inhibited S. aureus biofilm formation conserving the activity of teicoplanin versus 
planktonic cells and improving it towards adherent cells. Finally, cytotoxicity of NP-
TEICO was assessed on a cancer cell line and on a primary culture, SKOV3 and hASC 
respectively.  
To conclude, IONPs were successfully synthetized, functionalized and 
employed as a platform for biomolecules conjugation. Indeed two effective different 
nano-biocatalysts and a nano-antibiotic were obtained. 
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RIASSUNTO 
 
Negli ultimi anni, le nanotecnologie hanno catturato l’attenzione della comunità 
scientifica di tutto il mondo. Tra i nanomateriali, di grande interesse sono le 
nanoparticelle di ossido di ferro (IONPs) che possiedono proprietà magnetiche uniche, 
oltre ad una bassa tossicità ed un’alta biocompatibilità. Inoltre, le IONPs possono 
essere facilmente prodotte e, successivamente, funzionalizzate con diverse molecole. 
Queste hanno la funzione non solo di stabilizzare le IONPs, ma anche di introdurre 
gruppi reattivi che possono essere utilizzati per la coniugazione di molecole 
biologiche. Grazie alle loro caratteristiche, le IONPs sono ampiamente utilizzate sia 
in ambito industriale che in ambito biomedico. 
In questo progetto, le IONPs sono state sintetizzate tramite un metodo di co-
precipitazione per poi essere funzionalizzate con il 3-aminopropiltrietossi silano 
(APTES), una molecola che permette di stabilizzare le IONPs in soluzione acquosa, 
introducendo al contempo dei gruppi aminici sulla superficie della nanoparticella 
(NP) stessa. Le NP così prodotte sono state caratterizzate tramite diverse tecniche, 
quali microscopia elettronica a trasmissione (TEM), Dynamic Light Scattering (DLS), 
mobilità elettroforetica e magnetometria SQUID. I risultati ottenuti hanno dimostrato 
che un’elevata riproducibilità nella produzione delle NP sia in termine di forma che 
in termine di distribuzione delle loro dimensioni; inoltre, le NPs sono risultate 
superparamagnetiche e stabili chimicamente nelle condizioni considerate. 
Nella prima parte del progetto, le IONPs sono state utilizzate come piattaforma per la 
coniugazione di due enzimi termofili, L-aspartato ossidasi da Solfolobus tokidaii e α-
amilasi da Bacillus lichiniformis per ottenere un efficiente biocatalizzatore. A questo 
scopo, i due enzimi sono stati coniugati alle NP utilizzando diverse strategie, che 
hanno permesso di ottenere nano-sistemi che presentassero attività enzimatiche 
diverse. Queste ultime sono dovute ai diversi orientamenti della proteina e alla sua 
diversa deformazione strutturale, dovuta al legame con la NP tramite diversi residui 
amminoacidici. Le caratteristiche superparamagnetiche delle NP utilizzate sono state, 
poi, sfruttate per attivare gli enzimi ad esse coniugati, attraverso l’applicazione di un 
campo magnetico alternato (AMF). I risultati ottenuti hanno confermato la possibilità 
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di attivare gli enzimi termofili senza aumentare la temperatura totale del sistema. È 
stato inoltre possibile far lavorare contemporaneamente l’enzima D-amino acido 
ossidasi (DAAO) che presenta un optimum di temperatura pari a 37°C. 
Sorprendentemente, i nano-sistemi sono stati riutilizzati con successo per almeno tre 
cicli consecutivi di attivazione tramite AMF con la perdita di solo il 40% dell'attività 
iniziale. La nano-attivazione degli enzimi termofili con AMF ha potenziali 
applicazioni in diversi campi, infatti, processi multi-enzimatici, con enzimi aventi 
optimum di temperatura diversi, potrebbero essere condotti nello stesso reattore dove 
i prodotti termolabili potrebbero essere prodotti efficientemente dagli enzimi termofili 
senza soffrire per le alte temperature. 
La seconda parte del progetto è stata incentrata sullo sviluppo di un nano-antibiotico, 
utilizzando le IONPs come piattaforma per la coniugazione della teicoplanina, un 
antibiotico glicopeptidico (NP-TEICO). È noto che le IONPs sono ampiamente 
utilizzate come nano-carriers per gli antibiotici che possono essere diretti 
magneticamente ai siti di infezione per poi essere recuperati. L'efficacia antimicrobica 
di NP-TEICO, confrontata sia all’antibiotico libero che alle NP non coniugate, è stata 
valutata attraverso metodi microbiologici classici (analisi cinetica della crescita, 
minima concentrazione batteriostatica e battericida e test di diffusione su agar) e studi 
morfologici, tramite microscopia ottica a fluorescenza e microscopia elettronica a 
trasmissione. I risultati indicano chiaramente che la coniugazione della teicoplanina 
conferisce un'attività antimicrobica elevata e prolungata alle IONPs nei confronti dei 
batteri Gram-positivi, mentre non è stata rilevata alcuna attività antimicrobica nei 
confronti dei Gram-negativi. Sebbene IONP e NP-APTES non abbiano mostrato 
attività antimicrobica, i dati ottenuti indicano un’interazione con la superficie 
batterica. La sensibilità dei batteri alle NP varia in base alla superficie fornita dai 
batteri ed è specie-specifica. Le NP funzionalizzate con APTES, che presentano una 
superficie carica positivamente, tendono a stabilire interazioni elettrostatiche con 
batteri carichi negativamente. Inoltre, il nano-antibiotico ha inibito la formazione del 
biofilm di S. aureus conservando l'attività della teicoplanina rispetto alle cellule 
planctoniche e migliorandola verso le cellule aderenti. Infine, è stata valutata la 
citotossicità di NP-TEICO su una linea cellulare immortalizzata e su una coltura 
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primaria derivata da tessuto adiposo. In generale la presenza della teicoplanina sulla 
superficie della NP riduce la tossicità intrinseca delle NPs, migliorando la 
biocompatibilità del sistema. 
Per concludere, le IONP sono state sintetizzate, funzionalizzate e impiegate con 
successo come piattaforma per la coniugazione di biomolecole. 
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I. INTRODUCTION 
NANOTECHNOLOGY, NANOMATERIALS AND NANOPARTICLES 
In the last years, nanotechnology is emerging as a field of interest both for research 
and industry. It includes all the emerging technologies that deals with the 
manipulation of matter at the atomic and molecular level, the design, the 
characterization and the synthesis of structures of nanomaterials (NM)1. The European 
Commission defined NM as “natural, incidental or manufactured material containing 
particles, in an unbound state or as an aggregate or as an agglomerate and where, for 
50 % or more of the particles in the number size distribution, one or more external 
dimensions is in the size range 1 nm - 100 nm”2. According to the number of 
dimensions in the nanoscale, NM can be classified as nanoplates, nanofilm or 
nanolayers (one dimension), nanofibers or nanotubes (two dimensions), nanoparticles 
(NP, three dimensions). NPs can be classified by their origin into natural or anthropic: 
the natural ones are a key component of our ecosystem and are produced by fossil 
volcanoes, microbial agents and components of aquatic sediments; the anthropic, 
instead, could be incidental if derived from industrial processes (for example those 
generated by photochemical processes and combustion), or intentional if they are 
produced with a well-defined chemical composition3–5. The application of NMs is 
widespread from food safety 6,7, agriculture8,9 and cosmetics to industrial applications, 
such as sensors10 and photovoltaic devices11 and catalyst12, but also to medicine. 
The interest in nanostructured materials comes from the fact that they exhibit 
properties and functions that differ from bulk-sized materials13. The different scale 
structure causes the increase of the surface per unit mass resulting in a higher chemical 
reactivity, higher resistance to mechanical stress and in an alteration of the electrical 
properties, such as an increase of the conductivity14. Furthermore, the nanoscale 
affects the optical and magnetic behaviour of the material, because the quantum 
effects start to dominate the behaviour of matter15. 
It is well known that some non-magnetic elements, such as iron, nickel, manganese, 
platinum and palladium, acquire magnetic-like properties at a nanoscale level. These 
magnetic NPs (MNPs) offer abundant possibilities for biotechnology. First, they have 
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sizes comparable to those of the biomolecules. Second, the MNPs have a well-defined 
crystalline structure, high solubility, low intrinsic toxicity, high resistance to 
mechanical stress and  unique magnetic properties such as supermagnetism, high 
coercivity, low Curie temperature and high magnetic susceptibility. MNPs, indeed, 
obey to the Coulomb law and can be manipulated by the presence of an external 
magnetic field. Third, the large surface can be properly modified to conjugate 
biological agents16. 
Thus, magnetic NMs are used in the production of electronic devices to overcome 
some technical limits like data recording and storage17–19 and in fine chemicals such 
as catalysts in hydrogenation reactions or styrene production20,21. Magnetic NPs, 
helped also in the biomedical field to ameliorate diagnosis and therapy as theragnostic 
agents22–24 and to increase the sensitivity of biomedical techniques, such as magnetic 
resonance imaging (MRI) , in which magnetic NPs are used as novel contrast 
agents25,26.  
Iron oxide NPs 
Among MNPs, iron oxide NPs (IONPs) have aroused great interest in research over 
the last several years. IONPs belong to the class of inorganic particles having an iron 
oxide core, coated by either inorganic materials (silica, gold) or organic materials 
(phospholipids, fatty acids, polysaccharides, peptides or other surfactants and 
polymers)27,28.  
Sixteen different crystalline structure of IONPs are known, among these the most 
promising are hematite (α-Fe2O3), magnetite (Fe3O4) and maghemite (γFe2O3). 
Hematite is characterized by a rhombohedral structure in which oxygen ions form a 
close-packed hexagonal arrangement and the Fe+3 ions occupy two-thirds of the 
octahedral interstices in the crystalline structure (Figure 1a). Magnetite, instead, has 
an inverse spinel structure in which the Fe+2 ions occupy octahedral sites, while Fe+3 
ions are randomly distributed between octahedral and tetrahedral sites (Figure 1b). 
Maghemite presents a spinel structure similar to magnetite, but with vacancies in the 
cation sublattice; moreover, Fe+3 ions, that fill two-thirds of sites, are regularly 
arranged (Figure 1c)29–31.  
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Figure 1. Crystal structure of the hematite, magnetite and maghemite (the black 
ball represents Fe2+, the green ball represents Fe3+ and the red ball represents O2−)29. 
Each of these three iron oxides has unique biochemical, magnetic, catalytic properties 
which provide suitability for specific technical and biomedical applications. Hematite 
possesses weak ferromagnetic behaviour at room temperature, it is paramagnetic 
above its Curie temperature (956 °K) and it is the most stable iron oxide at room 
temperature. As hematite, maghemite it is an n-type semiconductor under ambient 
conditions. Magnetite, instead, can be both an n- and p-type semiconductor, as the 
Fe2+ ions present in its structure, can be partially replaced by other divalent ions (Co, 
Mn, Zn, etc)30. The most interesting aspect of IONPs is their high magnetization that 
can be triggered by applying an external magnetic field: this allows not only to 
generate heating in a localized point, but also to target the NPs to the area of interest27. 
Indeed, γ-Fe2O3 and Fe3O4 are readily magnetized thanks to their spinel structures.  
IONP synthesis 
During the last years, many publications have described different synthetic routes for 
the synthesis of IONPs with good shape-control, high stability and monodisperse 
distribution. Several popular methods including co-precipitation, thermal 
decomposition and hydrothermal synthesis can all be directed at the synthesis of high-
quality MNPs:  
§ Co-Precipitation: is an easy and convenient way to synthesize IONPs from 
aqueous Fe2+/Fe3+ salt solutions by the addition of a base at room 
temperature. The size, shape, and composition of the NPs depends on the 
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type of salts used (e.g. chlorides, sulfates, nitrates), the Fe2+/Fe3+ ratio, the 
reaction temperature, the pH value and ionic strength of the media. This type 
of synthesis guarantees high reproducibility and high yield of production. 
§ Thermal Decomposition: This method is based on the thermal 
decomposition of compounds in high-boiling organic solvents containing 
stabilizing surfactants. It produces monodisperse NPs with a control over size 
and shape. In principle, the decisive parameters for the control of the size and 
morphology of the NPs are the ratios of the starting reagents. 
§ Hydrothermal Synthesis: This method is based on a phase transfer and 
separation mechanism that occurs at the interfaces of the liquid, solid, and 
solution phases present during the synthesis under hydrothermal conditions. 
It leads to the production of NPs with a good uniformity in size and shape. 
Table 1 summarizes the advantages and disadvantages of the above mentioned 
synthesis.  
Table 1. Summary comparison of IONPs synthetic methods. 
 
Co-precipitation is preferred in terms of simplicity of the synthetic route, while 
thermal decomposition is the most reliable for size and morphology control. 
Hydrothermal synthesis, on the other hand, is a relatively little explored method for 
IONPs synthesis, although it allows the synthesis of high-quality NPs. 
However, all the synthesis methods generally lead to the production of metastable 
oxides that easily undergo to oxidation when exposed to air, leading to a partial loss 
of their magnetic behaviour. Thus, in an oxidative atmosphere, they tend to form 
Synthetic 
method 
Synthesis Reaction 
temp. [8C] 
Solvent Surface- 
agents 
Size 
distribution 
Shape 
control 
Yield 
co-precipitation 
very simple, 
ambient 
conditions 
20–90 water needed 
relatively 
narrow 
not 
good 
high/ 
scalable 
thermal 
decomposition 
complicated, 
inert atmosphere 
100–320 
organic 
compound 
needed very narrow 
very 
good 
high/ 
scalable 
hydrothermal 
synthesis 
simple, high 
pressure 
220 
water-
ethanol 
needed very narrow 
very 
good 
medium 
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aggregates. It is, therefore, necessary to stabilized the NPs surface with a specific 
coating32. 
Surface Modifications 
To increase colloidal stability and prevent agglomeration of IONPs, different surface 
modifications have been developed, using chemicals or biological materials during or 
after the synthesis process. The high interactions of IONPs and the surrounding media 
need to be contrasted by efficient coating, that protect and stabilize the surface, 
providing new physicochemical properties (optical, electrical and thermal)33.  
Different groups of materials can be applied as coating, including organic ligands, 
such as natural or synthetic polymers and/or surfactants, and inorganic materials, like 
silica, precious metals (Ag and Au) and metal oxides (NiO and CoO)34.  Figure 2 
depicts a graphical overview of different types of IONPs functionalization that have 
been designed for the required application.  
 
 
Figure 2. IONPs arrangements with molecules, polymers and inorganic chemicals (not 
at scale)35. 
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The different architectures created by functionalization allow the addition of reactive 
functional groups on the particle surface that can be exploited for conjugation of 
biologically active substances or biomolecules. Table 2 reports the most used coating 
compounds, classified on the functional end group present on the NPs surface after 
functionalization.  
Table 2. Chemical compounds, sorted by functional group, used for the primary 
coating and of IONPs.  
Functional end-group Compound 
-NH2 
-Chitosan 
-Polyethylenimine 
-Poly(L-lysine) 
-Polyethylene glycol with terminal -NH2 
-Ethylenamine 
-Aminosilane 
-OH 
-Polyethylene glycol 
-Dextran 
-Polyvinylalcohol 
-COOH 
-Polyacrylic acid 
-Carboxymethylcellulose 
-Polyethylene glycol with terminal -COOH 
-Alginate 
-Polymethacrylic acid 
-Citrate 
 
One of the most common group includes silane and its derivatives. Indeed, this 
compound is characterized by an easy controlled reaction and a wide number of 
commercially available silane derivatives with a well-documented chemistry. 
Furthermore, the use of silane-compounds guarantees an high surface coverage and a 
strong binding, that create very stable core-shell structures. The coating obtained 
presents the functional end-group oriented towards the external media and, through 
this active group in its structure, is able to combine with biomolecules, drugs and 
metals. Among the silane-compounds, the 3-Aminopropyltriethoxysilane (APTES) is 
of great interest36. Thanks to the high biocompatibility and the high number of 
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functional end groups that can be grafted on the NPs surface, it is considered a good 
candidates for the functionalization of IONPs. The general silanization sequence is 
reported in Figure 3.  
 
Figure 3. Reaction mechanism IONPs and APTES. First step is the hydrolysis of triethoxyl 
groups into trihydroxyl groups and then poly-condensation of the hydroxyl groups  and the 
reaction with the surface IONPs surface36. 
Briefly, when APTES is suspended in a solution of ethanol and water, reactive silanol 
groups are formed by the replacements of the alkoxide groups into hydroxyl groups. 
The silanol groups condense with other  silanol groups to produce siloxane bonds (Si–
O–Si) and with the -OH present on the NPs surface to produce NP-O-Si bonds37. The 
result is the formation of a three dimensional mesh around the core of the NPs 
characterized by the presence of functional groups (-OH or -NH2) exposed on their 
surface, that are available for functionalization with biopolymers38.  
APPLICATIONS 
Due to their chemical-physical characteristics, NPs are applied in many different 
fields and in particular in nanobiotechnology. This field deals with the design and the 
application of NPs combined to the biological world to achieve nanoscale tasks. Some 
of these are non-biological tasks and have applications in industrial areas, whereas 
others are related to biology or medicine39 (Table 3). 
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Table 3. Nanoparticles applications in industry, biomedicine, food and agriculture, 
environment. 
Field Applications 
Industry Reinforced plastics 
 
Industrial catalyst 
 
Functional nanocomposites 
 
Nanopigments 
 
Superplastic ceramics 
Biomedicine Cancer therapy 
 
Imaging 
 
Protein aggregation 
 
Drug delivery 
 
Antibacterial 
Food and agriculture Nutraceutical 
 
Food packaging 
 
Reduce pesticides 
 
Nutrient delivery 
 
Improving texture 
Environment UV protection 
 
Pollution monitoring sensors 
 
Pollutant s cavengers 
 
Biodegradable polymers 
 
Waste water treatment 
 
Industrial applications 
Currently there are many examples of nanomaterials used in industry. The cosmetic 
industry, for example, uses nanomaterials in the form of metal oxides as filters for UV 
radiation40,41, while the electronics uses carbon nanotubes as transmitters of field42,43. 
MNPs are used for the realization of technological products that confer properties 
such as anti-wear and anti-scratch in the paint industry. The food industry also is 
influenced by the use of nanomaterials, in fact the use of a nanocomposite coating 
allows to improve packaging of food through an antimicrobial action44,45. 
In particular, IONPs are employed in almost all fields from electronics to chemicals, 
from engineering to energy46. For example, IONPs are used as a coloring and anti-
corrosion agent in construction materials and coatings, as pigments in steel and 
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automobile primers to reduce corrosion of the metal itself 47. For food related 
applications, they have been used for enzyme immobilization, protein purification, 
and food analysis. The commonly used techniques have limitations such as the time-
consuming pre-treatments, expensive instrumentation or skilled operators. IONPs 
have been used also for a timesaving, scalable, gentle, easily automated magnetic 
separation of a target compounds from crude samples. The specific target can be 
purified after several rounds of magnetic separation and washing processes48. Thanks 
to their magnetic characteristics and their surface, IONPs have been also used in 
nanobiotechnology for the creation of nanobiocatalysts. Enzyme conjugated NPs can, 
indeed, overcome some of the limitations that enzymes49. 
Enzymes as biocatalysts 
Enzymes are highly effective biocatalysts, that commonly enhance, in organisms, 
reaction rates by a factor of 105 to 1017. They mediate a specific chemo-, regio-, and 
stereo-selectivity of reaction that demonstrate their superiority compared to chemical 
catalysts50, although chemical catalysts can be used at very high temperatures. Thanks 
to their characteristics and their green chemistry, enzymes are useful in many areas of 
research, including organic synthesis, immunoassays, and substrate sensing, and in 
industry, such as paper, textile and food industry51. Of great interest for industries are 
enzymes produced by microorganisms since they can be produced in high quantity 
and in a short time. Moreover, recombinant DNA techniques can be used to enhance 
the enzyme production or to modify the enzyme structure to obtain an enzyme that is 
stable in the desired conditions52,53. On the other hand, the application of free enzymes 
in industry is hampered by high cost, thermal instability, activity inhibition, 
denaturing agents sensitivity and the impossibility of separating/reusing the enzyme 
at the end of the reaction 54–56. To overcome such limitations, researchers attempted 
to immobilize enzyme on different solid supports, such as polymeric resins and 
inorganic materials57–60. Enzyme immobilization, indeed, aim to improve the enzyme 
stability, increase the volume loading of biocatalyst and simply both enzyme recycling 
and the downstream process61. 
Several works in literature report that immobilized enzymes have increased pH 
working range and improved thermal stability62. Furthermore the binding of the 
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enzyme on a solid support can enhance the enzyme activity and modify the substrate 
specificity63–65.  
The minimal diffusional limitation, the maximum surface area and the high effective 
enzyme loading make NPs one of the most interesting supports for enzyme 
immobilization 65,66.  If compared to other scaffold for enzyme immobilization, nano-
biocatalysts can load a higher amount of enzyme, enhancing significantly the mass 
transfer efficiency67. Among NPs, the use of MNPs has been extensively studied due 
to their magnetic properties that make easier the recovery of the nano-biocatalyst by 
the application of a magnetic field68,69. And in particular, IONPs have been studied for 
the biodiesel production and food processing70,71. 
L-aspartate oxidase 
L-aspartate oxidase (LASPO, EC 1.4.3.16) is a prokaryotic enzyme that catalyses the 
oxidative deamination of L-aspartate into oxaloacetate and ammonia, thanks to the 
reduction, in the first step of the reaction, and the subsequent re-oxidation of the FAD 
co-factor (Figure 4). 
Figure 4. Catalytic reaction of LASPO. L-aspartate is oxidized to iminosuccinate followed 
by a non-enzymatically hydrolyzation to oxaloacetate.  
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In prokaryotes, LASPO is involved in the first reaction step of the de novo 
biosynthesis of the nicotinamide adenine dinucleotide (NAD+). In vivo, the 
iminosuccinate produced by the reaction is condensed with dihydroxyacetone 
phosphate resulting in the production of quinolinate and, eventually, NAD+. While, in 
vitro, it was demonstrated that LASPO can use both O2 and fumarate in  the FAD re-
oxidation, allowing to catalyse its reaction both in aerobiosis and anaerobiosis. Under 
aerobic condition, the LASPO oxidizes L-aspartate to iminosuccinate, which is then 
hydrolyzed to oxaloacetate through a non-enzymatic pathway72.  
LASPO was isolated from different microorganism, such as E.coli, B. subtilis and P. 
putida, but the most interesting for industrial applications is those isolated from 
Solfolobus tokodaii, a thermophilic microorganism. This enzyme is a monomeric 
protein of 52 kDa composed by 472 residues that are organized in three distinct 
folding domains: a capping domain, a FAD-binding domain and a C-terminal 
domain73,74 (Figure 5).  
 
Figure 5. Solfolobus tokodaii LASPO overall structure: the FAD-binding, capping and C-
terminal domains are shown respectively in green, red and blue. The FAD cofactor is 
represented as a stick model (adapted from PDB entry 2E5V). 
LASPO has an high thermal stability that makes it very promising for industrial 
applications. Indeed, it is stable up to 80 °C without any remarkable changes in its 
activity. Besides the possibility to work at high temperature for more than 400 min, 
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LASPO is also attractive because it is stable in the 7-10 pH range, it presents a weak 
inhibition by the D-isomer of aspartate and by product of reaction (i.e., iminosuccinate 
or oxaloacetate), but also for its tight interaction with the cofactor74. For these 
characteristics, LASPO was expressed as a recombinant protein in E.coli, exploiting 
the molecular tools of this well studied microorganism to obtain an high yield of 
protein produced. The LASPO obtained was used for the resolution of a racemic 
solution of D,L-aspartate, leading to a pure solution of D-aspartate that is employed 
in the pharmaceutical industry for parenteral nutrition, as food additive and in 
sweetener manufacturing. Since the industrial application of LASPO is hampered by 
the high cost per enzymatic unit, various attempts to immobilized it on different 
supports are reported in literature. The amino groups of the enzyme were used for the 
conjugation to Relizyme™ H403/S R, a rigid methacrylic support previously 
activated with glutaraldehyde, and to SEPABEADS® EC-EP/S resin, a methacrylate 
hydrophobic support75. In these conditions, they obtained different conjugation yield, 
due to the different charge of the support, respectively 100 % and 50 %. Furthermore, 
the first conjugation approach lead to an high and rapid deamination of L-aspartate, 
while the second one reach the complete conversion of the racemic mixture in 4 hours. 
This thermostable enzyme was also immobilized as cross-linked enzyme aggregates 
(CLEA). This technology improved the performance of the enzyme because it is based 
on a single step process in which the purification and immobilization are a single 
operation. At the end of the process, LASPO retain 100% of the starting activity and 
the enzyme was successfully used for complete reactions for five consecutive times. 
Amylase 
Amylases are enzymes that hydrolyse starch molecules and, according to the sugars 
produced by the reaction, they can be classified into α-,  β- and γ-amylases. Starch is 
one of the most important energy source for a large number organisms76. It is a 
polysaccharide composed by amylose and amylopectin, which constitute the 20-25 % 
and the 75-80 % of the macromolecule, respectively. The first one is formed by a 
linear chain of glucose units linked by α-1, 4-glycosidic linkage, while the second one 
presents, every 15-45 glucoses, a branching where the glucose units are linked by α-
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1, 6 glycoside bonds (Figure 6). Starch hydrolysis leads to the production of destrins, 
maltose and maltotriose77.  
 
 
α-Amylase (1,4-a-D-glucan-glucanhydrolase, EC. 3.2.1.1) is an endo-enzyme that 
cleaves the glycoside bond within starch in non-crystalline regions, it cleaves the α- 
1-4 linkage. This class of enzyme has been isolated from different sources, from plant 
to animals78, but the most interesting for industrial applications are α-amylases 
isolated from microorganisms. Their production, indeed, has a high cost effectiveness, 
thanks to the small time and space required for production78. Among bacterial species, 
the most widely used are the Bacillus spp. and B. amyloliquefaciens and B. 
licheniformis. In particular, they are used for commercial production of the enzyme 
for industrial application such as food, fermentation, textiles and paper industries79. 
These two bacteria produce thermostable α-amylase80. Thermostability is an 
important characteristic as enzymatic liquefaction and saccharification of starch are 
performed at high temperatures (100–110°C). In particular, α-amylase isolated from 
B. licheniformis is a monomeric protein of 62 kDa composed by 483 residues that are 
organized in three distinct folding domains (Figure 7)81. 
Figure 6. Structure of starch units amylose and amylopectin. 
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This enzyme is stable in the pH range between 6 and 11 and its optimal temperature 
is 90°C82 and, for these reasons, it is very interesting for industrial applications. 
Several attempts have been done to immobilized α-amylase from different sources on 
different support, in order to create a feasible biocatalysts. The immobilization of α-
amylase from Aspergillus oryzae on two amino-functionalized silica-coated MNPs, 
bare or covered with chitosan, broaden the pH and temperature range of activity of 
the enzyme, increasing also its storage stability83. The immobilization of the 
thermostable amylase from Bacillus licheniformis on a calcium alginate matrix 
produces a biocatalyst that can be reused efficiently for seven cycles79. 
Nanoactuation 
Actuators operate by converting external stimuli into mechanical motion that can then 
be used to do work or move objects. At the micron scale, actuation is a extensively 
explored field that has been realized through the design of microelectromechanical 
systems. At a nanoscale, actuation can be defined as actuation of a specific action 
using a nanoscale object with the input of an external force acting on it.  
Among the unique properties of nanomaterials, the capability of absorbing energy, in 
form of radio-frequency, light and or magnetic field, have raised great interest in the 
Figure 7. Overall structure of amylase from Bacillus licheniformis. Domain A, B and 
C are shown in green, blue and red respectively (adapted from PDB entry 1BLI). 
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scientific community84. Gold NPs (AuNPs), for example, have been used for the 
remote control of biochemical reactions, selective control of gene interference, 
photothermal therapy and for drug delivery85–87. AuNPs can absorb light , in the near 
infrared (NIR) range, and can convert optical energy in thermal energy, transferring 
the heat generated to the surrounding matrix. Thanks to the strong absorbance over a 
wide range in the optical region, also carbon nanotubes (CNTs) have been remotely 
nanoactuated through the application of light. Near infrared light was efficiently used 
to activate thermophilic enzymes88. Even though it was demonstrated the production 
of heat through these methods, their use is limited due to the reduced depth penetration 
of NIR light. To overcome this limitation, the use of alternating magnetic field (AMF) 
has been explored for a localized production of heat89–91. 
The possibility to remotely actuate MNPs by a wide range of frequencies has opened 
new perspective not only in medicine but also in industrial application.  
Medicine can exploit the capability of the IONPs to produce heat under alternating 
magnetic field, a phenomenon known as magnetic hyperthermia29. Magnetic 
hyperthermia is based on the production of heat as a consequence of Neel and Brown 
relaxation (Figure 8). 
In contrast, the actuation of NPs for industrial application and in particular in the 
biocatalysis is still scarcely unexplored. Some authors, actuate the enzyme linked to 
the NPs by applying a low frequency AMF. They use the conversion of magnetic 
Figure 8. Nanoactuation of MNPs by applying an AMF. 
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energy into rotational motion of the enzyme-particle system to increase the collision 
rate with the substrate92,93, or to trigger conformational changes on the enzyme three-
dimensional structure94. The use of heat generated by magnetic NPs to regulate 
enzyme activity has been also reported, but limited to deswelling-swelling of 
thermosensitive polymers attached to the NP surface that force to interact substrate-
bound therapeutic drugs with enzymes that trigger their release95–97.The effect of the 
heat generated by high frequencies of AMF on enzymes directly attached to NPs has 
been tough scarcely studied. Only Suzuki and colleagues have recently reported the 
specific activation of α-amylase and DNA ligase immobilized on ferromagnetic 
microparticles triggered by AMF 56,98. However, this effect has not been reported yet 
using superparamagnetic NPs, nor it has been studied the effect of the enzyme 
orientation on the NP surface and of conformational changes caused by the 
conjugation strategy. In the case of ferromagnetic microparticles, the application of a 
magnetic field triggers their aggregation that cannot be easily reversed since it would 
be necessary to heat the particles above their Curie temperature (858 K for iron 
oxide)99. Instead, in the case of superparamagnetic NPs, their magnetic properties do 
not persist when the external magnetic field is removed. This is an important 
advantage of superparamagnetic NPs over ferromagnetic ones since it allows the reuse 
of the nanobiocatalyst.  
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Medical applications 
In the last decades we assisted to a great expansion of NPs as tools for medical 
applications. A high number of experimental evidences support the benefits of 
nanomaterial-based agents in terms of selectivity, sensitivity, affinity and detection 
limits. FDA reports that an average of ~13 nanomedicines per 5 years have been 
approved for specific clinical indications since the mid-1990s. This comprises 
approval for both novel materials along with the use of existing materials for new 
clinical indications100. The list includes liposomes, polymeric micelles, inorganic and 
polymeric NPs, as well as nanorods and quantum dots. Among all the NPs used, the 
application of IONPs is becoming increasingly important in biomedicine thanks to 
their high biocompatibility and their low toxicity in the human body, combined with 
the ability to manipulate them using an external magnetic field. IONPs have been 
described and used in drug delivery, hyperthermia, magnetic resonance imaging, as 
spoilers for magnetic resonance spectroscopy, and more recently as sensors for 
metabolites and other biomolecules and as microbial agents (Figure 9)35,101–107.  
 
Figure 9. IONPs applications in nanomedicine. 
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Antibiotic resistance and nano-antibiotics 
Antibiotics are low molecular weight molecules (200-2000 Daltons) that are able to 
inhibit bacterial growth through different mechanisms. They can be classified into 
natural, semi-synthetic and synthetic. The first group is produced by microorganisms 
as secondary metabolites, the second one is produced as chemical modification of the 
natural antibiotic, while the last group is the result of chemical synthesis. Antibiotics 
are grouped into classes according to their chemical structures, their chemical-
physical properties and their spectrum of action.  
According to the recent survey of the World Health Organization108, antibiotic 
resistance is one of the biggest threats to global health, contributing to longer hospital 
permanence, higher medical costs and increased mortality. At least 700,000 people 
die annually due to resistant bacterial infections and this number is predicted to 
increase up to 10 million by the 2050 with the consequent social and economic burden. 
This public health treat is exacerbated by the scarcity of novel antibiotics expected to 
enter in clinical therapy in the near future109. One promising approach in the field of 
antimicrobial therapy is the use of nanotechnology-tailored agents for preventing and 
treating bacteria-resistant infections. Among different nanomaterial, silver and zinc 
oxide NPs are the most extensively studied. They exhibit remarkable antimicrobial 
activity: they affect adversely different process in bacteria such as cell-wall synthesis 
and cell division, they destabilize and disrupt the outer membrane, inhibit respiration 
and purine metabolism, and reduces the intracellular ATP levels110–112. 
The research on IONPs as microbial agent is increasing in the last years as IONPs can 
be used as an alternative to conventional antimicrobial agents. Furthermore, they can 
also act as carriers for drugs that could kill bacteria species without damaging the 
human host cells. It is well known that the antimicrobial activity of IONPs depends 
on their crystalline structure, indeed, magnetite has been reported to have activity 
against both Gram positive and Gram negative bacteria, while maghemite is less 
active, but more stable113–117. Thus, the conjugation of antibiotic drugs to maghemite 
is necessary for its tuneable activity against specific microorganisms. 
“Nanoantibiotics” present some advantages, such as a reduced susceptibility to 
bacterial resistance, a fine delivery to the site of infection and the possibility to 
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stimulate them with different sources such as heat, pH, magnetic field, light, etc. The 
use of IONPs in combination with amoxicillin penicillin, ampicillin, streptomycin and 
vancomycin 118–122 has already been reported. These results indicate that 
biocompatible MNPs enable antibiotic delivery and promote its antimicrobial activity. 
The conjugation of antibiotics has been reported not only for their antimicrobial 
activity, but also as biosensor. Indeed, more recently, antibiotic-carrying IONPs have 
been used for the detection and enrichment of bacteria from infected samples 123. 
While, previous studies have reported that vancomycin-carrying IONPs could be used 
for the detection of a broad range of bacteria including Gram-positives such as S. 
aureus and Gram-negatives such as E. coli 124–126. 
 
Glycopeptide antibiotic 
Glycopeptide antibiotics (GPAs) are secondary metabolites produced by 
actinomycetes species. They have a heptapeptide core consisting of aromatic 
proteogenic and non proteogenic amino acids synthetized by the Non Ribosomal 
Peptide Synthetase (NRPS), an enzymatic complex that allows the cyclization the 
molecules through the formation of carbon-carbon or ether bonds. The amino acid 
residues, which together constitute the aglycone, present various substituents such as 
hydroxyls, methyls, sugars, chlorine atoms and lipid chains. 
The first GPA introduced in clinics was vancomycin, produced by the actinomycete 
Amycolatopsis  and the second one was teicoplanin, produced by Actinoplanes 
theichomyceticus. The new generation of glycopeptide antibiotics is composed of 
semi-synthetic derivatives of natural glycopeptides, among them telavancin, 
ornitavancin and dalbavancin have already been approved by FDA for clinical 
usage127,128. 
GPAs block the synthesis of peptidoglycan (or murein) of the bacterial cell wall. The 
peptide skeleton of the antibiotic binds, through five hydrogen bonds, to the D-Ala-
D-Ala dimer of the peptidoglycan precursor. The binding prevents transpeptidation 
and transglycosylation reactions necessary for peptidoglycan synthesis, leading to the 
death of the cell129,130. This class of antibiotics is therefore active only on Gram 
positive bacteria; the Gram negative have, indeed, an external lipopolysaccharide 
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membrane that does not allow the interaction with its molecular target. GPAs are 
frequently used to treat serious infections caused by Gram positive bacteria, such as 
Staphylococcus aureus, Enterococcus spp. and Clostridium difficile. They are 
considered "last resort" drugs used against methicillin-resistant S. aureus strains 
(MRSA), which, today, are the main cause of complex nosocomial infections that, in 
the most serious cases, can lead to the death of patient for septicemia. 
Teicoplanin 
Teicoplanin is a natural glycopepetide antibiotic produced by A. theichomyceticus 
ATCC 31121131. Although its chemical synthesis is possible, the complexity of its 
chemical structure makes the fermentation the only way used for its production. 
Indeed, teicoplanin is produced as a complex of molecules structurally related: the 
five major components are designated as A2-1 to 5, one is an hydrolysis component, 
designated as A3-1 , and four minor components designated RS-1 to 4 (Figure 10).  
The core is formed of seven aromatic amino acids all oxidatively linked. The S)-4-
hydroxyphenylglycine, in position 1, and 3,5-dihydroxyphenylglycine, in position 3, 
are linked together by an ether bond. The residues of tyrosine and β-hydroxytyrosine 
in positions 2 and 6 contain 2 chlorine atoms. In addition, to the aryl groups present 
Figure 10. Teicoplanin structure. On right side are represented the five major components. 
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in position 4, 6 and 7 are attached three sugar moieties, N-acyl-β-D-glucosamine, one 
of N-acetyl-β-D-glucosamine and one of α-D-mannose, respectively. The acyl moiety 
is a fatty acid residue containing 9 to 12 carbon atoms is present as a substituent of 
the N-acyl-β-D-glucosamine132. The presence of the fatty acid increases the 
teicoplanin antimicrobial activity, allowing a better penetration of the antibiotic at the 
cellular and tissue level. Compared to vancomycin, teicoplanin has a longer half-life 
(about 40 hours), a feature that allows a single daily administration of the antibiotic 
intramuscularly.   
The N and C terminal of the teicoplanin close around the D-ala D-ala, forming a 
binding pocket for the ligand: the mannose moiety in position 7, at the C termini of 
the antibiotic, interacts with the side chain of the amino acid 1 in the N-termini, 
through the hydroxyl group, forming the floor of the binding pocket. The back of the 
binding site is formed by both the backbone and the side chains of the aminoacid 2, 4 
and 6, while the top of the pocket is created by the sugar moiety attached to the residue 
4133(Figure 11). The acyl chain lies on the back face of the antibiotic, avoiding the 
formation of back-to back dimers observed in other GPAs, such as vancomycin134. 
 
Figure 11. Teicoplanin aglycone interaction with D-Ala-D-Ala. Dotted lines indicate the 
hydrogen bonds stabilizing the complex, bond distances are given in angstroms. Arrows mark 
the weak interaction between the resonating glycopeptide aromatic bonds and the D-Ala 
terminations135.  
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II. AIM OF THE PROJECT 
The overall aim of this PhD thesis is to synthesize and functionalize 
superparamagnetic iron oxide nanoparticles (IONPs) to create NP-systems that can be 
efficiently used in industry and in medicine. This project originates from the 
observation that, thanks to their magnetic and biocompatible characteristics, IONPs 
can be used as a platform for the biomolecule conjugation.  
The aim of first part of the project was to synthetize IONPs through a co-precipitation 
method to obtain an easy, reproducible and scalable method for their production. To 
better understand if the characteristics of the IONPs obtained were always similar, 
several chemical-physical characterizations were conducted. 
After obtaining a better comprehension of the system, the second part of this work 
was focused on the use of IONPs as a platform for the conjugation of enzymes of 
potential interest for industrial application. Taking into consideration the capability of 
L-aspartate oxidase (LASPO) and α-amylase (AMY) to work at high temperature and 
their widespread use in industry, this two enzymes were chosen for the creation of 
efficient nano-biocatalysts. To this aim, different conjugation strategies were 
developed and their chemical-physical characteristics were investigated. Next, a 
biochemical characterization was carried on. The conjugation of enzymes to NPs can 
provide the subsequent advantages: 
§ Enhancement of enzymes activity in a wider range of temperature and pH. 
§ Enhancement of the enzyme stability over temperature 
§ Capability of recover and reuse the NP-enzyme systems, reducing the costs 
per enzyme units. 
As a further improvement of the current industrial applications, this project aim was 
to evaluate the possibility to nano-actuate enzyme-NPs thanks to the capability of 
IONPs to respond to an AMF. The effect of the AMF on the NP-enzyme systems was 
studied varying the AMF parameters.  
The last part of this project was focused on the development of a platform for 
biomedical applications by the design of a nano-antibiotic that exploits the IONP 
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characteristics, such as biocompatibility and superparamagnetic behaviour, and the 
antimicrobial activity of the teicoplanin. This system can provide several putative 
advantages such as: 
§ protection of the nanoconjugated drug from degradation and oxidation 
§ increase solubility, antimicrobial activity and biodistribution  
§ controlled and sustained delivery of the antibiotic to the site of the infection. 
To this aim different techniques were used to investigate the antimicrobial activity: 
classical assay, such as MIC, MBC and agar diffusion assay, and morphological 
studies, fluorescence microscopy and electron microscopy. 
Papers 
Papers related to this PhD project are insert in the thesis chapter in which they can be 
useful to better explain the procedures or the results.  
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III. MATERIALS AND METHODS 
CHEMICALS 
APTES, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 
Hydroxysuccinimide (NHS), 4-amino antipyrine (4-AAP), L-aspartate acid, Phenol, 
Orange II, Tris-HCl; Sodium tetraborate, Starch from potatoes, Potassium sodium 
tartrate, tetrahydrate, 3,5-Dinitrosalicylic acid, D‑(+)‑Maltose, monohydrate 
teicoplanin,  iron trichloride (FeCl3· 6 H2O), iron dichloride (FeCl2 ·4 H2O), 
ammonium hydroxide (NH4OH), nitric acid (HNO3), ferric nitrate (Fe(NO3)3 · 9 H2O), 
sodium 2-(N-morpholino)ethanesulfonic acid hemisodium salt (MES), 2′,7′-
dichlorodihydrofluorescein (DCFH-DA), ethanol, phosphate-buffered saline (PBS), 
sodium chloride, formaldehyde, glutaraldehyde, sodium cacodylate, osmium 
tetroxide all purchased from Sigma Aldrich. Horse Radish Peroxidase, EIA grade 
(POD) was purchased from Roche (10814407001), sulfosuccinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC), bis (sulfosuccinimidyl) 
suberate (BS3) and LIVE/DEAD BacLight fluorescence assay kit were purchased 
from ThermoFisher Scientific. Amino terminated polyethylene glycol (700 Da PEG-
NH2) was purchased from Rapp Polymere. Epon-Araldite 812 was purchased from 
Electron Microscopy Science. 
 
SYNTHESIS 
A common co-precipitation method was used to synthetize IONPs. Briefly, 8.89 g of 
FeCl3·6 H2O and 3.28 g FeCl2·4 H2O were mixed in 380 mL of water under a vigorous 
stirring for 30 min, while slowly dropping 1.5 mL of HCl (37%) to completely 
dissolve the salts. Following this step, 25 mL of NH4OH (25%) were added. Particles 
were washed several times with MilliQ water and 40 mL of 2 M HNO3 were added 
and heated at 90°C for 5 min. The particles were separated by a magnet from the 
reaction mixture, then 60 mL of 0.34 M solution of Fe(NO3)3·9 H2O was added. The 
suspension was heated at 90°C for 30 min. The supernatant was removed and IONPs 
were collected by a magnet, suspended in MilliQ water and left in dialysis overnight. 
IONPs were stored at 4°C.  
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APTES FUNCTIONALIZATION 
For the amino functionalization of IONPs a1 mL of 1.5 M solution of APTES in 
ethanol was added to 150 mg of  IONPs and stirred for 1h at room temperature Then, 
the temperature was increased to 90°C and stirred for an additional hour. The amino-
modified IONPs (so far named NP-APTES) were collected by a magnet, washed 
several times and suspended in MilliQ water.  
CHARACTERIZATION 
Transmission Electron Microscopy (TEM) 
TEM bright field measurements were performed with the samples diluted in H2O 
MilliQ using a TECNAI G2 microscope operating at 200 kV for IONPs, NP-APTES, 
NP-LASPO and NP-AMY preparations; using JEOL 1010 electron microscope for 
NP-TEICO preparation. 
Dynamic Light Scattering (DLS) and electrophoretic mobility (z-
potential) Analysis 
The hydrodynamic diameter and polydispersity index (PDI) of NPs were measured in 
0.9 % NaCl after a proper dilution of the stock solution. z-potential measurements 
were performed at 25 °C with the samples diluted in 1mM KCl. For NP-APTES, 
stability measurements, DLS analysis and z-potential were carried out in 0.9 % NaCl 
in a range of pH from 3 to 12 and at different NaCl concentrations. Measurements 
were performed using 90 Plus Particle Size Analyzer (Brookhaven Instrument 
Corporation). 
Magnetic characterization of NPs 
SQUID magnetometry was used to determine the magnetic properties of IONPs and 
NP-APTES. 10 µL of the samples were dried on a piece of cotton and analysed with 
a field that vary from 50000 Oe to -50000 Oe at 300 K. using MPMS-XL (Quantum 
Design).  
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Amine group on the NPs-surface determination 
The amino content of the NPs was measured by the Orange II spectrophotometric 
assay136,137. 1 mL of a solution of 1 mM Orange II pH 3 was added to 1 mg of NPs 
and maintained under stirring for 30 min at 40°C. The particles were precipitated and 
washed with an acidic water solution until all the unbound dye was removed. To 
desorb the bound dye, a solution at pH 12 was added to the NPs. The amount of 
desorbed dye was then measured at a wavelength of 480 nm with a Varian Cary 50 
UV/vis spectrophotometer. 
ENZYME CONJUGATIONS 
Enzymes 
Amylase from Bacillus licheniphormis (AMY) was purchased from SIGMA (25,1 
mg/mL, 932 U/mg). L aspartate Oxidase (LASPO) used is this work is the wild type 
from Sulfolobus tokodaii that was overexpressed in Escherichia coli cells and purified 
to > 95% purity as described by Bifulco et al74. The purified batch of LASPO 
(2.255U/mL; 0.37U/mg) was stored in 20 mM Tris–HCl buffer at pH 7.5 and 10% 
glycerol. D-amino acid oxidase from Rhodotorula gracilis (DAAO) was produced as 
recombinant protein in E.coli and purified as stated. The purified DAAO ( 90 U/mg) 
was stored in 50 mM Potassium Phosphate buffer pH 7.5, 2 mM EDTA, 10% glycerol 
and 5mM 2-mercaptoethanol. LASPO and DAAO were provided by the laboratory of 
Prof. Loredano Pollegioni of the Biotechnology and Life Sciences Department of 
Università degli Studi dell'Insubria, Varese. 
L-aspartate oxidase reduction 
TCEP reducing gel. The enzyme reduction of LASPO was exploited through the 
TCEP reducing gel (PIERCE) according to the manufacturer protocol. Briefly, 1 mg 
of enzyme was added to an equal volume of TCEP reducing gel. The sample was 
incubated at RT under mechanical stirring for 45 min. The enzyme was centrifuged at 
1000 rpm for 30 seconds. The supernatant was removed and discarded. After 
incubation, the sample was transferred into a spincup column, previously placed in a 
new tube, and centrifuge at 1000 rpm for 1 minute.  
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DTT reduction. 500 uL LASPO were reacted at room temperature and under stirring 
with 100 mM DTT or 200 mM DTT for 1 h. The sample was loaded with 1.5 mL of 
buffer on a PD10 column after its conditioning with 5 mM Sodium Pyrophosphate 
Buffer at pH 8.5. The reduced protein was eluted with 2 mL of buffer and the yellow 
fraction of the column was collected. 
To determine the number of reduced thiol groups, was used the Ellman’s Reagent. 
This reagent reacts with sulphydryl groups to produce 1 mol of 2-nitro-5-thiobenzoic 
acid (which absorbs at 412 nm) per mole of sulphydryl group. 
Conjugations 
LASPO conjugation was performed with five different strategies: for the standard 
protocol, 16 mg of NP-APTES were sonicated in 5 mM sodium pyrophosphate buffer 
at pH 8.5. Then a solution of EDC (65 mM final concentration) and NHS (13 mM 
final concentration) were added under sonication in a final volume of 2 mL, following 
by the addition of 200 μg of pure LASPO. The reaction was carried for 2 h at room 
temperature on a rotating plate tube stirrer. Subsequently, LASPO conjugated NPs 
(NP-LASPO1) were collected by a magnet and washed twice with 2 mL of 5 mM 
sodium pyrophosphate buffer, pH 8.5.  
For the sulfo-SMCC- cysteine (NP-LASPO2), 1 mg of NP-APTES were suspended 
in 5 mM sodium pyrophosphate buffer pH 5, followed by the addition of a solution of 
sulfo-SMCC at a final concentration of 4 µM in a final volume of 1 mL. The reaction 
was incubated for 30 min at room temperature under mechanical stirring. After several 
washes, 1 mg of the previously reduced enzyme was added and the reaction was 
maintained under mechanical stirring for 30 min at room temperature. Then the 
particles were isolated by a magnet and suspended, after several washes, in 5 mM 
sodium pyrophosphate buffer pH 5.   
For the conjugation of LASPO through the enzyme primary amine (NP-LASPO3), a 
BS3 solution (10 µM final concentration) was added to 1 mg of NP-APTES in 10 mM 
borate buffer pH 8.2. The reaction was maintained under mechanical stirring for 30 
min at room temperature, then 1 mg of enzyme was added and the reaction was 
conducted at 40°C for 2 h in a final volume of 1 mL. After the addition of 100 mM 
Tris-HCl, the particles were isolated and, after several washes, were suspended in 1 
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mL of 10 mM borate buffer pH 8.2. For the NTA functionalization method (NP-
LASPO4), the NTA-Cu2+ (40 µM final concentration) was introduced onto the NP-
APTES following the same procedure of the BS3 functionalization method. The 
reaction was carried on in a final volume of 1 mL. The particles obtained were then 
incubated for 1 h at room temperature in presence of 1 mg of enzyme. The resulting 
NP-LASPO4 were isolated and, after several washes, were suspended in 1 mL of 10 
mM borate buffer pH 8.2.  
For the NP-LASPO3- pegylated, NP-APTES were modified with 18 µM of PEG-NH2 
in 1 mL final volume, using the BS3 protocol. After the addition of a BS3 solution, 
which reacted with the PEG-NP-APTES 30 min at room temperature, 1 mg of St-
LASPO was added and the reaction was conducted for 2 h at 40°C. The resulting 
conjugated enzyme was stored at 4 °C until use.  
8 mg of NP-APTES were sonicated in 20 mM sodium phosphate buffer and 6,7 mM 
HCl at pH 7 (NP-AMY1) or at pH 9 (NP-AMY2). Then a solution of EDC and NHS, 
in a final concentration of respectively 39 mM and 26 mM, was added under 
sonication in a final volume of 2 mL. Finally, 400 μg of α-amylase were added and 
the reaction was carried out for 24 h at 4°C on a rotating plate tube stirrer. 
Subsequently, α-amylase conjugated NPs were collected by a magnet and washed 
twice with 2 mL of buffer. For the conjugation of amylase  through the enzyme 
primary amine (NP-AMY3), a BS3 solution (10 µM final concentration) was added 
to 0.2 mg of NP-APTES in 10 mM borate buffer pH 8.2. The reaction was maintained 
under mechanical stirring for 30 min at room temperature, then 1 mg of enzyme was 
added and the reaction was conducted at 40°C for 2 h in a final volume of 1 mL. After 
the addition of 100 mM Tris-HCl, the particles were isolated and, after several washes, 
were suspended in 1 mL of 10 mM borate buffer pH 8.2. The resulting conjugated 
enzyme was stored at 4 °C until use.  
DAAO was conjugated as stated in the article entitled “Synthesis, characterization and 
programmable toxicity of iron oxide nanoparticles conjugated with D-amino acid 
oxidase” attached at the end of this chapter. 
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Enzymatic assay 
The LASPO and NP-LASPO activity was assayed as reported in detailed in the article 
entitle “L-aspartate oxidase magnetic nanoparticles: synthesis, characterization and 
L-aspartate bioconversion.” attached at the end of this chapter. Briefly, the activity 
was assayed by measuring the initial rate of production of hydrogen peroxide with a 
coupled peroxidase/dye assay. The standard assay mixture contained 10 mM L-
aspartate in 50 mM sodium pyrophosphate buffer, pH 8.5, 1.5 mM 4-aminoantipyrine, 
2 mM phenol, 20 mM FAD, 2.5 U of peroxidase, and StLASPO in a total volume of 
1 mL. The activity was detected spectrophotometrically at 505 nm (ε= 6.58 mM-1 cm-
1). One unit (U) is defined as the amount of enzyme that catalyzes the degradation of 
1 mmol of L-aspartate per min.  
The 3,5-dinitrosalicyclic acid colorimetric assay was used to assess the enzymatic 
activity of the free and conjugated AMY138. For all experiments, starch was prepared 
gelatinized by heating until boiling for 10 min in the buffer of desired pH.  
The NP-DAAO activity was determined as stated in the article entitled “Synthesis, 
characterization and programmable toxicity of iron oxide nanoparticles conjugated 
with D-amino acid oxidase” attached at the end of this chapter. Briefly, The activity 
was determined by measuring the absorbance increase accompanying the H2O2-
induced oxidation of O-dianisidine at 440 nm (~13 mM-1cm-1). The standard assay 
mixture contained 89 mM D-Ala, 1.3 M O-dianisidine in H2O MilliQ, 0.8 U of 
peroxidase and 4 µg NP-DAAO. One unit corresponds to the amount of enzyme that 
converts 1 µmol of substrate per min.  
Nanoactuation 
For LASPO the hyperthermia analysis were performed at 829 kHz and 252 Gauss. 
For AMY hyperthermia analysis were carried on in the range of 419-829 kHz 
frequency and an amplitude of 252 Gauss and with substrate at different pH values. 
For DAAO hyperthermia analysis were carried on in the range of 419-829 kHz 
frequency and an amplitude of 252 Gauss .The measurements were performed using 
D500 series (Nanoscale Biomaterial). 
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ANTIBIOTIC CONJUGATION 
Microbial Strains and Culture Conditions 
Escherichia coli ATCC 35218, Bacillus subtilis ATCC 6633 and Staphylococcus 
aureus ATCC 6538P were obtained from the American Type Culture Collection 
(ATCC). E. coli and B. subtilis were propagated overnight in Luria Bertani medium 
(LB, 2% tryptone, 2% yeast extract, 1% NaCl) while S. aureus in Muller Hilton broth 
(MHB) with continuous shaking at 200 rpm and 37°C.  For exponential growth, 
overnight cultures were transferred to fresh medium: inocula were prepared to start 
the cultures with an optical density at 600 nm (OD600 nm) of 0.1 in the final medium. 
For long-term preservation, bacterial cultures were stored at -20°C in 20% glycerol.  
Conjugation 
For the preparation of teicoplanin-conjugated NPs (NP-TEICO), a solution of 
teicoplanin (500 µg), 13 mM EDC and 26 mM NHS was prepared and added to the 
NP-APTES (4 mg/mL) dispersed in 30 mM MES buffer pH 6.0 in a final volume of 
1 mL. The reaction was mixed for 6 h at room temperature. NP-TEICO were washed 
twice and resuspended in fresh 30 mM MES buffer at pH6.  
HPLC Analysis 
Teicoplanin was measured by HPLC following the method previously reported131. 
HPLC analyses were performed on a 5-μm particle size Symmetry C18 (VWR 
International LCC, Radnor, PA, USA) column (4.6 × 250 mm). The column was 
eluted at 1 mL/min flow rate with a 30-minute linear gradient from 15% to 65% of 
Phase B, followed by 10 min with 100% Phase B. Phase A was 32 mM HCOONH4 
pH 4.5: CH3CN 90:10 (v/v) and Phase B was 32 mM HCOONH4 pH 4.5:CH3CN 
30:70 (v/v) mixture. The chromatography was performed with a model 1100 HPLC 
system (Elite Lachrom VWR Hitachi LL) and UV detection was at 236 nm. 
Binding Stability and activity stability 
To evaluate  the stability of NP-TEICO in different media and different temperatures, 
NP-TEICO were suspended in MES buffer at 5.5, 6.0 and 7.12 and stored at -20, 4 
and 25°C. At defined time point, the sample was centrifuged and the amount of 
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teicoplanin was quantified by spectrophotometric assay. Teicoplanin was 
appropriately diluted in MES buffer and the absorbance was measured at 280 nm, 
using quartz cuvette. 
Antimicrobial susceptibility test 
Antimicrobial activities of IONPs, NP-APTES and NP-TEICO were tested against the 
E. coli, B. subtilis and S. aureus strains by agar diffusion assay method139. Briefly, 
bacterial cultures after an overnight LB or MHB growth, were used to inoculate the 
test strains in agar plates containing Difco Nutrient Agar (DNA agar, Difco) for B. 
subtilis and E. coli or Muller-Hilton Agar (MHA) for S. aureus and left to dry. 10 μL 
of IONPs, NP-APTES, and NP-TEICO preparations in 30 mM MES buffer pH 6  and 
of teicoplanin solution in the same buffer were loaded directly on the inoculated 
plates. Plates were incubated at 37°C for 24 h. The diameters of zones of bacterial 
growth inhibition surrounding the droplets were measured.  
Determination of the minimum inhibitory concentration  
The minimum inhibitory concentrations (MICs) of teicoplanin and NP-TEICO were 
determined against B. subtilis and S. aureus by broth dilution method using MHB, as 
recommended by the Clinical & Laboratory Standards Institute guidelines140. About 
5 × 104 exponentially growing bacterial cells were inoculated into MHB containing 
increasing concentrations (in terms of teicoplanin of 0; 0.5, 1; 2; 4; 8; 16; 32; 64; 64; 
128 µg/mL)  of teicoplanin and NP-TEICO in 30 mM MES buffer pH 6, and shaken 
for 16 h at 37°C. MICs were the minimal concentrations of teicoplanin or of NP-
TEICO at which no turbidity was detectable.  
Determination of the minimum bactericidal concentration  
The minimum bactericidal concentrations (MBC) of teicoplanin and NP-TEICO were 
determined against B. subtilis and S. aureus according to Clinical & Laboratory 
Standards Institute guidelines. This is an extension of the MIC procedure: 200 μL of 
dilutions in which no visible bacterial growth was present were plated on MHA. After 
incubation at 37 ° C for 16 hours, the colonies on the plate were counted.  
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Determination of tolerance level 
Tolerance level of each strain against teicoplanin and NP-TEICO was determined as 
reported in literature using the formula: Tolerance = MBC/MIC141. 
Kinetic Growth Curve 
The growth kinetics of B. subtilis, S.aureus and E. coli in absence and presence of 
IONPs, NP-APTES and NP-TEICO. The mother cultures of test organisms were 
prepared in LB broth taking loop full of bacteria from the specified slant culture, and 
cultured overnight at 37 °C and 200 r.p.m agitation. The NPs stock solution was 
prepared by dispersing the IONPs, NP-APTES and NP-TEICO (4 mg/mL) in 30 mM 
MES buffer pH 6.0. The NPs stock solutions were added to bacterial cultures prepared 
in Falcon tube in a final volume of 10 mL. The growth kinetic studies were performed 
by measuring optical density (O.D.) at 600 nm using an UV-Vis V-560 
Spectrophotometer (JASCO, MD, USA) at regular time interval. The reaction 
mixtures without NPs and with free teicoplanin were taken as controls. Upon addition 
of IONPs, NP-APTES and NP-TEICO, data collection for growth curve was 
immediately started with dead time of 5 min. 
CFU measurement  
The number of viable cells were quantified by measuring colony forming units 
(CFUs) for all types of bacteria upon treatment with teicoplanin, IONPs, NP-APTES, 
and NP-TEICO, as reported above. For CFU measurement, 10 µL of sample from the 
stationary phase of growth kinetics were spread on the nutrient agar plates after 104 
and 105 times dilution in LB or MHB. The plates were incubated overnight at 37°C. 
The number of viable cells after treatment with teicoplanin, IONPs, NP-APTES, and 
NP-TEICO were quantified and compared with the control culture without any 
addition. 
Interaction pattern 
Fluorescence 
To visualize the interaction pattern of IONPs, NP-APTES and NP-TEICO with 
bacteria was used LIVE/DEAD BacLight fluorescence assay (L7007, Molecular 
probes, ThermoFisher Scientific). Following the manufacturer’s protocol, bacteria 
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were culture over night at 37 °C 200 rpm, appropriately diluted and treated. From 
these cultures, 10 mL of each bacterial solutions were centrifuged at 7000 r.p.m for 
15 min. The supernatants were discarded and the pellets were suspended in saline 
solution (0.9 %). Samples were incubated at RT for one hour (mixing every 15 min). 
The suspensions were centrifuged at 7000 r.p.m for 15 min, pellets were collected and 
suspended in an equal volume and centrifuged at 7000 r.p.m for 15 min. Finally, the 
pellets were suspended in saline solution (0.9 %). 3 μL of dye mixture were added to 
each 1 mL of the prepared bacterial samples and incubated in dark for 15 min after 
proper mixing of bacterial suspensions. Fluorescence images were taken by trapping 
5 μL of stained bacterial samples between a slide and cover slip. For imaging the 
samples, an optical microscope with appropriate filters was employed (Axiophot, Carl  
Electron microscopy  
The interaction pattern was also studied with TEM analysis. After 7 h of exposure to 
IONPs, NP-APTES, NP-TEICO and Teicoplanin, pellets were washed with PBS and 
fixed in Karnovsky solution (4% formaldehyde, 2% glutaraldehyde, 0.1 M sodium 
cacodylate, pH 7.2 overnight at 4 °C. Samples were washed three times in 0.1 M 
sodium cacodylate for 10 min and postfixed in dark for 1 hour with 1% osmium 
tetroxide in 0.1 M sodium cacodylate-buffer (pH 7.2) at RT. After dehydration with a 
series of ethyl alcohol, samples were embedded in an Epon-Araldite 812 1:1 mixture. 
Thin sections (90 nm), obtained with a Pabisch Top-Ultra ultramicrotome (Emme 3 
S.r.l., Milan, Italy), were observed with a Morgagni electron microscope (Philips, 
Eindhowen, NL) operated at 80 KeV. 
Cell cultures 
Two different cell lines were used to evaluate the NP-TEICO in vitro cytotoxicity: as 
a tumor model SKOV-3 cell line from ovary adenocarcinoma and as non-tumor cell 
line, the hASCs (human Adipose-derived Stem Cells) cell line. hASC were isolated 
and cultured as reported in the article entitled “Effects of Metal Micro and Nano-
Particles on hASCs: An In Vitro Model”, while SKOV-3 were cultured as stated in 
the article entitled “Synthesis, characterization and programmable toxicity of iron 
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oxide nanoparticles conjugated with D-amino acid oxidase”, attached at the end of 
this chapter. 
Cell Exposure and Viability 
Cell viability was determined measuring ATP content by the RealTime-Glo™ MT 
Cell Viability Assay (Promega, Milan, Italy) according to the manufacturer’s 
instructions. Briefly, 500 cells were plated in a 96-well plates in 200 µL of cell 
medium (RPMI for SKOV-3 and DMEM/DMEM F12 1:1 for ASC). After 24 h, cells 
were exposed to increasing concentrations (0, 6, 46, 364 µg/mL) of IONPs, NP-
TEICO and TEICO and a solution 2X of substrate and NanoLuc® Enzyme was added. 
Cells were incubated at 37°C and 5% CO2-humidified atmosphere for all the 
experiment period. Luminescence was read every 24h using the Infinite F200 plate 
reader (Tecan Group, Männedorf, Switzerland). 
Statistical analysis  
Each plotted value is the mean of three independent experiments. All data for were 
analyzed with one-way Analysis of Variance ANOVA (α = 0.05), completed with 
Dunnett’s test (p < 0.05) in order to determine which groups were significantly 
different from control. Statistical significant differences was fixed at p !"0.05 (*).  
 
 
  
Synthesis, characterization and programmable
toxicity of iron oxide nanoparticles conjugated with
D-amino acid oxidase†
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D-amino acid oxidase (DAAO) is an enzyme which generates reactive oxygen species (ROS) and it is believed
to have potential uses as a novel therapeutic molecule if internalized by cancer cells or if they are localized
close to their plasma membrane. When conjugated onto iron oxide nanoparticles (NPs), the enzyme can be
magnetically directed to targeted locations with an increased efficacy. A subsequent injection of DAAO
substrate D-alanine can initiate ROS production and induce apoptosis of cells surrounding the NP-DAAO
complex. Here, we describe a platform for optimal bioconjugation using monodisperse g-Fe2O3 NPs
(!10 nm) resulting in high DAAO loading, stable NP-DAAO dispersions and more than 90% enzymatic
activity recovery, which is retained using the particles in human serum. Lastly, since the NP-DAAO system
is designed for cancer therapy, we proved its efficacy in killing SKOV-3, U87 and HCT-116 cancer cells.
Nanobiotechnology has found widespread applications1 in
biomedicine as diagnostic imaging tools,2,3 drug delivery
systems,4,5 vaccines6,7 and in immunotherapy.8 NPs can be
employed to produce a great variety of bioconjugates by graing
biomolecules onto a NP carrier. In oncology, for example, recent
studies have shown that engineered NPs are capable of reaching
specic targeted areas of the body and of releasing the thera-
peutic drug locally.9–12 This novel approach has the potential
to increase the drug efficacy and to eliminate the side effects.13
To guide the bioconjugates through the body, one can use
magnetic NPs that, aer intravenous administration, can be
directed to the cancerous tissue with an external magnetic
eld.14 Magnetic NPs alone are used as an effective anticancer
agent during hyperthermic therapy in which NPs exposed to an
alternating magnetic eld produce heat that kills all the
surrounding cells.15–19
D-Amino acid oxidase from Rhodotorula gracilis (RgDAAO, EC
1.4.3.3) is a avoenzyme that utilizes D-amino acids to produce
reactive oxygen species (ROS)20 and can be used to induce
apoptosis. In particular the co-administration with D-alanine as
substrate, gives the corresponding a-keto acid, ammonia and
H2O2. Despite the benet in using this enzyme in therapeutic
applications, the main limitations are the low enzyme stability,
the low efficacy in cellular internalization and the lack of specic
molecular targeting. To overcome these limitations, in the past
few years different attempts have beenmade in the development
of NP-DAAO systems where the enzyme was covalently bound to
the amino groups of APTES functionalized NPs. That resulted in
an increased cellular internalization of the enzyme, a prolonged
enzymatic activity and storage stability, and the possibility of
targeting to the cancer mass with the help of an external
magnetic eld. However, while the APTES functionalization
represents a good amino group donor, its activation via glutar-
aldehyde can affect the enzyme integrity21 leading to a loss of
DAAO activity.22,23 Cappellini et al.24 reported a higher yield for
the NP-DAAO synthesis when conducted via EDC/NHS instead of
with glutaraldehyde. Furthermore, also the NP diameter and
aggregation inuence the amount of loaded enzyme.25
Here, we present a NP-DAAO system starting from the
synthesis of g-Fe2O3 NPs to obtain small and monodispersed
g-Fe2O3–APTES NPs to increase as much as possible the surface
area available for the surface functionalization.
g-Fe2O3 NP cores were synthetized following Geppert et al.
26
(ESI†) and they were subsequently functionalized with APTES
using a standard protocol and then conjugated with DAAO by
coupling with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide
hydrochloride (EDC) and N-hydroxysuccinimide (NHS), as
summarized in Fig. 1. The RgDAAO enzyme was provided by the
laboratory of Prof. Loredano Pollegioni of the Biotechnology
and Life Sciences Department of Universita` degli Studi
aDepartment of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
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† Electronic supplementary information (ESI) available: Synthesis of g-Fe2O3 NPs,
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dell'Insubria, Varese. The g-Fe2O3 NPs, NP-APTES and NP-
APTES–DAAO were characterized by Dynamic Light Scattering
(DLS), by Differential Centrifugal Sedimentation (DCS) and by
Transmission Electron Microscopy (TEM) (ESI†).
The DLS characterization analysis (Fig. 2a) reports a diam-
eter of about 38 nm for the synthetized g-Fe2O3 NPs and about
47 nm for the APTES functionalized ones. Aer conjugation
with the enzyme, the NP-DAAO complex acquires a larger
diameter of approximately 185 nm.
The DCS characterization (Fig. 2b) is similar to the one ob-
tained by DLS. The surface functionalization with APTES and
DAAO results in a change in the particle sedimentation time.
The NP-APTES and NP-DAAO have respectively an apparent size
of 24 nm and 76 nm: this is due to a change in sample density as
also reported elsewhere.27,28
At a glance, the TEM pictures (ESI†) do not suggest any
notable changes in NP size as shown by DLS and DCS analysis.
However, the TEM picture analyses (ESI†) reported that g-Fe2O3
NPs, NP-APTES and NP-DAAO possess an average size of
respectively 8.5, 10.3 and 11.0 nm. These results can be probably
due to a slight NPs aggregation during DLS and DCS analysis.
The amount of DAAO bound on the NP surface was deter-
mined by considering the difference between the starting
amount of RgDAAO and the protein recovered in the supernatant
at the end of the conjugation reaction. The quantication of
conjugated DAAOwas performed using the extinction coefficient
at 455 nm (!12.6 mM"1 cm"1)20 and an UV-Vis V-560 Spectro-
photometer (JASCO, MD, USA). The amount of stock DAAO used
for the conjugation to NP-APTES has been chosen starting from
the ratio of mg of DAAO per NP-APTES surface area (calculated
from the average particle diameter, assuming spherical parti-
cles) used by Cappellini et al.24 and then moving to DAAO
saturation per NP-APTES. For one mg of NP-APTES particles up
to 446 mg of RgDAAO was bound (Fig. 3a). Moreover, to deter-
mine the functionality of the NP-DAAO particles, we checked
their enzymatic activity by measuring the absorbance increase
accompanying the H2O2-induced oxidation of o-dianisidine.
This reaction was initiated by the addition of the enzyme and the
absorbance increase was monitored at 440 nm for 1 min.
The conjugation yield and the activity recovery of these
NP-DAAO particles were of 100% and 91% respectively (Fig. 3a).
Since the specic activity of the RgDAAO stock solution was 59 U
mg"1, we estimated up to 24 U per mg of NP-APTES. The NPs
here synthesized showed a smaller diameter compared to the
ones used by Cappellini et al.24 and this allowed a 7 fold increase
of the DAAO/NP (w/w) ratio.
Then, we detected the thermal stability of the NP-DAAO
system, as enzymatic residual activity, aer 1 hour incubation
Fig. 1 Schematic representation of the NP-DAAO system formation process.
Fig. 2 DLS (a) and DCS (b) analysis of g-Fe2O3 NPs, NP-APTES and NP-DAAO. The polydispersity index is from cumulant fitting.
1440 | RSC Adv., 2017, 7, 1439–1442 This journal is © The Royal Society of Chemistry 2017
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at different temperature (Fig. 3b) (ESI†). At 37 #C the NP-DAAO
system is about 1.8 fold more stable compared to free DAAO.
Since this NP-DAAO system, thought for cancer therapy, has
to be injected intravenously to perform its activity, we checked
its stability also at 37 #C when exposed to 10% human serum
(Sigma-Aldrich) (Fig. 3c). These results indicate that human
serum has an active role in preserving the activity of both DAAO
and NP-DAAO system.
Lastly, we tested the efficacy of the NP-DAAO system on the
three tumor cell lines SKOV-3, HCT116 and U87 (Sigma-Aldrich)
(Fig. 4). In this experiment, 10 000 cells were exposed for 24 h
to an increasing amount, expressed as DAAO units, of free
DAAO or NP-DAAO with or without D-alanine (D-Ala). Hence, the
cell viability was determined as ATP content by recording the
luminescent signal aer using the CellTiter-Glo Luminescent
Cell Viability Assay (Promega). The results reported in Fig. 4
show a very low cytotoxicity when cells are exposed to 7 mU
of NP-DAAO particles without D-alanine. However, when D-Ala
is added a full cell death was apparent. If compared to the
NP-DAAO particles present in literature,23 the new particles
result less cytotoxic whilst the effectiveness remains unchanged
in the presence of the substrate: this can be explained by the
lower amount of NP-DAAO particles required to reach the same
DAAO activity (ESI†). We have performed preliminary experi-
ments exposing human adipose stem cells (hASC), isolated
from adipose tissue, to NP-DAAO. The results have shown that
hASC are less responsive than tumor cell lines to the H2O2
produced by the NP-DAAO in presence of D-Ala.
Conclusions
In conclusion, the new NP-DAAO particles represent a remark-
able improvement of this NP-enzyme system.
With a reduced amount of NPs required for the same enzy-
matic activity, we have obtained a safer and more efficient
NP-DAAO system that might be used for cancer therapy, but also
for biocatalysis. The new NPs, thanks to their smaller size, can
bind about 7 times more enzyme than the previous ones28 thus
increasing the efficacy and reducing the NP-DAAO system
toxicity before external stimulation of ROS production (ESI†).
Since smaller NPs might result more cytotoxic,29 in vivo experi-
ments will be performed to assay their toxicity and half-life once
injected into the blood stream.
It has been previously reported that enzymes conjugated to
NPs may present a higher activity, a better specicity, a pro-
longed half-life, an enhanced thermal stability and, in some
Fig. 3 (a) NP-DAAO system features; U are enzymatic units of DAAO.
(b) Thermal stability, measured as enzymatic activity, of the NP-DAAO
system after 1 h incubation; (c) effect of 10% human serum (hS) on NP-
DAAO during 1 h incubation. Error bars represent mean $ SD, N ¼ 3.
Fig. 4 Cell viability is expressed as a percentage of ATP content after
24 h exposure to 3.5, 7 or 14 mU of NP-DAAO or free DAAO, with and
without the substrate D-Ala. Error bars represent mean $ SD, N ¼ 3.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 1439–1442 | 1441
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cases, even an enzymatic acceleration.30–32 In agreement with
these reports, we have observed a prolonged storage half-life
(ESI†) and an enhanced thermal stability (Fig. 3b). Conversely,
we did not notice an increase of the enzymatic activity.
In addition, the susceptibility of the NP-enzyme system to
a magnetic eld allows, in nanomedicine, its targeting to the
desired area of the body, and, in biocatalysis, its efficient
recovery enabling its reuse for several times and preventing the
contamination of the nal product.30
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L-aspartate oxidase magnetic nanoparticles:
synthesis, characterization and L-aspartate
bioconversion
Ilaria Armenia, a Riccardo Balzaretti, a Cristina Pirrone,a Chiara Allegretti,b
Paola D'Arrigo,bcd Mattia Valentino,cd Rosalba Gornati,ac Giovanni Bernardini *ac
and Loredano Pollegioniac
The FAD-containing enzyme L-aspartate oxidase (LASPO) catalyzes the stereospecific oxidative
deamination of L-aspartate and L-asparagine functioning under both aerobic and anaerobic conditions.
LASPO possesses distinctive features that make it attractive for biotechnological applications. In
particular, it can be used for the production of D-aspartate from a racemic mixture of D,L-aspartate,
a molecule employed in the pharmaceutical industry, for parenteral nutrition, as a food additive and in
sweetener manufacture. Since the industrial application of LASPO is hampered by the high cost per
enzymatic unit, several attempts have been performed to improve its reusability, such as LASPO
immobilization on various matrices. In this context, magnetic nanoparticles (NPs) have recently become
available for the immobilization of enzymes. In this work, we have covalently immobilized LASPO from
the thermophilic archaea Sulfolobus tokodaii on iron oxide NPs using 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide and hydroxysuccinimide as cross-linking agents. The NP-LASPO system showed a better
stability than the free enzyme, was reused five times reaching full L-aspartate conversion and yielded
a productivity (>3 mmol per h per unit) similar to that obtained with the free enzyme or with the enzyme
immobilized on classical chromatographic supports. The NP-LASPO system can be easily recovered after
each cycle. These results indicate that the prepared NP-LASPO system has promising industrial applications.
Introduction
The FAD-containing enzyme L-aspartate oxidase (LASPO, EC
1.4.3.16) catalyzes the stereospecic oxidative deamination of L-
aspartate and L-asparagine to the corresponding imino acid
and, following spontaneous hydrolysis, an a-keto acid (i.e.
oxaloacetate from L-aspartate) along with the production of
ammonia and hydrogen peroxide. The ability of LASPO to use
both O2 and fumarate in reoxidation of the reduced avin
cofactor enables it to function under both aerobic and anaer-
obic conditions.1 This agrees with the physiological role of the
enzyme in prokaryotes, which is to catalyze the rst step of
NAD+ biosynthesis. Notably, LASPO distinguishes from the
family members of the amino acid oxidases, most closely
resembling the succinate dehydrogenase/fumarate reductase
family of avoproteins; indeed, LASPO is not evolutionarily
related to the L-amino acid oxidase members.2
In past years, we focused on LASPO from the thermophilic
archaea Sulfolobus tokodaii (StLASPO), a monomeric protein
(comprising 472 residues, 52 kDa) which folds into three
distinct domains: a FAD-binding domain, a capping domain,
and a helical domain.3 StLASPO is produced as a recombinant
protein in E. coli, while classical L-amino acid oxidases with
a broad substrate specicity are not. It is produced as active
holoenzyme (the avin cofactor is tightly, but non-covalently,
bound to the protein moiety) reaching up to 9% of the total
proteins in the crude extract and 13.5 mg L!1 in the fermenta-
tion broth.3,4
We focused on this enzyme since it possesses distinctive
features that make it attractive for biotechnological applica-
tions.5 Indeed, LASPO possesses high thermal stability (it is
fully stable up to 80 "C), high temperature optimum, stable
activity in a broad range of pH (7.0–10.0), weak inhibition by
the product and by the D-isomer of aspartate, and a quite low
Km for dioxygen (0.3 mM). These properties make StLASPO
a potential useful novel tool in biocatalysis where it can be
used in applications resembling those developed for D-amino
acid oxidase of opposite enantioselectivity.6 In particular, it
can be used for the production of D-aspartate, a molecule
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employed in the pharmaceutical industry, for parenteral
nutrition, as food additive and in sweetener manufacturing.5
On this side, when applied in the free form, the resolution of
a 50 mM racemic mixture of D,L-aspartate was obtained in one
day using 9 U of StLASPO (nal e.e. > 99.5%).4
To facilitate industrial applications by improving reusability
and, hence, by reducing the costs, StLASPO was immobilized on
various matrices. The best results in terms of immobilization
yield and volumetric activity have been obtained through the free
amino groups of the enzyme by using the supports Relizyme™
HA403/S R and SEPABEADS® EC-EP/S or when prepared as cross-
linked enzyme aggregates. The Relizyme-StLASPO immobilized
preparation was reused for three cycles keeping full oxidation of
L-aspartate, in#2 hours starting from a 50 mM racemic mixture:
in a semi-preparative scale reaction, 66 mg of D-aspartate per day
were produced using 20 U of StLASPO.7
With the development of nanotechnology, magnetic nano-
particles (NPs) have become available for the immobilization of
enzymes. Magnetic NPs, when small enough, show super-
paramagnetic behaviors with a fast response to applied magnetic
elds and with negligible residual magnetism and coercitivity.
This means that these NPs can be magnetized with an external
magnetic eld and immediately redispersed once the magnet is
removed.8 We have recently functionalized iron oxide NPs with D-
amino acid oxidase for therapeutic purposes and obtained
a magnetic nano-enzymatic system capable of producing, in
presence of its substrate, reactive oxygen species.9,10 This system,
which possesses relatively low toxicity,11 might be driven to the
target area by an external magnetic eld. Magnetic nano-enzymes
can be used in several other elds such as biosensors for envi-
ronmental pollutants and clinical sensors for biomolecules. A
caveat, when using NPs, is always a concern about their safety.12
Iron NPs, however, have been shown to exert a relatively low
toxicity.11,13
The application of StLASPO has few limitations due to the
high cost per enzymatic unit and inability of separation. Among
the approaches useful to improve the enzyme stability, the
immobilization has proven particularly valuable. On this side,
signicant improvement has been made by enzyme immobili-
zation onto magnetic nanocarriers. They can be advantageously
employed as industrial catalysts since they have high surface
area, large surface-to-volume ratio, lower hindrance, allow to
regulate the orientation of the enzyme on the support and to
easily remove the enzyme by applying a magnetic eld.14,15
To generate an immobilized StLASPO system differing in
mechanical, physical and diffusional properties, we focused on
the setup of magnetic NP-LASPO that can be easily recovered
from the reaction mixture and, potentially, applied under
different practical conditions as compared to classical resin-
immobilized enzyme preparations. Following the optimization
of the immobilization procedure, the NP-LASPO system was
characterized for the main physical–chemical properties and
then used to convert L-aspartate into oxaloacetate and
ammonia. The avoenzyme system can be reused for 4 cycles
with no loss of activity. This result paves the way to the set-up of
innovative biocatalytic processes.
Experimental
Chemicals
Iron oxide nanoparticles (Fe3O4NPs, <50 nm), (3-aminopropyl)
triethoxylsilane (APTES), 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide (EDC), hydroxysuccinimide (NHS), 4-amino anti-
pyrine (4-AAP), L-aspartic acid, glycine, phenol: all purchased
from Sigma Aldrich (Milan, Italy). Horseradish peroxidase
(POD) was purchased from Roche (Milan, Italy).
Enzyme preparation
StLASPO was overexpressed in E. coli cells and was puried to
>95% purity by the procedure described by (ref. 4). The puried
StLASPO was stored in 20 mM Tris–HCl buffer at pH 7.5 and
10% (v/v) glycerol; its specic activity was #0.43 U mg!1 of
protein on L-aspartate as substrate.
Functionalization of NPs with APTES
Fe3O4NPs were functionalized according to the protocol of (ref.
16). Briey, 5 mL of 2% (v/v) APTES in milliQ water were added
to a suspension of Fe3O4NPs (150 mg) and the reaction was
maintained under mechanical stirring for 5 h at 50 "C. Amino-
functionalized nanoparticles (NP-APTES) were then separated
from unbound APTES by a commercial parallelepiped
neodymium magnet (Webcra GmbH, Uster, Switzerland; Ni–
Cu–Ni plated; magnetization: N45; size: 30 $ 30 $ 15 mm),
washed several times with water and anhydried with ethanol
overnight. NPs were suspended in water, isolated and dried at
50 "C overnight.
Synthesis of NP-LASPO
16 mg of NP-APTES were sonicated in 5 mM sodium pyro-
phosphate buffer at pH 8.5. Then a solution of EDC (65 mM
nal concentration) and NHS (13 mM nal concentration) were
added under sonication in a nal volume of 2 mL. Finally, 200
mg of pure StLASPO were added and the reaction was carried out
for 2 h at room temperature on a rotating plate tube stirrer.
Subsequently, StLASPO conjugated NPs (NP-LASPO) were
collected by a magnet and washed twice with 2 mL of 5 mM
sodium pyrophosphate buffer, pH 8.5. The resulting conjugated
enzyme was stored at 4 "C until use.
Characterization
Shape, size, and size distribution of Fe3O4NPs, NP-APTES and
NP-LASPO were investigated by transmission electron micros-
copy (TEM) with JEOL 1010 electron microscope (JEOL, Tokyo,
Japan). Samples were dispersed in milliQ water on carbon
coated copper grids and dried at room temperature.
Activity assay
Activity of StLASPO and NP-LASPO was assayed by measuring
the initial rate of production of hydrogen peroxide with
a coupled peroxidase/dye assay at different temperatures. The
standard assay mixture contained 10 mM L-aspartate in 50 mM
sodium pyrophosphate buffer, pH 8.5, 1.5 mM 4-
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 21136–21143 | 21137
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aminoantipyrine, 2 mM phenol, 20 mM FAD, 2.5 U of peroxi-
dase, and 30 mg of StLASPO in a total volume of 1 mL. The
colored product generated by peroxidase from H2O2 and 4-
aminoantipyrine was detected spectrophotometrically at
505 nm (3 ¼ 6.58 mM!1 cm!1).4 One unit (U) is dened as the
amount of enzyme that catalyzes the degradation of 1 mmol of L-
aspartate per min.
Oxidation of L-aspartate by conjugated StLASPO
The oxidation of L-aspartate was carried out by adding 50 mL of
50 mM amino acid solution (in water, prepared and adjusted to
the desired pH with 0.5 M NaOH) and 150 mL of water to the
immobilized enzyme (4 mg of support corresponding to z
0.104 U of StLASPO). All reactions were performed at 70 "C, in
a thermomixer set to 600 rpm and at different pH values (in the
8–11 range). The dependence of the residual activity aer
60 min of incubation on pH was tted using an equation for
a single ionization according to Harris and Colleagues.17
To investigate the stability of NP-LASPO on temperature, the
same reaction was performed at pH 10.0 in the 25–80 "C range:
samples were collected at different time intervals for measure-
ments. For the recycling of the NP-LASPO, at the end of each
cycle NPs were collected with a magnet, washed several times
and stored in the storage buffer. In all cases, the oxidation of L-
aspartate was assayed by HPLC separation (see below).
HPLC analysis
The OPA-NAc reagent was prepared by dissolving 4 mg of ortho-
phthalaldehyde (OPA) in 300 mL of methanol, followed by the
addition of 250 mL of 0.4 M borate buffer at pH 9.4.18 To this
mixture, 15 mL of 1 M N-acetylcysteine (NAc) in 1 M NaOH were
added, and then the solution was diluted with 435 mL of distilled
water. At xed intervals, 10 mL aliquots were withdrawn from the
reaction mixture and diluted with 40 mL of distilled water: 10 mL
of this solution were derivatized with 25 mL of OPA-NAc reagent,
diluted with 25 mL of HPLC eluent and analyzed by HPLC chro-
matography on a symmetry C8 column (100 A˚, 5 mm, 3.9 mm $
150 mm; Waters, Milano, Italy). Eluent: 50 mM sodium acetate
buffer, pH 5.2/acetonitrile 9/1; isocratic ux ofz 1 mL min!1;
absorbance detection at 340 nm.7 The separation allows to easily
distinguish and quantify L-aspartate from glycine (used as
internal standard) and thus to calculate the bioconversion yield;
Rt (glycine): 10.5 min, Rt (L-aspartate) 4.5 min.
Results and discussion
Optimization of StLASPO conjugation
StLASPO was conjugated to NP-APTES using EDC/NHS reaction
by a two-step process. The scheme of NP activation and enzyme
conjugation is illustrated in Fig. 1. With this two steps reaction,
different conjugations can occur (Fig. 1): an enzyme molecule
could interact with just one NP-APTES (product A), an enzyme
molecule could react with amino groups of different NPs
(product B) and an enzymemolecule could react withmore than
one amino groups of the same NP (product C).19,20
In order to identify the best conditions for the enzyme
conjugation, several factors have been taken into consideration:
EDC : NHS ratio, NPs: enzyme ratio, the presence of FAD (the
enzyme cofactor), substrate or product (Table 1). At each
condition, the immobilization yield and the enzyme activity
bound to NP-APTES were determined.
The concentrations of EDC and NHS have to be carefully
chosen to yield complete activation of the binding sites and, at the
Fig. 1 Synthetic route for StLASPO conjugation on Fe3O4NPs (not in scale). The protein structure corresponds to PDB code 2E5V. (1) Func-
tionalization of Fe3O4NPs with APTES; (2) conjugation of StLASPO through covalent linkage via EDC/NHS. The enzyme can interact with just one
NP-APTES (product A) or with amino groups of different NPs (product B) or with more than one amino groups of the same NP (product C).
21138 | RSC Adv., 2017, 7, 21136–21143 This journal is © The Royal Society of Chemistry 2017
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same time, to prevent formation of unwanted surface by-prod-
ucts,21 such as the N acetyl-substituted, derivative of the unstable
intermediate of the EDC. Indeed, during the reaction in aqueous
solution, O-acetyl urea is formed and, if it fails to react with an
amine, undergoes to hydrolysis.22 Furthermore, an excess of EDC
may promote unwanted polymerization due to the abundance of
both amines and carboxylates on protein molecules leading to
a protein-to-protein cross-linking.20 There is also the risk that the
NHS esters formed on the protein molecule may then couple to
other protein molecules to give poorly dened polymers.23 As
a general rule, the amount of StLASPO activity bound to the NPs
increases at higher EDC : NHS ratios (reaching the maximum at
a 5 : 1 value) and using increasing NP-APTES amounts.
The presence of FAD signicantly increases both the units
and the amount of the enzyme bound to NPs at low (1 : 2)
EDC : NHS ratio. The positive effect of the avin cofactor is less
evident at higher EDC : NHS ratios (e.g., its presence resulted in
a 1.3 fold increase in immobilized StLASPO activity at 5 : 1
EDC : NHS ratio and using 4 mg of NP-APTES).
Similarly, the substrate L-aspartate also positively affects
StLASPO immobilization in an active form, while the product
analogue succinate does not. Notably, the use of the FAD and L-
aspartate together results in an enzyme conformational change
that does not favor its immobilization.
Under the best experimental conditions – i.e. 16 mg of NP-
APTES in 5 mM sodium pyrophosphate buffer, pH 8.5, 65 mM
EDC, 13 mM NHS, 200 mg of enzyme, nal volume 2 mL – the
amount of enzyme bound to NPs was approximately 100%, with
an enzymatic activity of 0.026 Umg!1 of NPs and a relative activity
of 15% (Table 1). Relative activity values strongly depend on the
enzyme and the conditions used. Indeed, relative activities
ranging from less than 10% to more than 80% in relation to the
diameter of the NP, its functionalization and the immobilized
enzyme are reported in the literature.24–26 Furthermore, the
reduction of relative activity might be due also to the chemistry of
EDC/NHS conjugation that determines non-specic bindings
between NP-APTES and the enzymemolecules. Actually, when the
covalent bonds are formed close to the active site, an activity loss
due to conformational changes can occur.27,28 Under the best
conjugation conditions, the specic activity of the immobilized
enzyme for the L-aspartate is 0.43 U mg of enzyme (Table 1),
comparable to the specic activity of the free enzyme. As for the
Table 1 Conditions for StLASPO conjugation to Fe3O4NPs. StLASPO was used at concentration of 100 mg mL
!1; EDC : NHS molar ratios are
reported in the second columna,b,c
NP-APTES (mg) EDC : NHS ratio Other components Vf (mL) Yield (%) Relative activity (%)
Specic activity
(U mg!1 enzyme)
4 1 : 2 — 1 75 4 0.32
4 1 : 2 FAD 1 100 14 0.43
4 1 : 2 L-Aspartate 1 100 15 0.43
4 1 : 2 Succinate 1 77 5 0.33
4 1 : 2 L-Aspartate + FAD 1 86 5 0.37
4 1 : 2 Succinate + FAD 1 77 7 0.33
8 1 : 2 — 2 84 4 0.36
8 1 : 2 FAD 2 100 15 0.43
8 1 : 2 L-Aspartate 2 100 12 0.43
8 1 : 2 Succinate 2 92 5 0.40
8 1 : 2 L-Aspartate + FAD 2 85 6 0.37
8 1 : 2 Succinate + FAD 2 88 7 0.38
8 1 : 1 — 2 91 8 0.39
8 1 : 2 — 2 84 4 0.36
8 2 : 1 — 2 85 8 0.37
8 2 : 2 — 2 88 9 0.38
8 2 : 3 — 2 75 10 0.32
8 3 : 2 — 2 74 10 0.32
8 5 : 1 — 2 67 13 0.29
8 5 : 5 — 2 79 8 0.34
8 10 : 1 — 2 86 11 0.37
8 10 : 5 — 2 80 8 0.34
4 5 : 1 — 2 39 6 0.17
8 5 : 1 — 2 95 11 0.41
16 5 : 1 — 2 100 15 0.43
24 5 : 1 — 2 100 12 0.43
4 5 : 1 FAD 2 37 8 0.16
8 5 : 1 FAD 2 52 10 0.22
16 5 : 1 FAD 2 94 10 0.41
24 5 : 1 FAD 2 95 12 0.41
a Reaction conditions: during StLASPO conjugation, 100 mMFAD 1mM L-aspartate and/or 200 mM succinate were added. b Yield has been calculated
from units present in the supernatant of the immobilization reaction relatively to the total units. c Relative activity is reported as the ratio between
the activity assayed for the NP-LASPO and the activity of the free enzyme.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 21136–21143 | 21139
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relative activity, specic activity depends on the enzyme and the
conditions of the immobilization process. Therefore, the conju-
gation can affect also the specic activity.29–31
NP-LASPO properties
TEM images indicate that Fe3O4NPs and NP-APTES show
a spherical shape, with an average diameter of 14.6 & 3.8 nm
and 17.2 & 3.2 nm respectively, and with a good dispersion
(Fig. 2A and B). On the other end, NP-LASPO show the tendency
to aggregate and a more irregular shape, with an average
diameter of 38.0 & 9.8 nm (Fig. 2C). This slight tendency to
aggregation can be explained by the possibility that several
carboxylic groups located on the enzyme surface may react with
the amine groups of different NP-APTES causing a cross-linking
leading to aggregation.32 However, this phenomenon is not
massive since no NPs precipitation was apparent.
The immobilized NP-LASPO maintains the absolute stereo-
selectivity of the free enzyme, i.e., the D-isomer of L-aspartate
is not oxidized. The addition of exogenous, free FAD positively
affect the activity of NP-LASPO: a 2-fold increase in the activity
of the enzyme immobilized on the NPs was obtained in the
presence of a large excess of exogenous cofactor in the HRP-
coupled assay mixture, this indicating that half of StLASPO is
immobilized in the apoprotein, inactive form.
To investigate the storage stability, the NP-LASPO system was
stored in 5 mM sodium pyrophosphate buffer (pH 8.5) at 25 "C:
70% of the initial activity was maintained aer 35 days.
The effect of pH on the catalytic activity of NP-LASPO was
investigated in the 8.0 to 11.0 range, by following the disap-
pearance of the L-aspartate peak by HPLC separation (Fig. 3).
Fig. 4, panel A le, displays the activity curves of the enzyme at
different pH values. At pH 9, 10 and 11 the complete oxidation of L-
aspartate is observed in 3 hours, while at pH 8 the reaction stops to
approximately 90% of conversion. When compared to the free
enzyme form, the immobilized enzyme shows a full stability at pH
values 9–11 aer 60 min of incubation, while for the free StLASPO
the stability strongly decreases at pH > 8 (Fig. 4A, right). Similarly,
earlier studies demonstrated that immobilized enzymes are
frequently more stable than free enzymes in an alkaline
environment.24,29
The effect of temperature on the catalytic activity of conju-
gated StLASPO was investigated in the 25–80 "C range (Fig. 4B).
The NP-enzyme system shows a good activity in the range of 60–
80 "C: the fastest L-aspartate oxidative deamination is apparent at
70 "C. Only at #37 "C a partial conversion of the 50 mM L-
aspartate solution was obtained aer 420 min. Fig. 4B right
shows that the thermostability of NP-LASPO aer 30 min of
incubation parallel the behavior observed for the free enzyme.
The catalytic parameters of StLASPO immobilized on the Fe3-
O4NPs were determined by a HRP-coupled spectrophotometric
assay at pH 10.0 at 25 "C. The apparent Vmax at air oxygen-
saturation for the NP-LASPO system is 0.11 mmol per min
Fig. 2 Transmission electron microscopy (TEM) and size distribution of Fe3O4NPs (A and D), NP-APTES (B and E), NP-LASPO (C and F). Bars in
panel A–C indicate 100 nm.
Fig. 3 HPLC separation of L-Asp solution during oxidation by NP-
LASPO. Conditions: 50 mL of 50mM L-aspartate inmilliQwater, pH 9.0,
added of 8 mg of NP-LASPO (0.10 U) and incubated at 70 "C. (—)
before NP-LASPO addition; (-.-) 30 and (/) 60 min after NP-LASPO
addition. Glycine, Rt 10.5 min, was used as internal standard.
21140 | RSC Adv., 2017, 7, 21136–21143 This journal is © The Royal Society of Chemistry 2017
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per mg of protein and Km for L-aspartate is 4.3 mM. The corre-
sponding values for the free enzyme form are 0.98 mmol per min
permg enzyme and 1.3mM at pH 8.0 and 37 "C.4 The higher Km of
NP-LASPO suggests a lower affinity for L-aspartate by the immo-
bilized enzyme so a higher substrate concentration is needed to
achieve a given enzyme activity. Diffusional limitations and steric
effects may contribute to the increased apparent Km value due to
a decrease in the accessibility of substrate to the enzyme active site.
Similar effects are frequently reported for enzyme immobilized
with EDC/NHS protocol, e.g., Tee and colleagues33 suggest that the
high loading of the enzyme molecules using a zero-length cross-
linker might restrict the access of the substrate to the active sites.
Bioconversion by NP-LASPO
The enzyme immobilization on magnetic NPs allows a simple
recovery of the biocatalyst and its reuse, making this system
interesting for industrial applications. To determine the
number of reaction cycles that immobilized StLASPO can carry
out, the same batch of enzyme was reused for subsequent
cycles. Full oxidative deamination of 50 mL of 50 mM L-aspartate
was obtained in 240 min using optimal operational conditions,
i.e., at pH 10, 50 "C and using 0.2 U of the NP-enzyme system.
Under these conditions, a full conversion was observed for three
sequential cycles, while a longer reaction time was required for
the following cycles (Fig. 5): aer 420 min of reaction, #70% of
the substrate was converted in the h and sixth cycle. Notably,
under optimized conditions, the Relizyme-StLASPO fully con-
verted 25 mM L-aspartate for three sequential cycles of 4 hours
Fig. 4 (A) Left: effect of pH on the time course of oxidation of L-aspartate. Conditions: 50 mL of 50 mM L-aspartate, 0.10 U of NP-LASPO, 70 "C.
Right: comparison of residual activity after 60 min of incubation as function of pH for free StLASPO (open symbols) and NP-LASPO (filled
symbols). Data are expressed as percentage of the activity values measured at the beginning of the reaction. (B) Left: effect of temperature on the
time course of oxidative deamination of L-aspartate. Conditions: 50 mL of 50 mM L-aspartate at pH 10.0, 0.208 U of NP-LASPO. Right:
comparison of residual activity after 30 min of incubation as function of pH for free StLASPO (open symbols) and NP-LASPO (filled symbols). The
value at 37 "C was set as 100%. The values are the average of at least three measurements; bars represent standard error.
Fig. 5 Dependence of NP-LASPO activity at 50 "C and pH 10 on
recycling. Conditions: 50 mL of 50 mM L-aspartate, 0.20 U of NP-
LASPO, 50 "C and pH 10. The values are the average of at least three
measurements; bars represent standard errors.
This journal is © The Royal Society of Chemistry 2017 RSC Adv., 2017, 7, 21136–21143 | 21141
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onlyd,7 pointing to partial inactivation of the immobilized a-
voenzyme. Taking into consideration the four cycles that
resulted in full L-aspartate oxidation, 50 mmoles of substrate
were converted per unit of NP-LASPO. As compared to the free
enzyme form, which fully converted 30 mL of 25 mM L-aspartate
in 24 h by using 9 U of StLASPO4 corresponding to 3.5 mmoles
per h per unit, the NP-LASPO converted 3.1 mmole per h per unit
at pH 10.0 and 50 "C. Indeed, the Relizyme-StLASPO – using 10
mL of 100 mM D,L-Asp, at pH 10.0 and 70 "C – converted 1
mmoles per h per unit (or #4.4 mmoles per h per unit using 0.5
mL of 142 mM D,L-Asp).7
Conclusions
In this work, the stereo-selective avoenzyme L-aspartate
oxidase from the thermophilic archaea Sulfolobus tokodaii has
been covalently immobilized on Fe3O4NPs using EDC and NHS
as cross-linking agents. The optimal conditions for the enzyme
immobilization were identied by investigating the interaction
effect of different variables.
The NP-LASPO showed a better stability than the free enzyme
at pH $ 9.0 and was reused ve times reaching full L-aspartate
conversion, similarly to that previously obtained for the
Relizyme-StLASPO preparation which employed a 2.5-fold
higher amount of enzyme and longer times.7 L-Aspartate
conversion by NP-LASPO yielded a productivity similar to that
obtained using the free enzyme (that cannot be recycled) or the
enzyme bound to the amino support Relizyme™HA403/S R (3.1
vs. 1–4 mmol per h per unit of enzyme at 50 mM L-aspartate
concentration). These results indicate that the prepared NPs are
favorable for immobilization of LASPO and the immobilized
enzyme has promising industrial applications.
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Abstract: As the knowledge about the interferences of nanomaterials on human staminal cells are
scarce and contradictory, we undertook a comparative multidisciplinary study based on the size
effect of zero-valent iron, cobalt, and nickel microparticles (MPs) and nanoparticles (NPs) using
human adipose stem cells (hASCs) as a model, and evaluating cytotoxicity, morphology, cellular
uptake, and gene expression. Our results suggested that the medium did not influence the cell
sensitivity but, surprisingly, the iron microparticles (FeMPs) resulted in being toxic. These data were
supported by modifications in mRNA expression of some genes implicated in the inflammatory
response. Microscopic analysis confirmed that NPs, mainly internalized by endocytosis, persist
in the vesicles without any apparent cell damage. Conversely, MPs are not internalized, and the
effects on hASCs have to be ascribed to the release of ions in the culture medium, or to the reduced
oxygen and nutrient exchange efficiency due to the presence of MP agglomerating around the cells.
Notwithstanding the results depicting a heterogeneous scene that does not allow drawing a general
conclusion, this work reiterates the importance of comparative investigations on MPs, NPs, and
corresponding ions, and the need to continue the thorough verification of NP and MP innocuousness
to ensure unaffected stem cell physiology and differentiation.
Keywords: cytotoxicity; cellular uptake; cell morphology; gene expression; adipose stem cells
1. Introduction
It is well known that many human tissues, including skin, liver, muscle, pancreas, lung, adipose
tissue, placenta, bone marrow, peripheral blood, as well as neural tissue, contain an undifferentiated cell
population facilitating tissue repair and remodelling over the course of a lifetime [1,2]. The research
on adult stem cells (SCs) began in the 1950s when researchers discovered that the bone marrow
contained at least two kinds of SCs: hematopoietic and mesenchymal stem cells. In recent years,
there has been a considerable increase in the comprehension of SC biology for their involvement in
maintaining the homeostasis of healthy tissues or in tumour formation and proliferation. Furthermore,
SCs have shown great potential in many medical applications, such as regenerative medicine, bone
marrow transplantation, orthopaedic injuries, autoimmune diseases, and cardiovascular and liver
diseases [3–5]. It is, therefore, evident how dangerous it could be to perturb SC homeostasis acting
Nanomaterials 2017, 7, 212; doi:10.3390/nano7080212 www.mdpi.com/journal/nanomaterials
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on their turnover, which may lead to SC depletion that, in turn, is responsible for pathological
consequences [6]. In this scenario, a circumstance that has also to be taken into account is the
exponential growth that nanotechnology has had in this last decade in several areas, including medical
biotechnology within which the theranostics plays an important role. Theranostics is a discipline that
combines diagnostic and therapeutic properties in the same compound [7]; this concept refers to the
optimization of medical nanotechnologies, which are in search of the ideal system, able to recognize
and target, in a peculiar way, the area of interest to promote an efficient site-directed action and
provide accurate imaging for diagnostic follow-up. In this context, magnetic nanoparticles (NPs) with
intrinsic theranostic characteristics can give an optimal solution [8–11]. Considering this overview,
it is easy to imagine that the human body is easily exposed to the possibility of coming into contact,
intentionally or not, with NPs that may enter the body, encounter SCs of different tissues, then act
on them perturbing their physiology. Consequently, SCs might represent a possible weak point, and
their susceptibility to NPs should be carefully evaluated. Moreover, appropriate assessment of the
biological effects of NPs is particularly arduous as their in vitro and in vivo behaviours depend on
several factors, including composition, shape, size, dosage, and route of exposure [12–14]. Although
Ni represents a well-known problem for allergy and dermatitis [15], Fe, Co, and Ni are very promising
for nanotechnological applications. In nanomedicine, for instance, iron and cobalt in particular, find
applications as highly-sensitive contrast agents in magnetic resonance imaging (as an alternative
to radionuclides), vectors for drug delivery, and theranostics, combining imaging analysis and
hyperthermia therapy [8,10,16–18]. Moreover, we think that SCs, due to their higher sensitivity
to the xenobiotic compounds, will play an increasingly important role in in vitro cell based tests for
developmental toxicology studies, as well as target organ toxicity [6].
For all these reasons, and with the purpose to face some of these aspects, we have planned
to study the behaviour of microparticles (MPs) and NPs of iron (Fe), cobalt (Co), and nickel (Ni),
three transition metals of the group 8 of the periodic table, on SCs. In this paper, we reported our
findings on cytotoxicity, morphology, cellular uptake, and gene expression of human adipose-derived
mesenchymal stem cells (hASCs) exposed to zero-valent metal MPs, NPs, or salts.
2. Results
2.1. Micro- and Nanoparticle Characterization
The MPs and NPs used in this research were analysed by microscopy (Figure 1). Scanning electron
microscopy images (SEM) observations displayed MPs with different sizes, irregular round shapes,
and a strong tendency to cluster in aggregates. The MPs showed an average diameter of 6 µm ± 1.5;
0.8 µm ± 0.15 and 4 µm ± 0.5 for Fe, Co, and Ni, respectively, confirming the label information
(Figure 1a–c). Transmission electron microscopy (TEM) analysis of NPs showed particles of different
shape whose size is between 10 and 50 nm (Figure 1d–f).
2.2. Cell Viability
Figure 2 indicates cytotoxicity induced by Fe, Co, and Ni MPs, NPs, and ions evaluated measuring
cellular adenosine triphosphate (ATP) content after 96 h exposure of hASCs maintained in CHANG
MEDIUM® C or Dulbecco’s Modified Eagle Medium/Dulbecco’s Modified Eagle Medium Nutrient
Mixture F12 (DMEM/DMEM-F12) to be sure that the cell toxicity was due only to the MPs, NPs,
and ions exposure and not influenced by the cell culture medium. The response was, in most
cases, concentration-dependent, and no differences were evidenced between the two culture media.
As expected, the effects were significantly different among the three metals. The most striking data
are those referred to Fe and Ni MPs (Figure 2a,c) which evidenced a high toxicity for Fe MPs and
no effect for Ni MPs compared to the other two formulations. Conversely, Co MPs, NPs, and CoCl2
elicited a dose-dependent response similar in all the three formulations (Figure 2b). In addition, NiNPs
exposure showed a cell toxicity comparable to that of CoNPs.
Nanomaterials 2017, 7, 212 3 of 14
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Figure 1. Scanning electron microscopy images of metal microparticles deposited on a glass 
coverslip: Fe ( ), Co ( and Ni ( ) and transmission electron microscopy images of metal 
nanoparticles deposited on formvar carbon-coated grids: Fe ( ), Co ( ), and Ni ( ). Certain 
heterogeneity in the size and shape is observed for all the particles. 
2.2. Cell Viability 
Figure 2 indicates cytotoxicity induced by Fe, Co, and Ni MPs, NPs, and ions evaluated 
measuring cellular adenosine triphosphate (ATP) content after 96 h exposure of hASCs maintained 
in CHANG MEDIUM  C or Dulbecco’s Modified Eagle Medium/Dulbecco’s Modified Eagle 
Medium Nutrient Mixture F12 (DMEM/DMEM-F12) to be sure that the cell toxicity was due only to 
the MPs, NPs, and ions exposure and not influenced by the cell culture medium. The response was, 
in most cases, concentration-dependent, and no differences were evidenced between the two culture 
media. As expected, the effects were significantly different among the three metals. The most 
striking data are those referred to Fe and Ni MPs (Figure 2a,c) which evidenced a high toxicity for Fe 
MPs and no effect for Ni MPs compared to the other two formulations. Conversely, Co MPs, NPs, 
and CoCl  elicited a dose-dependent response similar in all the three formulations (Figure 2b). In 
addition, NiNPs exposure showed a cell toxicity comparable to that of CoNPs. 
i re 1. Scan i g electron microsc py images of metal icroparticles deposited on a glass coverslip:
Fe (a), Co (b), and Ni (c) and transmission electron microscopy images of metal nanoparticles deposited
on formvar carbon-coated grids: Fe (d), Co (e), and Ni (f). Certain heterogeneity in the size and shape
is observed for all the particles.
, 212 4 of 15Nanomaterials 2017, , 121  4 of 15 
Figure 2. Percentage of ATP content, normalized to control, in hASCs exposed to Fe, ( ), Co ( ), and 
Ni ( ), microparticles (MPs), nanoparticles (NPs), or salt for 96 h. Bars represent standard errors.  
* Dunnett’s test,  < 0.05. Each plotted value is the mean of three independent experiments. 
2.3. Cellular Uptake and Morphology 
Figure 3 shows the cellular uptake of MPs and NPs evaluated by optical microscopy after 24 h 
of exposure. Although Fe, Co, and Ni MPs appear different in shape and size, none of them 
appeared to enter the cells (Figure 3a,c,e). Conversely, several Fe, Co, and Ni NPs seemed to be 
inside the cells (Figure 3b,d,f). Cell appears to maintain the classical fibroblast-like morphology 
characteristic of unexposed hASCs [4]. 
2. of ATP content, normalized to control, in hASCs exposed to Fe, ( ), Co ( ), and
Ni ( ), microparticles (MPs), nanoparticles (NPs), or salt for 96 h. Bars represent standard errors.
* Dunnett’s test, < 0.05. Each plotted value is the mean of three independent experiments.
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2.3. Cellular Uptake and Morphology
Figure 3 shows the cellular uptake of Ps and NPs evaluated by optical microscopy after 24 h of
exposure. Although Fe, Co, and Ni MPs appear different in shape and size, none of them appeared
to ent r the cells (Figure 3a,c,e). Conversely, several Fe, Co, and Ni NPs seemed to be inside the
cells (Figur 3b,d,f). Cell appears to m intain the classic l fibrob t-like morphology characteristic of
unexposed hASCs [4].
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Figure 3. Optical microscopy photographs of hASCs exposed for 24 h to micro and nanoparticles and 
stained with haematoxylin-eosin solution. Micro- and nanoparticles are visible as black corpuscles. 
FeMPs ( ), FeNPs ( ), CoMPs ( ), CoNPs ( ), NiMPs ( ), and NiNPs ( ). All cells maintain the 
classical fibroblast-like morphology. Original magnification: 20×. Bar indicates 40 µm. 
TEM analysis, reported in Figure 4, confirmed the optical microscopy observations. Both MPs 
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identified as high electron density material as NPs preserve the morphology observed in the cell-free 
environment (Figure 1). The cell membrane is characterized by pronounced pseudopodia-like 
Figure 3. Optical microscopy photographs of hASCs exp sed for 24 h to micr and nanoparticles and
stained with haematoxylin-eosin solution. Micro- and nanoparticles are visible as black corpuscles.
FeMPs (a), FeNPs (b), CoMPs (c), CoNPs (d), NiMPs (e), and NiNPs (f). All cells maintain the classical
fibroblast-like morphology. Original magnification: 20×. Bar indicates 40 µm.
TEM analysis, rep rted in Fig re 4, confirm d the optical microscopy ob erva ions. Both MPs and
NPs, at the concentration and exposure time used in these experiments, provoked some ultrastructural
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modifications, but no severe cellular damage. The cell body was rounded and the nucleus was large,
indented, and eccentric, with abundant euchromatin and a prominent nucleolus (not shown in these
pictures). Even though we have not observed NPs inside the nucleus, nor in the mitochondria, we
cannot exclude their internalization in these compartments. Ultrastructural analysis seemed to also
exclude rough endoplasmic reticulum (RER) and Golgi apparatus involvement compared to unexposed
cells. Vesicles and lysosomes of different size, containing low electron-dense material, were present
in the cytoplasm (Figure 3b,d). These characteristics suggested that exposed hASCs maintained the
typical characteristics [19]. However, it is clear that NPs were massively internalized as agglomerations,
mainly by endocytic mechanisms (Figure 4b,d,f). Once internalized, most of the NPs remained inside the
cytoplasmic vesicles which may also contain amorphous cellular material (Figure 4b,d). No differences
were observed among the three considered NPs and the internalization appeared to be nonspecific.
In these pictures, NPs are identified as high electron density material as NPs preserve the morphology
observed in the cell-free environment (Figure 1). The cell membrane is characterized by pronounced
pseudopodia-like protrusions, especially in MPs exposed cells that also show several empty vacuoles
(Figure 4a–c). These findings represent the typical alterations of an early apoptotic state.
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Figure 4. Transmission electron microscopy images of typical hASCs exposed for 24 h to FeMPs
(a), FeNPs (b), C MPs (c), CoNPs (d), NiMPs (e), an NiNPs (f). NPs were identified as
high-electron-density objects when inside the cell and localized inside the vesicles (black arrows).
No differences were observed among the three considered NPs and the internalization appeared to
be nonspecific. White arrows indicate lysosomes of different sizes containing amorphous material.
Several pronounced pseudopodia-like protrusions (*) are present both in NP- and in MP-exposed cells.
Nuclei and mitochondria do not contain NPs. Arrowheads indicate lipid droplets.
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Conversely, these cells seemed unable to internalize the MPs (Figure 4a,c,e). TEM observations
were supported by SEM analysis. In particular, important information was obtained by using secondary
electrons (SE) (Figure 5a,c,e) and backscattered electrons (BSE) (Figure 5b,d,f). Figure 5b,d,f show
micrographs of cells covered with large electron-dense materials (bright spots) confirming that all the
MPs resided around and not inside the cells.Nanomaterials 2017, , 121  7 of 15 
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Figure 5. Scanning electron micrographs of typical hASCs exposed for 24 h to FeMPs (a,b), CoMPs
(c,d), and NiMPs (e,f). The same field of view is shown with secondary electron (SE, left) and
backscattered electron (BSE, right) imaging. In BSE imaging, the clusters of metal microparticles
appear as bright spots.
2.4. Gene Expression
The genes considered in this research are those implicated in some cell processes, such as oxidative
stress, apoptosis, inflammatory response, neovascularization, tissue regeneration, and internalization.
In Figure 6 we have reported only the results of those genes whose expression was significantly
changed. As reported in Figure 6a, Fe MPs induced upregulation of vascular endothelial growth factor
A (VEGFA), interleukin 8 (IL8), interleukin 1b (IL1b), and a downregulation of superoxide dismutase
1 (SOD) after 96 h of exposure. Although not statistically significant, iron, in all its formulation,
induced the expression of adaptor-related protein complex 2 alpha 1 subunit (AP2A1). Figure 6b
shows an upregulation of IL1b and B-cell lymphoma 2 (BCL2) genes after 24 h of Fe NP exposure.
Surprisingly, cobalt caused only the downregulation of interleukin 6 (IL6) expression after 96 h of
exposure (Figure 6c).
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Figure 6. Real-time PCR of the most significant gene expression modifications. VEGF, IL8, IL1b, SOD
and AP2A1 in cells exposed for 96h to Fe MPs, NPs and ion (a). IL1b and BCL2 in cells exposed for 24 h
to Fe MPs, NPs and ion (b). IL6 in cells exposed for 96h to Co MPs, NPs and ion (c). Normalization
has been done with at least three housekeeping genes. The mRNA expression is reported as the fold
change compared to the unexposed cells whose expression has been fixed at one. * Dunnett’s test,
p < 0.05. Each plotted value is the mean of three independent samples.
3. Discussion
Differences in the toxicological characteristic of nanosized and non-nanosized particles have been
extensively studied for titanium dioxide particles [20,21]. Conversely, formulations, based on iron,
cobalt, and ni kel, w ich als have several applications that have not received th same attention.
Furthermore, notwithstanding the ncreasing literature on nanotoxicity, still scarce and contradictory
a e the papers that deal with possible interfer nces of nanomaterials on SCs. Som authors did not
find any infl ence of NPs on SC viability/proliferation and differentiation [22–25]; other researchers
have instead observed m rked effects [26–28]. In th s paper, we have faced a compar tive study based
on size–effect of commercially zerovalent iron, cobalt, and nickel MPs a d NPs using the hASCs as a
model. Th re ar everal factors that intervene to maintain the SC microenv ronment hic are critical:
oxygen tension, hormon s, growth factors, cytokin s, nutrients and ext acellular m trix; this is why we
first evaluated cell viability of hASCs maintained in two different culture media. Our results suggested
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that, in our experimental conditions, the medium did not influence the behaviour of the exposed
hASCs. Even though our experiments confirmed the previous results on cell viability for the NP
formulation whose cytotoxicity ranking was CoNPs > NiNPs > FeNPs, conversely, hASCs appeared
more sensitive to NP exposure. As cytotoxicity could be ascribed to metal dissolution in growth media
during exposure, cobalt, which easily releases ions when placed in aqueous systems, displayed the
same effect for the three formulations [14]. Unforeseen was the high cytotoxicity shown by FeMPs, and
this behaviour was supported by our results on gene expression but, to our knowledge, not from the
literature [29,30]. The NiMPs, often used as electrodes catalysts or components of catalytic converters,
resulted in a lack of toxicity [31,32]. The Ni ion is introduced with the diet and it is a component
of some enzymes of our body; as in the culture medium, NiNPs release less than 10% as Ni2+ [14],
a low toxicity would be expected . On the contrary, as also reported by Ahamed [33], our results
showed that both NiNPs and Ni ions exert significant effects on hASCs. To note, the medium does not
influence cytotoxicity.
Our investigations, conducted by TEM, confirm that zero-valent metal NPs are mainly internalized
by endocytosis and persist in the cytoplasm inside vesicles [34,35]. These results are also supported by
our previous paper in which we have proved that cobalt oxide NPs, but not zero-valent cobalt NPs,
can cross the plasma membrane [36]. Conversely, SEM analysis proved that MPs are not internalized;
consequently, any effects on hASCs have to be ascribed to the release of ions in the culture medium,
or to the reduced oxygen and nutrients exchange efficiency, due to the presence of MP agglomerate
around the cells. As assessed with various in vitro assays, exposed cells can die by apoptosis and/or
necrosis, phenomena that depend on the concentration, chemical nature, and size of metal NPs [37].
At low toxic doses, however, metal NPs can induce pro-inflammatory effects. The literature reports
that macrophages exposed to AgNP were rapidly induced to secrete IL8 and oxidative stress genes,
such as hemeoxygenase-1 and heat shock protein 70 (Hsp70), in a size-dependent way [38]. Moreover,
the ability to induce the innate immunity, measured as production of IL1b, and the induction of
inflammasomes was higher for small AgNPs and ZiONPs [39].
The gene expression of the exposed hASCs conducted in this research does not appear heavily
influenced nor strictly related to the cytotoxicity dose-response curves or to the size, as well as to
the nature, of the compounds used in this study. The overall picture shows modifications in mRNA
expression of some genes involved in the inflammatory response; the main noteworthy changes are
due to FeMPs after 96 h of exposure that clearly induce IL8, IL1b, and VEGFA. Even though not
statistically significant and independently to the size, iron raises the mRNA expression of AP2A1,
a protein involved in clathrin-dependent endocytosis; consequently, its induction may be related
to an increase in NP endocytosis [40]. CoMPs and CoNPs, after 96 h of exposure, influenced IL6,
a multifunctional cytokine [41] that, together with VEGFA, it is known to be a putative paracrine factor
secreted by hASCs and involved in cytoprotection, proliferation, and angiogenesis [42]. None of the
formulations used affected stress-related genes (catalase, CAT; SOD, metallothionein 1A, MT1A; Hsp70)
even though their main function is to protect cells from various injuries, such as elevated temperature,
mechanical damage, hypoxia, and reactive oxygen species [14]. Lastly, the genes related to apoptosis
(tumour protein 53, P53; caspase 3, CASP3; early growth response protein 1, EGR1; BCL2) are not
influenced by the treatment; the only exception was the increase of BCL2, a protein that blocks the
programmed cell death and apoptosis pathway, after 24 h exposure to FeNPs.
It is known that each cell line has its own sensitivity to NP and MP exposure and, notwithstanding
the multidisciplinary approach adopted in this research, the results depict a heterogeneous scene
with regard to the interactions of nanoparticles, microparticles, and salts with hASCs. In this context,
is difficult to depict a general conclusion. Nevertheless, it is rather clear that parameters such as
chemistry, shape, and size sometimes greatly affect the behaviour of hASCs, but do not alter their
natural differentiation time. Probably, MPs lead cells to an apoptotic state due more to the presence
of agglomerates around the cells, than to their composition. This work reiterates the importance of
comparative investigations on MPs, NPs, and the respective ions to avoid experimental artefacts in
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the evaluation of nanotoxicity. Furthermore, we think that it is necessary to stress the adoption of in
silico toxicology methods to conceive informative models on the in vitro and in vivo effects. Therefore,
it will be indispensable to continue the thorough control of NPs’ and MPs’ innocuousness to ensure
that they do not perturb SC homeostasis acting on their physiology, differentiation, and turnover that
may lead to SC depletion that, in turn, is responsible for pathological consequences.
4. Materials and Methods
All subjects gave their informed consent for inclusion before they participated in the study.
The study was conducted in accordance with the Declaration of Helsinki, and the protocol was
approved by the Ethics Committee of University of Insubria, Varese.
4.1. Micro- and Nanoparticle Characterizations
MPs were purchased from American Elements (Los Angeles, CA, USA) with the following
characteristics: FeMPs (purity 99.9%, aerodynamic particle size < 10 µm), CoMPs (purity 99.8%,
aerodynamic particle size < 2 µm), and NiMPs (purity 99.9%, aerodynamic particle size < 5 µm). NPs
were purchased from IOLITEC (Heilbronn, Germany) with the following characteristics: FeNPs (purity
99.9%, aerodynamic particle size < 25 nm), CoNPs (purity 99.8%, aerodynamic particle size < 28 nm)
and NiNPs (purity 99.8%, aerodynamic particle size < 20 nm).
For MP characterization, 5 µL of a diluted ethanol suspension were deposited on a glass coverslip
and analysed by SEM (FEI XL-30 FEG, Eindhoven, The Netherlands) operated at an acceleration
voltage of 7 kV. Conversely, 5 µL of a diluted ethanol suspension of NPs were deposited on a
formvar carbon-coated copper grid and observed by TEM microscope (Morgagni, Philips, Eindhoven,
The Netherlands) operating at 80 kV [14].
4.2. Patient Samples
hASCs were isolated from mammary adipose tissue, obtained from five healthy women (average
age 43 ± 4) who underwent surgery for gigantomasty at the “Ospedale di Circolo”, Varese, Italy.
All patients were in good health who have not undergone to heavy weight loss diet, their body mass
index (BMI) was from 18.8 to 29 kg/m2 (mean 24.58 ± 5.24 kg/m2), non-smokers, without a history of
metabolic disorders, and not receiving medications at the time of surgery. Gigantomastia allowed us
to obtain large amounts of adipose tissue from the same depot. Furthermore, the severe selection of
the patients guaranteed adipose tissue of good quality and rich in hASCs.
4.3. hASC Isolation and Culture
The stromal cellular fraction of human mammary adipose tissue, obtained according to Gronthos
and Zannettino protocol [43], was divided in two fractions. Half of these cells were seeded in a flask
with complete 1:1 DMEM/DMEM-F12 medium (Sigma Aldrich, Milan, Italy) containing 10% FBS,
2 mM L-glutamine, 1% penicillin/streptomycin, and 0.1% gentamicin. The remaining fraction of cells
was seeded in CHANG C medium (Irvine Scientific, Santa Ana, CA, USA) supplemented with 2 mM
L-glutamine, 1% penicillin/streptomycin. After 6 h non-attached cells were removed and adherent
stem cells were fed with fresh medium. hASCs were characterized by flow cytometry, as reported in
our previous paper [4]. For all subsequent experiments hASCs were used at passage 5.
4.4. Cell Exposure and Viability
Cell viability was determined measuring ATP content by the CellTiter-Glo® Luminescent Cell
Viability Assay (Promega, Milan, Italy) according to the manufacturer’s instructions and as reported
by Bava et al. [44]. This experiment was conducted in hASCs cultured in DMEM/DMEM-F12 and
CHANG medium. Briefly, 300 cells were seeded into 96-well plates and treated after 24 h. Cells were
exposed for 96 h in increasing concentrations (0, 0.5, 1, 3 µg/200 µL) of Fe, Co, or Ni MPs and NPs
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and their corresponding salts (FeCl3, CoCl2·6H2O, NiCl2). MPs and NPs were resuspended in fresh
culture media and then dispersed by an ultrasonic bath for 15 min before each treatment. The range of
concentrations of each metal has been determined in preliminary experiments. After the exposure,
plates were equilibrated for 30 min at room temperature then the culture medium was replaced by
1:1 phosphate buffered saline (PBS):CellTiter-Glo reagent. Plates were shaken for 2 min and left at
room temperature for 10 min before recording luminescent signals using the Infinite F200 plate reader
(Tecan Group, Männedorf, Switzerland).
4.5. Uptake and Morphology
These experiments were performed in steady state. For optical microscopy 5000 cells were
cultured in DMEM on 24 mm2 coverslip into a six-well culture plates, cultivated at 37 ◦C in 5% CO2
and then exposed to 1.2 µg/200 µL of Fe, Co, or Ni MPs and NPs for 24 h. After the exposure, MPs and
NPs were removed; cells were washed with PBS, fixed for 10 min with methanol at room temperature,
and then stained with haematoxylin-eosin solution according to the standard procedures.
For TEM analysis, 100,000 cells were cultured in a T25 flask, and exposed as above reported. After
the exposure, MPs and NPs were removed; cells were washed with PBS, harvested, fixed, embedded as
previously described [45], and finally observed by a Morgagni electron microscope (Philips, Eindhoven,
The Netherlands) operating at 80 kV. For SEM observation, 1000 cells were cultured on a 24 mm2
coverslip, placed into a six-well culture plates, and treated as above. After the exposure, MPs and
NPs were removed; cells were washed with PBS and fixed in Karnovsky solution (4% formaldehyde,
2% glutaraldehyde, 0.1 M sodium cacodylate, pH 7.2) for 1 h. Samples were then dehydrated with a
series of ethanol (20%, 50%, 70%, 90%, 100%), treated with hexamethyldisilazane (HMDS), mounted
on standard SEM stubs with conductive carbon-based adhesive, and gold-coated in an Emitech K-550
sputter-coater (Emitech Ltd., Ashford, UK) in a controlled argon atmosphere at a pressure of 0.1 mbar.
All observations were carried out on a FEI XL-30 FEG field emission scanning electron microscope
(FEI, Eindhoven, The Netherlands) operated at an acceleration voltage of 7 kV.
4.6. RNA Isolation, Reverse Transcription, and Real-Time PCR
A suitable number of cells (20,000–80,000) were seeded into six-well plates and exposed for 24 or
96 h to Fe, Co, or Ni MPs and NPs (exposure concentration was 1.2 µg/200 µL at 24 h and 0.6/200 µL
at 96 h, referred to a cell ATP reduction of about 60–80%). Exposed and not exposed cells were then
washed twice with PBS and harvested. We have also arranged a set of samples in which cells were
exposed to FeCl3, CoCl2·6H2O, or NiCl2 at a nominal concentration of 6 and 3 µg mL
−1 in terms of
Fe, Co, and Ni. Total RNA was isolated using the Direct-zol RNA Miniprep (Zymo Research, Milan,
Italy) according to the protocol, quantified by the QuantiFluor® RNA System (Promega, Milan, Italy)
and reverse transcribed by iScriptTM cDNA Synthesis Kit (Bio-Rad, Segrate, Italy) according to the
manufacturer’s instructions. The Quantitative Real-Time PCR (qPCR) was performed with iTaq™
Universal SYBR® Green Supermix (Bio-Rad, Segrate, Italy) technology using CFX Connect® Real-Time
PCR Detection System apparatus (Bio-Rad, Segrate, Italy). Specific primers were designed by Beacon
Designer 7® (Bio-Rad, Segrate, Italy) within their own sequence, and on an exon-exon junction (possibly
separated by an intron of at least 1000 bp) in order to prevent genomic DNA amplification. The analysis
was performed on genes involved in oxidative stress (CAT; SOD; MT1A; Hsp70), apoptosis (P53;
CASP3; BCL2; EGR1), inflammatory response (IL6; IL8; IL1b), neovascularization, tissue regeneration
(HIF1α; VEGFA), and internalization (AP2A1), see Table 1 [46–52]. Housekeeping genes (ACTβ: β-actin;
B2M: beta-2-microglobulin; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; RPL13A: ribosomal protein
L13A; RPS18: ribosomal protein S18; PPIA: peptidylprolyl isomerase A) were selected as described in
Palombella et al. [53]. qPCR reaction was set up with 300 nM of each primer and 5 ng of cDNA in
a total volume of 10 µL. The thermocycler program included an initial hot start cycle at 95 ◦C for
3 min followed by 40 amplification cycles consisting of a denaturation step at 95 ◦C for 10 s and an
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annealing-extension phase at 60 ◦C for 30 s. A melt-curve was performed at the end of each run.
Technical triplicates were run for all samples.
Table 1. Primers used in this work. Fw: forward, Rv: reverse.
Gene Name Sequence 5′–3′ Amplicon Leght (bp) NCBI Accession Number
ACTβ
Fw ATGGGTCAGAAGGATTCC
78 NM_001101.3
Rv CTCGATGGGGTACTTCAG
B2M
Fw CTATCCAGCGTACTCCAA
93 NM_004048.2
Rv GAAACCCAGACACATAGC
GAPDH
Fw TTTGGCTACAGCAACAGG
107 NM_001289746.1
Rv GGTCTCTCTCTTCCTCTTG
RPL13A
Fw TATGAGTGAAAGGGAGCC
82 NM_001270491.1
Rv ATGACCAGGTGGAAAGTC
RPS18
Fw GAGGTGGAACGTGTGATC
109 NM_022551.2
Rv GGACCTGGCTGTATTTTC
PPIA
Fw AACCACCAGATCATTCCTT
86 NM_001300981.1
Rv GCGAGAGCACAAAGATTC
MT1A
Fw CTCCTGCAAGAAGAGCTG
87 NM_005946.2
Rv TTCTCTGATGCCCCTTTG
Hsp70
Fw AGGCGGAGAAGTACAAAG
85 NM_005345.5
Rv ATGTTGAAGGCGTAGGAC
CAT
Fw TACCCTCTCATCCCAGTT
85 NM_001752.3
Rv GGTCGAAGGCTATCTGTT
SOD
Fw CAGATGACTTGGGCAAAG
82 NM_000454.4
Rv CCAATTACACCACAAGCC
P53
Fw CCACCATCCACTACAACT
92 NM_000546.5
Rv GGAGTCTTCCAGTGTGAT
CASP3
Fw GAGGCCGACTTCTTGTAT
92 NM_004346.3
Rv CAAAGCGACTGGATGAAC
BCL2
Fw CCTTCTTTGAGTTCGGTG
98 NM_000633.2
Rv CAGGTACTCAGTCATCCA
EGR1
Fw GCAGAAGGACAAGAAAGC
94 NM_001964.2
Rv CGGGTAAGAGGTAGCAAC
HIF1α
Fw CAAGTCCTCAAAGCACAG
75 NM_001530.3
Rv TGGTAGTGGTGGCATTAG
VEGF
Fw GGAGTCCAACATCACCAT
80 NM_001171623.1
Rv GCTGTAGGAAGCTCATCT
IL6
Fw ACTCACCTCTTCAGAACG
113 NM_000600.3
Rv CCTCTTTGCTGCTTTCAC
IL8
Fw GCCAAGGAGTGCTAAAGA
103 NM_000584.3
Rv TGGTCCACTCTCAATCAC
IL1b
Fw CTACGAATCTCCGACCAC
90 NM_000576.2
Rv AACCAGCATCTTCCTCAG
AP2A1
Fw CTGGTGGAATGTCTGGAG
117 NM_014203.2
Rv GATGATGAGGCTGATGGT
4.7. Statistical Analysis
Cytotoxicity results were expressed as mean F ± SE. With respect to qPCR, the comparative
∆∆Ct method was used to present normalized gene expression. All data were analysed with one-way
Analysis of Variance ANOVA (α = 0.05), completed with Dunnett’s test (p < 0.05) in order to determine
which groups (NPs, MPs, ions) were significantly different from control. Statistical significant
differences was fixed at p ≤ 0.05 (*). Each plotted value is the mean of three independent experiments.
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IV. RESULTS AND DISCUSSION 
SYNTHESIS AND FUNCTIONALIZATION 
In the literature, various methods to synthesize IONPs are described, among these 
procedures the chemical co-precipitation of Fe2+ and Fe3+ ions by an alkali such as 
NH4OH, in an aqueous solution is the most commonly used. For these thesis project, 
IONPs were synthetized by a co-precipitation method described in the in the article 
entitled “Synthesis, characterization and programmable toxicity of iron oxide 
nanoparticles conjugated with D-amino acid oxidase” attached at the end of the 
Materials and Methods Chapter. The synthesis lead to the production of NPs with a 
diameter of 9.37 ± 0.5 nm as measured by transmission electron microscopy (Figure 
12, a-d). The co-precipitation method employed is a relatively easy and convenient 
way to synthesize iron oxides as it works at low temperatures (<90°C), with low 
reaction times and with a high production yield and reproducibility29,142.  
To create a platform for biomolecule conjugation, amino-groups were introduced on 
the particles surface by 3-aminopropyltriethoxysilane (APTES) coating. The 
functionalization mechanism is based on the formation of the Fe-O-Si bond between 
the NP and the silane. The general sequence of silanization involves the hydrolysis of 
the trietoxylated groups in trihydroxy groups and, therefore, the polycondensation of 
the hydroxyl groups of the silane with the hydroxyl groups from the NP surface38. 
DLS and ζ potential analysis were used to verify the correct coating of the particles. 
DLS shows that APTES coated NPs (NP-APTES) present a hydrodynamic radius of 
35.5 ± 0.5 nm, double respect to that of uncoated IONPs (Figure 12 e). An higher 
hydrodynamic size of NPs measured by DLS, in comparison with the TEM analysis, 
can be attributed to the formation of extra hydrate layers in aqueous solutions and the 
fact that DLS cannot discriminate between inorganic and organic material143,144. ζ 
potential measurements confirmed the APTES functionalization, indeed, the 
superficial charge of NP-APTES increased up to three-fold respect to that of IONPs, 
i.e., 33.49 ± 0.2 mV versus 11 ± 0.8 mV. This increase can be explained by the 
presence of free positive amine groups of APTES on the NP surface. The amount of 
primary amine groups that were present on NP surface and available for subsequent 
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functionalization were quantified by the Orange II assay136,137. This assay is based on 
the electrostatic interactions between the anionic dye and the protonated amino groups 
in acidic solution. By this assay, it was estimated that each NP-APTES carries an 
average of 22 amino groups on its surface.  
IONPs and NP-APTES were further characterized performing vibrating sample 
magnetometry analysis. The saturated magnetization value of the IONPs and that of 
NP-APTES were 58.7 and 36.4 Am2/kg Fe2O3, respectively. These values are in the 
range of those of the bulk material, for IONPs, while for the NP-APTES are slightly 
low. The coating with APTES reduced the response to the magnetic field. Surface 
coating, on the other hand, does not affect the superparamagnetic behaviour of the 
particles, both IONPs and NP-APTES show indeed a superparamagnetic behaviour 
(Figure 12 f).  
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Another important parameter for IONPs is the specific absorption rate (SAR) that is 
defined as the amount of energy/power absorbed by the sample per mass unit (W/kg). 
For IONPs and NP-APTES, this parameter was analysed under an AMF of 710 kHz 
and 300 Gauss. SAR values confirm the magnetic heating ability of the NPs 
synthetized after the APTES functionalized even if we assist to a decrease in SAR 
value. Indeed, the SAR is 393 ± 9 W/g for IONPs and 242 ± 13 W/g for NP-APTES. 
Figure 12 Characterization of IONPs and NP-APTES.  a, b) TEM micrograph of 
IONPs and NP-APTES, scale bar 50 nm. Size distribution of IONPs (c) and NP-APTES 
(d). e) DLS analysis of IONPs (black) and NP-APTES (red). f) Vibrating magnetometry 
analysis of IONPs (black) and NP-APTES (red).  
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As the coupling reaction of the biomolecules is carried on different pH and ionic 
strength conditions, the colloidal stability of the NP-APTES was studied in a range of 
3 to 12 pH and in the range to 0.01-100 mM NaCl (Figure 13).  
Figure 13. Stability of NP-APTES in different pH medium (a,b) and NaCl concentration 
(c, d). Results a media of three independent measurements. 
No significant stability loss was observed in the 3 to 7 pH range and no significant 
increase in the hydrodynamic diameters is observed in that range. Contrariwise, a 
significant loss of stability occurs at alkaline conditions and at high NaCl 
concentration (≥ 100 mM), indeed it is possible to observe a weak ζ potential.  
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NPS-ENZYME SYSTEMS 
Nanobiocatalysis, as the combination of nanotechnology and biocatalysis, is rapidly 
emerging as a new frontier of biotechnology. Immobilized enzymes have a lot of 
advantages over their soluble counterparts, mainly related to stability, reusability and 
operational processing. Because of their singular properties, such as biocompatibility, 
large and modifiable surface and easy recovery, IONPs facilitate separation of the 
linked enzymes that can be easily obtained, lowering dramatically the costs of 
enzymes, by applying an external magnetic field. 
L-aspartate oxidase 
The FAD-containing enzyme LASPO catalyzes the stereospecific oxidative 
deamination of L-aspartate to oxalacetate, ammonia and hydrogen peroxide. This 
flavoenzyme from the thermophilic archea Sulfolobus tokodaii (LASPO) presents an 
high thermostability and a stable activity in a broad range of pH values that make it 
very attractive for biotechnological applications. LASPO can be used for the 
production of D-aspartate, a molecule employed in the pharmaceutical industry, for 
parenteral nutrition, as food additive and in sweetener manufacturing. Since the 
industrial application of this enzyme is hampered by the high cost per enzymatic unit, 
here are reported different conjugation strategies. 
Optimization of enzyme conjugation 
It is demonstrated that the conjugation of enzymes to NPs has a critical role on their 
activity because of deleterious conformational changes, reduction of flexibility, 
alteration of the hydration shell and blockage or hindering of the active site 145–147. 
Therefore, taking into consideration the L-aspartate oxidase structure, we design 
different conjugation strategies with the aim to obtain different orientations of the 
enzyme on the NPs and to secure enzyme-NP systems with both good conjugation 
yield and high relative activity (Figure 14): 
 
§ Strategy 1 (NP-LASPO1): the enzyme molecules are directly conjugated to 
the amino groups of the NP-APTES through their carboxylate moieties after 
their activation with EDC and NHS using the carbodiimide chemistry. The 
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analysis of LASPO crystalline structure (PDB entry 2E5V), showed the 
presence of a high number of exposed carboxylic groups that were reacted 
with the EDC forming an active O-acylisourea intermediate that could be 
displaced by the nucleophilic attack of the amino groups present on the NP-
APTES surface.  
§ Strategy 2 (NP-LASPO2): enzyme molecules are covalent bound via thiol 
groups from cysteine residues present on their surface. The presence of a 
unique cysteine residue exposed on the LASPO surface ensure the site-
directed attachment of the enzyme through an orientation far from its active 
site. For this strategy, the amino groups of the NPs need to be transformed to 
thiol-reactive groups by modification with sulfosuccinimidyl 4-(N-
maleimidomethyl)cyclohexane-1-carboxylate) (Sulfo-SMCC) and the 
protein need to be reduced.  
§ Strategy 3 (NP-LASPO3): enzyme molecules are covalently bound via their 
amine reactive moieties after the activation of the amine moieties of NP-
APTES with bis(sulfosuccinimidyl)suberate (BS3). Thus, playing with the 
pH reaction, it should ensure  a conjugation through the amino terminal of the 
enzyme, with a specific orientation of the enzyme in which its active site is 
facing the NP surface.  
§ Strategy 4 (NP-LASPO4): enzyme molecules are  bound in an oriented way 
through their histidine tag by coordination with Cu+2. The established bond, 
although non-covalent, is strong as hexa histidine tags show the apparent 
equilibrium dissociation constant in the nM range148. The His-tagged is 
present in the C-terminus of the protein that is placed opposite to the active 
site. Thus, this binding strategy should also render a site-directed orientation 
with the binding site far from the active site of the enzyme. 
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Figure 14. Conjugation chemistry used to functionalize IONPs. On the left, from top to 
bottom, we have schematized the above-described strategies 1) APTES, 2) APTES-sulfo-
SMCC, 3) APTES-BS3, and 4) APTES-NTA-Cu2+. On the right, is reported the three-
dimensional structure of the LASPO and are highlighted the residues involved in each 
conjugation strategy. From top to bottom: carboxylic groups (strategy 1), cysteine (strategy 2), 
amino-groups (strategy 3) and histidine tag (strategy 4). The enzyme structure was taken from 
the Protein Data Bank (PDB) entry 2E5V and visualized using PyMol v2.1. 
To identify the best conditions for the enzyme conjugation for each strategy several 
factors have been taken into consideration: pH of reaction, amount of cross-linker, 
time of reaction.  
It is well known that ionic interaction can occur between NPs and biomolecules 
depending on the pH of reaction media. Thus to better understand the orientation of 
the enzyme after ionic interaction with NP-APTES, a study of the 3D structure was 
carried on in more detail. It is well known that the side of the protein with the higher 
charge residues is the one that will faster react with the NP-APTES via a rapid ionic 
adsorption and that a slower site-directed covalent binding reaction occurs via 
activated amino-groups. Given that, the enzyme charge distribution was studied 
(Figure 15). 
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Figure 15. 3D structure of LASPO showing the positive and negative charge surface 
distribution. The enzyme structure was taken from the Protein Data Bank (PDB) entry 2E5V 
and visualized using PyMol v2.1. Negative and positive charges are displayed in red and blue, 
respectively. (a) graphic representation of interaction plane of the enzyme. (b) Number of 
charged residues per plane of interaction. 
Results underline that the region in which the active site is located (front side) is the 
one with the highest negative charged residues, while the region with the lowest 
negative charge is on the bottom part of the LASPO molecule. Interestingly, the region 
with the active site is also the one with the highest positive charges. Accordingly, the 
region of the enzyme that will react faster is the one in which the active site is present.  
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To confirm the possibility of ionic interactions, further analysis were carried on. An 
analysis of the surface potential of the enzyme was performed using the Adaptive 
Poisson-Boltzmann Solver (APBS). This software is designed to analyze the solvation 
properties of small molecules as well as macro-molecules, such as proteins149. 
The surface potential was calculated at the different pH that were used in the 
conjugation conditions. Figure 16 shows the surface potential (a) and the electrostatic 
potential iso-contours (b), positive and negative charged surface are indicated in blue 
and red, respectively. 
Figure 16 depicts an high concentration of negative charge (red) near the active site, 
were the N-terminus is located in all the condition considered, even though at pH 7 it 
is possible to observe the highest density of negative charges. At pH 8.2, instead, the 
concentration of negative charges are lower, suggesting the possibility of less ionic 
interactions. 
Table 4 reports the results of the best condition for each strategy: it is possible to 
notice that the different coupling strategies led to different relative activities and 
number of conjugated enzyme molecules per NP.  
Figure 16. Analysis of the surface potential of the enzyme. The PDB entry 2E5V was 
selected for this 3D representation. APBS was used to calculate the surface potential and the 
analysis results were visualized using Pymol v2.1. (a) ±10 kT/e electrostatic potential of 
LASPO in PyMOL plotted on the solvent-accessible surface. (b) ±0.6 kT/e electrostatic 
potential isocontours of LASPO in PyMOL. The enzyme molecules are oriented to visualized 
the surface potential in the nearby of the residue used for the conjugation. 
pH 5  pH 7 pH 8.2 pH 8.5 
a) 
b) 
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Table 4. Enzyme-NPs conjugated reaction parameters. 
 
Cross 
linker 
µgenzyme/mgNPs Relative Activity (%)* Active enzyme molecules/NP 
NP-LASPO1 EDC/NHS 7 17 5 
NP-LASPO2 
Sulfo-
SMCC 
25 87 22 
NP-LASPO3 BS3  37 86 17 
NP-LASPO4 NTACu2+  6 25 2 
*Relative activity is the ratio between the activity assayed for the enzyme-conjugated NPs and the 
activity of the free enzyme. 
 
Strategy 1 was the worst one not only in terms of recovered activity after enzyme 
immobilization, but also in number of molecules per NP. Although the concentrations 
of EDC and NHS was carefully chosen to yield complete activation of the binding 
sites and, at the same time, to prevent formation of unwanted surface by-products, the 
low relative activity obtained with this strategy suggest the presence of protein-to-
protein crosslinking due to the abundance of both amines and carboxylates on protein 
molecules150.  
For strategy 2, the NP-APTES were further modified to have thiol-reactive groups 
on the particles surface using Sulfo-SMCC. To evaluate the correct functionalization 
of the NP-APTES, the residual amino groups present on the NP surface were 
quantified using Orange II assay: the number of amino-group per mg of NPs decreased 
from 15 to 11 nmol. Results indicate a reduction of the amino groups of the 27 % 
suggesting the presence of thiol-reactive groups. A reduction step was needed to 
activate the cysteine of the enzyme: Tris[2-carboxyethyl] phosphine hydrochloride 
(TCPE) was used to reduce the cysteine present on the enzyme surface. TCEP is 
known to be an efficient reductant of alkyl disulfides in a wide pH range. Furthermore, 
it is stable in aqueous solutions and does not undergo to rapid oxidation that often 
occurs with other reducing agents such as dithiotreitol (DTT) and β-mercaptoethanol 
(BME, 2-ME)151 Additionally, TCEP does not interfere with commonly used 
sulfhydryl-reactive reagents (e.g., maleimide crosslinkers). Using this strategy, the 
best relative activity and the highest number of molecules per NP was obtained (NP-
LASPO2). The binding through the cysteine moiety was confirmed, as only when the 
protein was previously reduced with TCPE reducing gel the conjugation was possible. 
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Besides, to demonstrate that the binding of the enzyme was achieved through the 
cysteine present on the enzyme molecule and not through unspecific binding, the NP-
LASPO2 was incubated with DTT to reduce the disulfide bond: the reversibility of 
the disulphide bond formed was checked, the 100% of the enzyme molecules was 
released and no activity is detected in the NP-LASPO after the DTT addition.  
Also Strategy 3 resulted in a high relative activity and a high number of molecules 
per NP. In this case, the immobilization conditions were set in order to promote the 
direct covalent binding of the enzyme via the primary amine group of its N-terminus. 
Thus, the pH of reaction selected was 8.2, slighter higher than its pKa but lower than 
that for e-amine of lysine residues (~ 10.5)152. Moreover, in literature, is reported that 
the pKa value of the amine of lysine residues can be lower than the tabled values, 
depending on the surrounding environment153,154. However, at this pH value the 
enzyme has net negative charge (pI 6.75) while BS3-activated NPs have a net positive 
one, as demonstrated also by ζ potential measurements (+27,95 mV). Thus, we cannot 
ensure the covalent binding via the enzyme amino terminus, as ionic adsorption 
reactions are much faster than covalent ones. Indeed, a slight ionic adsorption was 
observed when NP-APTES without BS3 activation were used as control, i.e. 10 µg of 
the enzyme is bound to 1 mg of NPs.  
Taking into consideration the APBS data, it is possible to speculate that first, an initial 
rapid ionic adsorption of LASPO through this front plane of interaction occurred 
followed by a much slower site-directed covalent attachment via reaction of amino-
groups facing the NP surface with its BS3 activated aminated groups. Although we 
cannot ensure a direct binding via its amino-terminal group, the final enzyme 
orientation obtained should be similar in both cases.  
A further step was carried on to avoid this ionic adsorption and higher ionic 
strengths were used during enzyme immobilization. As this strategy did not work, we 
also tried to diminish the net positive charge of the NPs by carrying out the partial 
modification of its amino groups with an aminated-750 Da polyethylene glycol 
(PEG)27,28 after their activation with BS3. However, the decrement in the net surface 
charge of the PEGylated-NPs was not enough to avoid LASPO ionic adsorption.  
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Finally, the enzyme we also bound by chelation of its histidine tag present on the 
C-terminus of the protein (Strategy 4), to orientate the enzyme so that its active site 
is completely exposed to the reaction media. Although, the orientation obtained 
should be similar to Strategy 3, this strategy has the advantage that it is not necessary 
to modify the enzyme previously. To confirm the specific orientation of the enzyme 
through its His-tag and exclude the possibility of ionic interactions the reaction of  
was carried on in presence of imidazole: no immobilization was observed. However, 
with this binding strategy we have obtained the worst results in terms of relative 
activity and enzyme molecules per NP.  
These results confirm that the activity of the NP-enzyme systems strongly depends 
on the chemistry of conjugation that can cause conformational changes of the enzyme 
or lead to non-specific bindings with the NPs155,156. 
The enzyme-NPs systems obtained, were then analyzed by DLS and ζ potential (Table 
5). After the enzyme conjugation, negative ζ potential values of the enzyme 
functionalized NPs is expected as LASPO has a net negative charge at the pH value 
of the measurements. With all the conjugation strategies a partial aggregation of the 
NPs was observed, although NP-LASPO4 was the one showing more aggregation. In 
this case, the surface functionalization of the particles, reduced their net charge, 
causing a decrease in their colloidal stability. 
Table 5. Physical parameters of the different enzyme-NP systems. 
 NP-LASPO1 NP-LASPO2 NP-LASPO3 NP-LASPO4 
radius [nm] (TEM) 5.2 ± 0.5 4.9 ± 1.2 4.9 ± 1.4 5.6 ± 1.3 
diameter [nm] (DLS) 84.4 ± 0.2   341 ± 0.8 220 ± 0.4 930 ± 0.4 
Polydispersity Index (DLS) 0.319 0.2 0.212 0.301 
ζ-potential [mV] -22.9 ± 0.5 -32.6 ± 1.2 -16,45 ± 0.5 -15.88 ± 0.2 
 
Biochemical characterization 
The nano-systems produced were biochemically characterized and the catalytic 
parameters of the conjugated LASPO were determined by HPR-coupled 
spectrophotometric assay at pH 8.5 at 25°C, as previously reported74. The apparent 
Vmax at air oxygen saturation for all the NP-LASPO systems and Km for L-aspartate 
are reported in Table 6.  
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Table 6. Catalytic parameters of all the NP-LASPO conjugations. 
 Specific activity  Vmax, app Km 
 (U/mg enzyme) (µmol x min x mg enzyme) (mM) 
NP-LASPO1 0.36 0.33 4.55 
NP-LASPO2 0.40 0.094 4.17 
NP-LASPO3 0.34 0.289 1.17 
NP-LASPO4 0.15 0.37 1.56 
The different enzyme systems results in different Km: for NP-LASPO 3 and NP-
LASPO 4 is similar to the one of the free enzyme (i.e. 1.3 mM), while the Km values 
for the others preparations are higher, suggesting a lower affinity for L-aspartate, so a 
higher substrate concentration is needed to achieve a given enzyme activity. This 
behaviour can be attributed to diffusional limitations and steric effects that cause a 
reduction in the accessibility of substrate to the enzyme active site. Furthermore, data 
in literature suggest that a high loading of enzyme molecules can cause a substrate 
accessibility reduction to the active site of the enzyme79.  
The effect of temperature on the catalytic properties of all the NP-LASPO systems 
was studied in the range of 25-70°C.  
Figure 17. Effect of temperature on the activity conjugated or non-conjugated 
LASPO  after 30 min of incubation: LASPO (orange), NP-LASPO 1 (black) NP-
LASPO 2 (green), NP-LASPO 3 (blue) and NP-LASPO 4 (red) 
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Figure 17 reports the activity of the nanosystems after  30 min of reaction. NP-
LASPO1, NP-LASPO2 and NP-LASPO3 have their optimum at 70°C  black, green 
and blue curves) that is similar to that of the free LASPO, while the optimal 
temperature of NP-LASPO4 resulted shifted to 50°C (red curve). These results 
indicate that the conjugation of the enzyme through different residues influences the 
enzyme activity, acting on the enzyme 3D structures. The conjugation may avoid the 
stretching and the natural conformational changes that are necessary for the enzyme 
activity.  
To further characterize the NP-LASPO systems, it was also studied the 
thermostability of all the batches incubating the enzyme at different temperatures and 
assessing the residual activity of the systems after 0 to 60 min of incubation (Figure 
18).  
As Figure18 suggests, all the NP-LASPO preparations are stable for at least 60 min 
for all the temperature considered. From 25°C to 90°C no significant differences were 
observed in term of activity loss between the different preparations. Except for NP-
LASPO1, all the preparation retained the 90% of the starting activity.  
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Figure 18. Thermal stability of NP-LASPO1 (red), NP-LASPO2(blue), NP-LASPO3 
(green) and NP-LASPO4 (black) at different temperature: 25°C (a), 37°C (b), 50°C (c), 
70°C (d), 80°C (e) and 90°C(f). Triplicate experiments were done for each condition, standard 
errors were lower than 5%.  
Remote enzyme activation by AMF nanoactuation.  
To evaluate the possibility to activate the immobilized enzymes solely by an AMF 
without heating the medium in which they are suspended, an AMF of 252 Gauss and 
829 kHz was applied on the different NP-enzyme systems obtained.  
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As shown in Figure 19, by applying an AMF at a frequency of 829 kHz, it was possible 
to nanoactuate the LASPO enzyme immobilized on the NPs. To assess this, the values 
of the enzymatic activity detected after exposure to the AMF were compared to those 
obtained heating the sample during the same time, but using conventional thermal 
energy transfer (i.e., incubating test tubes in a thermoblock). NP-LASPO1, NP-
LASPO2 and NP-LASPO3, when exposed to an AMF, show an activity that 
corresponds to that obtained incubating the NP-enzyme systems in a thermoblock at 
30°C, 60°C and 45°C, respectively. Since the curve of the activity of NP-LASPO4 is 
not monotonic (Figure 16), for this NP-enzyme system, we cannot discriminate if the 
activity is comparable to the one obtained at 40°C or at 60°C. The global temperature 
in all cases was 21ºC, as expected as the volume fraction of the NPs was very low 
and, thus, it is possible to consider them thermally isolated from each other.  
The obtained results clearly showed that it was possible to nanoactuate the enzymes 
by AMF application whatever conjugation strategy was used without increasing the 
whole media temperature. 
Comparing the activation efficiency in the case of NP-LASPO2 and NP-LASPO3, 
there are not significant differences between both enzyme-NPs preparations in terms 
of mean diameter after NPs functionalization, number of enzyme molecules per NP 
30°
C 
40°
C 
60°
C 
45°
C 
Figure 19. Activity of conjugated thermophilic enzymes under a 252 Gauss AMF with a 
frequency of 829 kHz and after 30 min.  
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or their relative activity after immobilization. Besides, the optimal temperatures of 
both immobilized enzyme preparations were similar to  that of the free enzyme when 
heated using conventional thermal energy transfer systems. Though, when NPs were 
placed under an AMF, the enzyme activation efficiency was clearly better in the case 
of NP-LASPO2. The differences between the enzyme preparations could be attributed 
to the orientation of the enzyme once conjugated to the NPs. In the case of NP-LASPO 
2 the active site is located far away from the NP surface while the opposite occurs in 
the case of NP-LASPO 3. Thus, it seems that orientation of the enzyme once attached 
to the NP surface could also play a critical role in the efficiency of the enzyme 
activation triggered by AMF. This should be a consequence of a different mechanism 
of thermal energy transference and inherent different rigidities of the zones through 
which the enzyme is attached to the support. Checking the 3D structure of LASPO, 
its back-region where binding took place when using Strategy 2 is much more rigid 
than the region near the active site used for the attachment in Strategy 3. This last zone 
has to be intrinsically more flexible to allow the conformational changes that are 
triggered by the presence of the enzyme substrate. The higher the rigidity of an 
enzyme area, the less is the susceptibility to its denaturation when exposed to a 
denaturant agent (co-solvents, temperature, etc).  
Operational stability under an AMF 
As one of the advantages of immobilized enzymes is the possibility to recover and 
reuse the enzyme, the operational stability of NP-LASPO preparations with the 
highest relative activity (NP-LASPO2 and NP-LASPO3) was evaluated after 
consecutive cycles of AMF activation. The operational stability is indicated as the 
number of reactions that could be carried on using the same batch of immobilized 
enzyme. Each cycle consisted of 30 min of reaction under a 252 Gauss and 829 kHz 
AMF. After each cycle of reaction, the immobilized enzyme was recovered through 
magnetic separation and reused to catalyze L-aspartate oxidation. Figure 20 shows 
that NP-LASPO 2 maintained all its activity for 3 cycles, while, after the same number 
of repeated uses, NP-LASPO3 retained only half of its original activity. Although the 
mechanism of energy transfer should be different from when the reaction media is 
heated globally, these results not only showed that it is possible to reuse the nano-
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enzymes but also reinforce the importance of enzyme orientation to develop more 
efficient enzymatic processes under AMF activation. 
 
Figure 20. Operational stability of NP-LASPO2 and NP-LASPO3 systems exposed to an 
AMF of 829 kHz and 252 Gauss. 
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α-amylase 
α-amylase is an endo-enzyme that cleaves the glycosidic bond within starch in the 
non-crystalline regions (cleaves a- 1-4 linkage) leading to the production of destrins, 
maltose and maltotriose. This enzyme has been isolated from different sources, from 
plant to animals. For industrial applications, the a-amylase from isolated from 
microrganisms are the most used due to the cost effectiveness, the less time and space 
required for production and the easy modification of the genome for the optimization. 
The protein isolated from Bacillus licheniformis seems to be very interest for the paper 
and textile industries thanks to the high temperature optimum of 100°C and the wide 
stability over pH values.  
Optimization of enzyme conjugation 
As for the conjugation of LASPO, the conjugation of α-amylase was carefully design 
taking into consideration its 3D structure. Two different conjugation strategies were 
used to obtain an enzyme-NP systems with both good conjugation yield and high 
relative activity. (Figure 21): 
§ Strategy 1: the carboxylic group of the enzyme were used to react with the 
amino groups of the NP-APTES after their activation with a carbodiimide 
chemistry. The analysis of its crystal structure (PDB entry 1BLI), showed the 
presence on the surface of a high number of exposed carboxylic groups. In 
this case, the reaction was carried on at two different pH of reaction, i.e. pH 
7 (NP-AMY1) and pH 9 (NP-AMY2). 
§ Strategy 2: enzyme molecules are covalently bound to the NP-APTES 
through via their amine reactive moieties after the NP-APTES activation with 
BS3 (NP-AMY3). In particular, the reaction carried on at pH 8.2 should 
ensure a conjugation through the amino terminal of the enzyme. 
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Figure 21 Conjugation chemistry used to functionalize IONPs. On the left, from top to 
bottom, we have schematized the above-described strategies 1) APTES, 2) APTES-BS3. On 
the right, is reported the three-dimensional structure of the amylase and are highlighted the 
residues involved in each conjugation strategy. From top to bottom: carboxylic groups in green 
and in orange the C-terminus (Strategy 1), amino-groups in blue and N-terminus in yellow 
(Strategy 2). The enzyme structure was taken from the Protein Data Bank (PDB) entry 1BLI 
and visualized using PyMol v2.1. 
 
First of all, to better understand the possible ionic interactions of the enzyme with the 
NP-APTES the charge surface distribution of amylase was studied through a 
computational approach (Figure 22). The structure of the enzyme was visualized with 
Pymol v.2.1 and the positive and negative were counted taking into account different 
plane of interactions.   
 
 
 
 
 
64 
 
 
Figure 22. 3D structure of amylase showing the positive and negative charge surface 
distribution. The enzyme structure was taken from the Protein Data Bank (PDB) entry 
1BLI and visualized using PyMol v2.1. Negative and positive charges are displayed in red 
and blue, respectively. (a) graphic representation of interaction plane of the enzyme. (b) 
Number of charged residues per plane of interaction. 
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The study of the 3D structure of amylase revealed that the back region of the enzyme 
is those that presents the highest number of positive charges, while the left one is the 
less charged region of the enzyme. Interestingly, the region with the active site is the 
one with the highest negative charges. Thus, the regions of the enzyme that will react 
faster are located on the opposite side and the upper side of the enzyme, respect to the 
active site.  
The possibility that ionic interactions occur between the enzyme and the NP was 
analyzed by an in silico study of surface potential of the through the APBS software. 
The surface potential was calculated at the different pHs that were used in the 
conjugation conditions. Figure 23 shows the surface potential (a) and the electrostatic 
potential iso-contours (b), positive and negative charged surface are indicated in blue 
and red, respectively. 
 
Figure 23. Analysis of the surface potential of the enzyme. The PDB entry 1BLI was 
selected for this 3D representation. APBS was used to calculate the surface potential and the 
analysis results were visualized using Pymol v2.1. (a) ±10 kT/e electrostatic potential of 
LASPO in PyMOL plotted on the solvent-accessible surface. (b) ±0.6 kT/e electrostatic 
potential iso-contours of LASPO in PyMOL. The enzyme molecules are oriented to 
visualized the surface potential in the nearby of the residue used for the conjugation. 
a) 
pH 7 pH 8.2 pH 9 
b) 
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No significant differences in the surface potential of the enzyme were observed at the 
considered conditions. So it is possible to hypothesize that the medium pH is not 
affecting the immobilization in term of surface charge modifications.   
For amylase, only two different conjugation strategies were used as this protein does 
not present cysteine residue and it is not a His-tagged recombinant variant. The 
amylase crystal structure showed, instead, a homogenous distribution of carboxylic 
groups within its surface. Thus, Strategy 1 should lead to a random binding of the 
enzyme with respect to the orientation of its active site towards the NP surface, as 
depicted also by Figure 21.  
However, this conjugation strategy could also promote the formation of a covalent 
cross-linked enzyme@NP network depending on the pH of reaction. Thus, as 
consequence of the presence on amylase´s surface of primary amine groups with 
different pKa values from the N-terminus (pka 7.8) and lysine residues (pka 10.4). 
At pH 7.0 (NP-AMY1), only the N-terminus residue would be deprotonated and thus 
reactive towards the carboxylic groups of neighboring enzyme molecules activated as 
NHS-esters. Thus, their covalent conjugation to the most abundant amine groups of 
the NP surface is favoured. However, at alkaline pH values (NP-AMY2), ε-amine of 
lysine’s side chain become reactive towards the activated carboxylic moieties. Thus, 
due to the high abundance of Lys moieties at AMY surface, the crosslinking among 
enzyme molecules could compete with the direct covalent binding to the NPs. Indeed, 
although the two conditions used to link the enzyme (pH 7 and pH 9) led to similar 
conjugation yields, different relative activities were obtained (61 and 36 %, 
respectively) (Table 7).  
Strategy 2, resulted in similar reaction parameters than NP-AMY, but whit a 
lower relative activity. The reaction conditions promote the direct covalent binding of 
the enzyme via the primary amine group of its N-terminus. The reaction media pH 8.2 
is slighter higher than its pKa but lower than that for e-amine of lysine residues (~ 
10.5)152.  
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Table 7. Enzyme-NPs conjugated reaction parameters. 
 
Cross 
linker 
pH µgenzyme/mgNPs Relative Activity (%) 
Active enzyme 
molecules/NP 
NP-
AMY1 
EDC/ 
NHS 
7 22.5 61 3 
NP-
AMY2 
EDC/ 
NHS 
9 22 36 3 
NP-
AMY3 
BS3 8.2 23 54 3 
 
The obtained conjugation yield was confirmed by the measurement of remaining 
unreacted amino-groups on the NPs surface after the enzyme binding. For all pH 
conditions used, the number of amino groups per mg of NPs decreased from 15 to 6 
nmol. Although the final amount of enzyme attached was the same in all cases ( ̴ 22 
µg/mg NP), the lower enzyme activity of the enzyme@NPs obtained for NP-AMY 2 
should be a consequence of the crosslinking effect mentioned above. Indeed, 
AMY@NPs obtained at this pH has a larger mean hydrodynamic diameter (Table 8).  
Negative ζ potential values of the enzyme functionalized NPs is expected as amylase 
has a net negative charge at the pH value of the measurements. With all the 
conjugation strategies a partial aggregation of the NPs was observed, although NP-
AMY2 was the one showing more aggregation. 
Table 8. Physical parameters of the different enzyme-NP systems. 
 NP-AMY1 NP-AMY2 NP-AMY3 
radius [nm] (TEM) 6.1 ± 0.6 6.2 ± 0.8  6.2 ± 0.5 
diameter [nm] (DLS) 392 ± 0.6 873.3 ± 0.3 197.7 ± 0.4 
Polydispersity Index (DLS) 0.185 0.321 0.191 
ζ-potential [mV] -9.04 ± 0.7 -38. 05± 0.676 -19.04 ± 0.8 
 
Biochemical characterization 
The nano-systems produced were biochemically characterized and the catalytic 
parameters of the conjugated NP-AMY were determined by 3,5-dinitrosalicyclic acid 
colorimetric assay. The apparent Vmax all the NP-AMY systems and their Km for 
starch are reported in Table 9. 
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Table 9. Catalytic parameters of all the NP-AMY conjugations. 
 Specific activity  Vmax, app Km 
 (U/mg enzyme) (µmol x min x mg enzyme) (mM) 
NP-AMY1 763 1592 0.073 
NP-AMY2 566 1023 0.051 
NP-AMY3 603 1065 0.052 
 
The NP-AMY systems were further investigated studying the effect of the temperature 
on their enzymatic activity (Figure 24).  
The optimal temperature of NP-AMY1 was the same of that of the free enzyme, i.e., 
90°C, while that of NP-AMY2 resulted shifted to 70°C, the optimum temperature of 
NP-AMY 3, instead, is 80°C. 
As the enzyme works at high temperature, i.e. 70-90°C, the NP-AMY systems were 
further characterized studying their thermostability at different temperatures and 
assessing the residual activity of the systems after 60 min of incubation (Figure 25).  
 
Figure 24. Effect of temperature on the activity of conjugated and non-conjugated 
amylase after 30 min of incubation: Amylase (green), NP-AMY 1 (black) NP-AMY 2 (red) 
and NP-AMY3 (blue). 
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Figure 25. Thermal stability of NP-AMY1 (red), NP-AMY2(blue) and NP-AMY3 (green) 
at different temperature: 25°C (a), 37°C (b), 50°C (c), 70°C (d), 80°C (e) and 90°C(f). 
Triplicate experiments were done for each condition, standard errors were lower than 5%. 
As shown in Figure 25, the three different conjugation strategies of amylase lead to 
the production of thermostable nano-enzymatic systems. At all the temperatures 
considered, indeed, the activity loss in 60 min was only of 6 % in case of NP-AMY2, 
while for both NP-AMY1 and NP-AMY3 was observed only the 4% of activity loss. 
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Remote enzyme activation by AMF nanoactuation.  
As shown in Figure 26, by applying an AMF at a frequency of 829 kHz, we have been 
able to remotely activate all the AMY. To assess this, we compared the values of the 
enzymatic activity detected after exposure to the AMF to those obtained heating the 
sample during the same incubation time, but incubating test tubes in a thermoblock.  
After 30 min of exposure to AMF, NP-AMY1, NP-AMY2 and NP-AMY3 produced 
140, 74 and 99 µmol x min of maltose, respectively (Figure 26). These activities 
obtained with AMF are comparable to those that can be obtained heating the sample 
for 30 min in a thermoblock at 90°C for NP-AMY1, at 70°C for NP-AMY2 and 80°C 
for NP-AMY3. 
To further study the effects of AMF on the nano-conjugated amylase, the frequency 
of the AMF was varied from 410 to 829 kHz, while the field was maintained at 252 
Gauss (Figure 27). 
Figure 26. Activity of conjugated amylase under a 252 Gauss AMF with a frequency 
of 829 KHz and after 30 min. 
71 
 
 
Figure 27. Dependence of the enzymatic activity on AMF frequency. NP-AMY 1 (black), 
NP-AMY 2 (red) and NP-AMY3 (blue) were exposed to a 252 Gauss AMF with frequencies 
ranging from 410 to 829 kHz.  
It was observed an increase of enzyme activity when increasing the frequency of the 
applied AMF. The higher the frequency of the applied field, the higher the increase in 
the amount of heat generated by the particles, which resulted in turn in a higher 
activation of the immobilized enzyme.  
All these results clearly show that, by means if an AMF, we have transferred energy 
to the IONPs and to their linked enzymes. However, the efficiency of this activation 
was different depending on the coupling strategy, being the best options NP-AMY1 
for the amylase. In the case of NP-AMY2 and NP-AMY3, the low activation 
efficiency observed could be a consequence of the thermal enzyme destabilization 
caused by both immobilization strategies. However, we cannot exclude a contribution 
due to the observed NPs aggregation triggered by enzyme binding, as it is well known 
that the heating efficiency of NPs drastically decreases after aggregation157. In all the 
conditions considered, the application of the magnetic field and de subsequent 
activation of the thermophilic enzyme immobilized on them, did not caused an 
increase in the reaction media. This can be explained by the fact that the amount of 
NPs used were thermally isolated due to the low concentration used. 
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To confirm that the reaction media temperature do not increase during the application 
of the AMF of 829 kHz and 252 Gauss, a reaction containing the NP-AMY 
preparations and the thermolable enzyme D-aminoacid oxidase (DAAO) were carried 
on. Table 10 reported the activity register for the two enzyme used.  
Table 10. Activity of conjugated amylase and of the free DAAO under an AMF of 829kHz 
and 252 Gauss. 
 U (µgmaltose x mgNP) U (µgsubstate x mgenzyme) 
NP-AMY1/DAAO 115 ± 0.5 33 ± 0.2 
NP-AMY2/DAAO 75 ± 0.7 33 ± 0.3 
NP-AMY3/DAAO 98 ± 0.4 33 ± 0.8 
 
It is possible to observe that the enzymes are both active: NP-AMY was activated as 
it is at 90°, 70°C and 80°C for NP-AMY 1, NP-AMY 2 and NP-AMY 3 respectively. 
While DAAO show an enzymatic activity comparable of the one obtained when the 
reaction is carried on at room temperature. These data prove that the application of a 
magnetic field in presence of NPs does not cause an excess of heating in the reaction 
media. Thus, it will be possible to carry on multi-enzymatic processes of 
biotechnological interest in which one of enzyme/substrate/product is thermolable, 
while the other needs an high temperature to work. 
As further proof of the heating transfer from the NPs to the enzyme, DAAO was 
immobilized on NP-APTES as reported in the article entitled “Synthesis, 
characterization and programmable toxicity of iron oxide nanoparticles conjugated 
with D-amino acid oxidase” attached at the end of the Material and Method chapter. 
Then an AMF field of 252 Gauss and frequencies in the 410 to 829 kHz range was 
applied in presence of NP-DAAO and free amylase (Figure 28). 
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Figure 28. Dependence of the enzymatic activity of NP-DAAO on AMF frequency (410 
to 829 kHz). 
Figure 28 depicts that as the frequency of the AMF gets higher, the enzyme activity 
became lower, as the enzyme was incubated in increasing reaction temperature. 
DAAO is indeed a themolable enzyme with an optimum temperature of 37°C, that 
gets partially denaturated when the temperature increase. On the other hand, the free 
amylase, present in the reaction media, registered an activity comparable to those 
obtained incubating the enzyme at room temperature. 
Operational stability under an AMF 
The possibility to recover and reuse the NP-AMY preparations was evaluated under 
an AMF of 252 Gauss and 829 kHz. Each cycle consisted of 30 min of reaction. After 
each cycle, the conjugated enzyme was recovered using a magnet and reused it to 
digest starch (Figure 29).  
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Figure 29. Operational stability of NP-AMY 1, NP-AMY2 and NP-AMY3 systems 
exposed to an AMF of 829 KHz and 252 Gauss. 
Figure 29 shows that the three different NP-AMY systems maintained the full activity 
for 2 cycles. After three cycles, the activity of NP-AMY3 significantly decrease of 
40% of the starting activity. As for NP-LASPO systems, these results not only showed 
that it is possible to establish reuse cycles but also reinforce the importance of enzyme 
orientation in order to develop more efficient enzymatic processes under AMF 
activation. 
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NP-ANTIBIOTIC SYSTEM 
In recent years, the widespread use of antibiotics has led to the onset of resistance in 
microorganisms. Even the use of last resort antibiotics such as teicoplanin and 
vancomycin undergo to restrictions because of the emerging resistance in enterococci 
and staphylococci with the subsequent need to develop new antibiotics products134. In 
this context, the advent of nanotechnology has given a large contribution to the 
problem. Indeed, there are many studies concerning nanomaterials, and in particular 
NPs, as antimicrobial agents. Although iron oxide is not considered antibacterial, this 
material in the form of NPs acquires characteristics such good biocompatibility and 
low toxicity and superparamagnetism, that make it interesting as antibiotic support for 
applications in the biomedical field. 
Here, IONPs are used as a platform for the conjugation of the glycopeptide antibiotic 
teicoplanin, which has been in clinical practice since 1988 in Europe and 1998 in 
Japan158. 
Results regarding this section are reported in detailed in the paper entitled “Magnetic 
nanoconjugated teicoplanin: a novel tool for bacterial infection site targeting”, 
attached at the end of this chapter. 
NP-TEICO binding and activity stability 
Supplementary information to the paper “Magnetic nanoconjugated teicoplanin: a 
novel tool for bacterial infection site targeting”. 
The stability of NP-TEICO was studied at different pHs (5.5, 6 and 7.1) and 
temperatures of storage (-20°C, 4°C and 25°C). The release of teicoplanin was 
measured in the supernatant by the HPLC analyses: the 100% of antibiotic remained 
bind for one month at all the conditions tested (Figure 30).  
 
76 
 
On the other hand, the antimicrobial activity of NP-TEICO - measured by the 
antimicrobial susceptibility test versus B. subtilis - was maintained from 60 to 90% of 
its initial antimicrobial activity after three weeks depending on the storage conditions. 
When store at pH 5.5, the nano-antibiotic system shows the worst maintenance of its 
microbial activity at all the storage temperature (Figure 30a). Conversely, if the NP-
TEICO are store at pH 6.0 at 4°C and 25°C they maintain the 90% of the staring 
activity after 28 days (Figure 30b). Storage at physiological pH, indeed, lead to the 
loss of 20-40 % of the starting activity (Figure 30c). In the same conditions, a water 
solution of teicoplanin (500 μg/mL) maintained the 90% (± 0.5) of its initial 
antimicrobial activity.  
 
Figure 30. Antimicrobial time stability of NP-TEICO stored at pH 5.5 (a), pH 6.0 (b) and 
pH 7.2 (c) and temperature: -20°C (red), 4°C (blue) and 25°C (green).  
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Nanoconjugated antibiotics can be regarded as next-generation drugs as they possess
remarkable potential to overcome multidrug resistance in pathogenic bacteria. Iron oxide
nanoparticles (IONPs) have been extensively used in the biomedical field because of their
biocompatibility and magnetic properties. More recently, IONPs have been investigated
as potential nanocarriers for antibiotics to be magnetically directed to/recovered from
infection sites. Here, we conjugated the “last-resort” glycopeptide antibiotic teicoplanin
to IONPs after surface functionalization with (3-aminopropyl) triethoxysilane (APTES).
Classical microbiological methods and fluorescence and electron microscopy analysis
were used to compare antimicrobial activity and surface interactions of naked IONPs,
amino-functionalized NPs (NP-APTES), and nanoconjugated teicoplanin (NP-TEICO)
with non-conjugated teicoplanin. As bacterial models, differently resistant strains of three
Gram-positive bacteria (Staphylococcus aureus, Enterococcus faecalis, and Bacillus
subtilis) and a Gram-negative representative (Escherichia coli) were used. The results
indicated that teicoplanin conjugation conferred a valuable and prolonged antimicrobial
activity to IONPs toward Gram-positive bacteria. No antimicrobial activity was detected
using NP-TEICO toward the Gram-negative E. coli. Although IONPs and NP-APTES
showed only insignificant antimicrobial activity in comparison to NP-TEICO, our data
indicate that they might establish diverse interaction patterns at bacterial surfaces.
Sensitivity of bacteria to NPs varied according to the surface provided by the bacteria
and it was species specific. In addition, conjugation of teicoplanin improved the
cytocompatibility of IONPs toward two human cell lines. Finally, NP-TEICO inhibited the
formation of S. aureus biofilm, conserving the activity of non-conjugated teicoplanin
versus planktonic cells and improving it toward adherent cells.
Keywords: antibiotic resistance, iron oxide nanoparticles, glycopeptide antibiotics, antimicrobial activity,
teicoplanin, Staphylococcus aureus biofilm
INTRODUCTION
According to a recent survey of theWorld Health Organization (WHO, 2017), antibiotic resistance
represents one of the greatest threats to global health today and contributes significantly to longer
hospital permanence, higher medical costs, and increased mortality. At least 700,000 people die
annually because of infections caused by resistant bacteria. This number is predicted to increase up
Frontiers in Microbiology | www.frontiersin.org 1 October 2018 | Volume 9 | Article 2270
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to 10 million by 2050 and is consequentially associated with
a social and economic burden. This public health threat
is exacerbated by the paucity of novel antibiotics expected
to enter clinical use in the near future (Fedorenko et al.,
2015). A corollary to acute illness is the increased number of
chronic bacterial infections due to the prevalence of biofilm
colonization (Arciola et al., 2018). Currently, medical device-
related infections account for more than 60% of all the hospital-
acquired infections in the United States (Weiner et al., 2016).
Biofilms are complex, three-dimensional bacterial communities
living in a self-produced extracellular matrix. The biofilm-
forming bacteria survive better than their free-living (planktonic)
counterparts in hostile environments; they are 10 to 100 times less
susceptible to antimicrobial agents and are protected against the
host immune system, making the treatment of these infections
quite challenging (Davis, 2003; Venkatesan et al., 2015).
One promising approach in the field of antimicrobial therapy
is the use of nanotechnology-tailored agents for preventing and
treating infections caused by resistant bacteria. Unique and
well-defined features distinguish nanoparticles (NPs) from their
bulk counterparts, such as large surface area-to-volume ratio
and dimensions that are comparable to those of biomolecules,
effectively providing a platform with a high number of
functional sites and possible interactions with bacterial cells
and biofilms. Of all the NPs tested for antimicrobial activity
thus far, silver NPs (AgNPs) have been studied most intensively
(Natan and Banin, 2017). Although researchers have widely
agreed that the broad-spectrum antibacterial activity of AgNPs
can be predominantly ascribed to the release of Ag ions,
AgNPs demonstrate unique properties because they adhere to
the bacterial surface, altering membrane properties and thus
delivering Ag ions more effectively to the bacterial cytoplasm and
membrane (Durán et al., 2016). Consequently, the antibacterial
effect of AgNPs is observed at concentrations with a 10-
fold lower magnitude than those used for bulk Ag ions. The
antibacterial activity of AgNPs is reported to be mediated by
a multiplicity of still-not-completely understood mechanisms
following their interaction with the bacterial surface, which act
in parallel (i.e., oxidative stress, membrane depolarization, and
protein and DNA interaction), thus explaining why bacterial
resistance does not easily arise (Hajipour et al., 2012; Natan and
Banin, 2017; Baranwal et al., 2018). Very recent studies (Xiang
et al., 2017; Xie et al., 2017, 2018) show that the antibacterial
activity of AgNPs may be successfully exploited in preparing
nanocomposite materials to be used as antibacterial coatings of
titanium-based metallic implants and poly(ether ether ketone)
medical devices, which are both widely employed in dentistry and
orthopedic applications. Entrapping AgNPs in graphene oxide
nanosheets wrapped with a thin layer of collagen (Xie et al.,
2017), in hybrid polydopamine/graphene oxide coatings (Xie
et al., 2018), or in biocompatible polymers such as poly(lactic-co-
glycolic) acid (Xiang et al., 2017) endows medical implants with a
long-lasting self-antibacterial activity. In vivo studies using these
innovative coatings in animal models confirm that combining the
unique properties of different nanomaterials prevents bacterial
infection and provides a good cytocompatibility of the medical
devices (Xie et al., 2017, 2018).
A synergic, but as yet less exploited strategy when developing
nano-based antimicrobial agents involves using NPs as
nanocarriers for antibiotics, taking advantage of the high
surface-to-volume ratio platform that they offer for attaching
a large number of molecules. The advantages of using NPs
in this way depend on the nature of both the NPs and the
drugs under consideration, as recently reviewed (Natan and
Banin, 2017). These advantages might include (i) protecting
the nanoconjugated drug from degradation and oxidation;
(ii) increasing drug solubility, antimicrobial activity, and
biodistribution; (iii) delivering the antibiotic to the site of the
infection; and (iv) enhancing drug penetration into biofilms,
facilitating the killing of encased bacteria. As antibiotic
nanocarriers, iron oxide nanoparticles (IONPs) have recently
attracted increased interest thanks to their unique magnetic
properties (Dinali et al., 2017). In fact, IONPs can be guided
by an external magnetic field to a targeted organ/biofilm and
specifically localized at the site of infection (Wu et al., 2015;
Stepien et al., 2018). In addition, IONPs are easily produced and
functionalized, and they possess a high drug-loading capacity,
low cell toxicity, and high biocompatibility (Ali et al., 2016;
Dinali et al., 2017). In the last decade, relatively few studies
have investigated the potential of surface-modified IONPs as
antibacterial agents in depth. Core-shell Fe3O4-AgNPs were
tested as antimicrobial agents against Gram-positive and Gram-
negative bacteria where the silver shell was responsible for
antimicrobial action (Chudasama et al., 2009). Biocompatible
polyvinyl alcohol-coated IONPs were used in biomedical
applications and reported to be active against Staphylococcus
aureus in a dose-dependent manner (Tran et al., 2010).
Similarly, chitosan-coated IONPs were shown to have a higher
antimicrobial activity than naked IONPs due to the positive
surface potential, which interacted better with negatively
charged bacterial cell surfaces (Arakha et al., 2015a). According
to other authors (Huang et al., 2010; Ebrahiminezhad et al.,
2014), IONP surface functionalization with (3-aminopropyl)
triethoxysilane (APTES) elicited an antimicrobial effect by
creating a high density of amino groups, which could interact
with negatively charged sites on the bacterial cells through
electrostatic interactions. The well-developed surface chemistry
of IONPs made it possible to incorporate a variety of commonly
used antibiotics such as the β-lactam amoxicillin, penicillin,
and ampicillin, the aminoglycoside streptomycin, and the
glycopeptide vancomycin (Chifiriuc et al., 2013; Grumezescu
et al., 2014; Hussein-Al-Ali et al., 2014; El Zowalaty et al., 2015;
Wang et al., 2017), providing evidence that biocompatible
magnetic NPs might enable site-specific antibiotic delivery.
Vancomycin-carrying, folic acid-tagged chitosan NPs were
successfully used to deliver vancomycin to bacterial cells
(Chakraborty et al., 2010, 2012), and vancomycin-modified
mesoporous silica NPs were used for selective recognition and
killing of Gram-positive bacteria over macrophage-like cells
(Qi et al., 2013). An alternative use of IONPs functionalized
with vancomycin – an antibiotic that binds to bacterial cell
walls – was to apply them as ligands for the affinity capture
of a wide range of bacteria from biological samples, including
Gram-positive bacteria such as S. aureus and Gram-negative
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bacteria such as Escherichia coli (Gu et al., 2003; Lin et al.,
2005; Kell et al., 2008). Because of the magnetic properties
of vancomycin-functionalized IONPs, vancomycin-captured
bacteria can be magnetically separated and concentrated from
large volumes into much smaller volumes, allowing bacterial
analysis and detection based on, for example, genomic DNA
(Kell et al., 2008; Zhu et al., 2015).
In this work, we employed IONPs as carriers of the
lipoglycopeptide antibiotic teicoplanin, which has been used
in clinical practice since 1988 in Europe and 1998 in Japan.
Teicoplanin is considered a drug of “last resort” for treating
severe infections by multiresistant Gram-positive pathogens,
including the methicillin-resistant S. aureus (MRSA) and
the anaerobe Clostridioides difficile (Marcone et al., 2018).
Teicoplanin is a complex molecule with a peptide core of seven
aromatic amino acids tailored with sugar residues, chlorine
atoms, methyl groups, and a lipid chain. It forms five specific
hydrogen bonds with the D-alanyl-D-alanine terminus of the
peptidoglycan precursors of the bacterial cell wall, blocking its
synthesis and consequently causing cell lysis (Binda et al., 2014).
The antibacterial spectrum of teicoplanin activity against Gram-
positive bacteria is similar to that of vancomycin, but teicoplanin
shows an increased potency, particularly against some resistant
clinical isolates belonging to Staphylococcus, Streptococcus,
and Enterococcus genera (Van Bambeke, 2006). In addition,
teicoplanin is active on vancomycin-resistant enterococci with
VanB-phenotype (Van Bambeke, 2006; Binda et al., 2014).
The superior antimicrobial potency of the lipoglycopeptide
teicoplanin in comparison to the glycopeptide vancomycin is
due to the in vivo membrane anchoring of the hydrophobic
tail of teicoplanin, which strengthens the bond to membrane-
localized peptidoglycan precursors and promotes synergic back-
to-back dimerization of antibiotic molecules (Allen and Nicas,
2003; Treviño et al., 2014). In addition, lipidation seems to
represent the key functional difference between vancomycin and
teicoplanin, which is related to their differing abilities of inducing
glycopeptide antibiotic resistance response in enterococci and
actinomycetes (Dong et al., 2002; Binda et al., 2018). To the
best of our knowledge, this is the first study exploring the
feasibility of conjugating teicoplanin to IONPs and testing the
potential of nanoconjugated teicoplanin as a promising tool for
treating bacterial infections caused by resistant bacteria.
MATERIALS AND METHODS
Materials
All chemical reagents, including acetonitrile (CH3CN),
ammonium formate (HCOONH4), ammonium hydroxide
(NH4OH), APTES, boric acid (H3BO3), crystal violet
(C25N3H30Cl), 2
′,7′-dichlorodihydrofluorescein (DCFH-
DA), N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide
hydrochloride (EDC), ethanol (C2H6O), ferric nitrate
[Fe(NO3)3 × 9H2O], formaldehyde (CH2O), glutaraldehyde
(C5H8O2), iron dichloride (FeCl2 × 4H2O), iron trichloride
(FeCl3 × 6H2O), N-hydroxysuccinimide (NHS), nitric acid
(HNO3), osmium tetroxide (OsO4), phosphate-buffered
saline (PBS), sodium cacodylate (C2H7AsO2), sodium
chloride (NaCl), sodium hydroxide (NaOH), sodium 2-(N-
morpholino)ethanesulfonic acid hemisodium salt (MES), and
teicoplanin, were purchased from Sigma-Aldrich, Milan, Italy.
The LIVE/DEAD BacLight fluorescence assay kit was purchased
by Thermo Fisher Scientific, Monza, Italy. Epon-Araldite 812
was purchased from Electron Microscopy Sciences, Hatfield,
PA, United States. All the chemical reagents were used without
additional purification.
Microbial Strains and Culture Conditions
Escherichia coli ATCC 35218, Bacillus subtilis ATCC 6633,
S. aureus ATCC 6538P (methicillin susceptible S. aureus, MSSA),
S. aureus ATCC 43300 (MRSA), Enterococcus faecalis ATCC
29212, and E. faecalis ATCC 51299 (VanB phenotype) were
obtained from the American Type Culture Collection (ATCC).
E. faecalis 9160188401-EF-34 (VanA phenotype) is a clinical
isolate, which was kindly provided by Laboratorio Microbiologia
Clinica – Ospedale di Circolo, Varese, Italy. E. coli and B. subtilis
were propagated overnight in Luria Bertani medium (LB, 2%
tryptone, 2% yeast extract, and 1% NaCl), and the S. aureus
and E. faecalis strains in Müller Hinton broth 2 (MHB2, 0.3%
beef infusion solids, 1.75% casein hydrolysate, and 0.15% starch)
with continuous shaking at 200 rpm and 37◦C. For exponential
growth, overnight cultures were transferred to fresh medium:
inocula were prepared to start the cultures with an optical density
at 600 nm (OD600 nm) of 0.1 in the final medium. For long-
term preservation, bacterial cultures were stored at−20◦C in 20%
glycerol. Media were acquired from Sigma-Aldrich, Milan, Italy,
unless otherwise stated.
Synthesis of the IONPs
Iron oxide (Fe2O3) NPs were synthesized using the
coprecipitation method reported by Balzaretti et al. (2017).
Briefly, under vigorous stirring for 30 min, 8.89 g of
FeCl3 × 6H2O and 3.28 g FeCl2 × 4H2O were mixed in
380 mL of water, while slowly adding 1.5 mL of HCl (37%)
dropwise into the solution to completely dissolve the salts.
Following this step, 25 mL of NH4OH (25%) was added. Particles
were washed several times with Milli-Q water and 40 mL of
2 M HNO3 was added and heated at 90
◦C for 5 min. Then,
particles were separated by a magnet from the reaction mixture;
subsequently, 60 mL of 0.34 M solution of Fe(NO3)3 × 9H2O
was added. The suspension was heated at 90◦C for 30 min. The
supernatant was removed and IONPs were collected by a magnet,
suspended in Milli-Q water, and left in dialysis overnight. IONPs
were stored at 4◦C.
Functionalization With APTES
To prepare functionalized IONPs, a standard protocol (Balzaretti
et al., 2017) was followed: a 1.5 M solution of APTES in
ethanol was added to 150 mg of IONPs and stirred for 1 h
at room temperature. Then, the temperature was increased to
90◦C and the solution was stirred for an additional hour. The
amino-modified IONPs (NP-APTES) were collected by a magnet,
washed several times, and suspended in Milli-Q water.
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Teicoplanin Conjugation to NP-APTES
To prepare teicoplanin-conjugated NPs (NP-TEICO), a solution
containing teicoplanin (500 µg), 13 mM EDC, and 26 mM NHS
was prepared and added to the NP-APTES (4 mg/mL) dispersed
in 30 mM MES buffer at pH 6.0 in a final volume of 1 mL. The
reaction was mixed for 6 h at room temperature. NP-TEICOwere
washed twice and resuspended in fresh 30 mM MES buffer at
pH 6.0.
Characterization of NPs
The shape, size, and size distribution of IONPs, NP-APTES,
and NP-TEICO were investigated by transmission electron
microscopy (TEM) using a JEOL 1010 electron microscope
(Tokyo, Japan). Samples for TEMwere dispersed inMilli-Q water
on carbon-coated copper grids and dried at room temperature.
The hydrodynamic diameter size and polydispersity index (PDI)
of IONPs, NP-APTES, and NP-TEICO were measured in 0.9%
NaCl. Zeta potential was measured on samples diluted in
1 mM KCl at 25◦C. Measurements were performed at 25◦C
using a 90 Plus Particle Size Analyzer (Brookhaven Instruments
Corporation, NY, United States).
HPLC Analysis
Teicoplanin was measured by HPLC according to the method
previously reported in Taurino et al. (2011). HPLC analyses
were performed on a 5-µm particle size Symmetry C18
(VWR International LCC, Radnor, PA, United States) column
(4.6 mm× 250 mm). The column was eluted at a 1 mL/min flow
rate with a 30-min linear gradient from 15 to 65% of Phase B,
followed by 10 min with 100% Phase B. For Phase A we used
a 32 mM HCOONH4, pH 7.0:CH3CN 90:10 (v/v) mixture, and
for Phase B a 32 mM HCOONH4, pH 7.0:CH3CN 30:70 (v/v)
mixture. Chromatography was performed with a model 1100
HPLC system (Elite Lachrom Hitachi LLC, VWR, Milan, Italy)
and UV detection was at 236 nm.
Agar Diffusion Test
Antimicrobial activities of IONPs, NP-APTES, and NP-TEICO
were tested against E. coli ATCC 35218, B. subtilis ATCC 6633,
and S. aureus ATCC 6538P by employing an agar diffusion
assay (Finn, 1959). Briefly, bacterial cultures were grown in
MHB2 until an OD600 nm of 0.4 was reached and then used
to prepare agar plates containing Müller-Hinton Agar (MHA).
10 µL of IONPs, NP-APTES, NP-TEICO (4 mg/mL loaded with
500 µg/mL of teicoplanin in the case of NP-TEICO), and of
teicoplanin (500 µg/mL) in 30 mM MES buffer, pH 6.0, were
loaded manually onto the inoculated plates. The plates were
incubated at 37◦C for 24 h. The diameters of the zones of bacterial
growth inhibition surrounding the droplets were measured.
Determination of Minimum Inhibitory
Concentration and Minimum Bactericidal
Concentration
Minimum inhibitory concentrations (MICs) of non-conjugated
and nanoconjugated teicoplanin were determined toward
B. subtilis, S. aureus, and E. faecalis strains by applying the
broth dilution method using MHB2, as recommended by the
Clinical and Laboratory Standards Institute guidelines (CLSI,
2018). About 5 × 105 exponentially growing bacterial cells were
inoculated into MHB2 containing increasing concentrations of
teicoplanin and NP-TEICO in 30 mM MES buffer, pH 6.0,
and shaken for 16–20 h at 37◦C. NP-TEICO concentrations
to be added were calculated considering the amount of
teicoplanin loaded onto IONPs (nanoconjugated teicoplanin)
under the reaction conditions described above. MICs were the
minimal concentrations of nanoconjugated and non-conjugated
teicoplanin at which no turbidity could be detected.
To evaluate the minimum bactericidal concentrations
(MBCs), 100 µL of bacterial cultures used for the MIC test were
plated ontoMHA and incubated at 37◦C for 24 h. MBCs were the
minimal concentrations of nanoconjugated and non-conjugated
teicoplanin at which no growth could be detected. The tolerance
level of each tested bacterial strain toward nanoconjugated and
non-conjugated teicoplanin was determined according to May
et al. (1998) using the following formula: Tolerance =MBC/MIC.
Growth Kinetic Analysis
Growth kinetics of B. subtilis ATCC 6633, S. aureus ATCC 6538P,
and E. coli ATCC 35218 populations were followed by measuring
OD600 nm using an UV-Vis V-560 Spectrophotometer (JASCO,
MD, United States) at regular time intervals. Preinocula were
prepared from overnight cultures in LB or MHB2 at 37◦C and at
200 rpm. Experiments were conducted in 50-mL tubes containing
a final volume of 10 mL of LB or MHB2 added after 1 h of growth
from inocula with equivalent volumes of IONPs, NP-APTES,
and NP-TEICO preparations (4 mg/mL) previously resuspended
in 30 mM MES buffer, pH 6.0, or with the teicoplanin control
solution (500 µg/mL).
Viability Assay
Viable counts (expressed as colony-forming units per mL,
CFU/mL) were estimated by employing the plate count
technique. For CFU measurement, a standard volume (10 µL)
of undiluted or serially diluted samples collected from stationary
phase cultures on treatment with teicoplanin, IONPs, NP-APTES,
and NP-TEICO, as reported above, were plated on nutrient agar.
Plates were incubated for 24 h at 37◦C to evaluate the viable cells.
Fluorescence Microscopy Analysis
To investigate the effect of IONPs, NP-APTES, and NP-TEICO
on bacterial cells, the LIVE/DEAD BacLight fluorescence assay
was used (L7007, Molecular probes, Thermo Fisher Scientific).
Following the manufacturer’s protocol, bacteria were cultivated
overnight at 37◦C and agitated at 200 rpm, appropriately diluted,
and treated for 5 h with 4 mg/mL of IONPs, NP-APTES, and NP-
TEICO and teicoplanin (500µg/mL). From these cultures, 10 mL
of each bacterial solution was centrifuged at 7000 rpm for 15 min.
The supernatants were discarded and the pellets were suspended
in saline solution (0.9%). The samples were incubated at room
temperature for 1 h (mixing every 15 min) and then washed
twice with saline solution. Finally, the pellets were resuspended
in an equal volume of saline solution (0.9%). Then, 3 µL of
dye mixture was added to each 1 mL of the prepared bacterial
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samples and incubated in the dark for 15 min after properly
mixing the bacterial suspensions. Fluorescence images were taken
by trapping 5 µL of stained bacterial samples between a slide and
a cover slip. For imaging the samples, an optical microscope with
appropriate filters was employed (Axiophot; Carl Zeiss, Milan,
Italy). ImageJ (Schneider et al., 2012) was used to quantify total
fluorescence intensity of the bacteria. Intensities were expressed
as percentage (%) relative to the saturation fluorescence within
the field; red and green fluorescence stains corresponded to live
or dead bacteria, respectively (Borcherding et al., 2014; Arakha
et al., 2015a,b).
Transmission Electron Microscopy
Analysis
The interaction pattern of NPs with bacteria was also studied
by TEM. After 5 h of exposure to 4 mg/mL IONPs, NP-APTES,
NP-TEICO, or teicoplanin (500 µg/mL), pellets were washed
with PBS and fixed in Karnovsky solution (4% formaldehyde,
2% glutaraldehyde, 0.1 M sodium cacodylate, pH 7.2) overnight
at 4◦C. The samples were washed three times with 0.1 M
sodium cacodylate for 10 min and postfixed in the dark for
1 h with 1% osmium tetroxide in 0.1 M sodium cacodylate
buffer, pH 7.2, at room temperature. After dehydration with a
series of ethyl alcohol, the samples were embedded in an Epon-
Araldite 812 1:1 mixture. Thin sections (90 nm), obtained with a
Pabisch Top-Ultra ultramicrotome (Emme 3 S.r.l., Milan, Italy),
were observed with a Morgagni electron microscope (Philips,
Eindhoven, Netherlands) operated at 80 keV.
Biofilm Assay
S. aureus ATCC 6538P cultures, grown overnight in LB,
were diluted in fresh medium to reach a cell density of 107
CFU/mL and dispensed in 24-well plates, adding increasing
concentrations of nanoconjugated or non-conjugated teicoplanin
(2.5, 5, and 10 µg/mL) and of naked IONPs or NP-APTES
(20, 40, and 80 µg/mL). The amounts of NPs to be added took
into account the teicoplanin loaded on NPs under the reaction
conditions described above. Following incubation at 37◦C for
24 h, the adherent biomass was quantified by crystal violet (CV)
staining. Biofilms were stained with CV 0.1% for 20 min, washed
twice with PBS, and air dried overnight at room temperature;
the CV was then dissolved in 33% acetic acid for 10 min. The
amount of solubilized dye was spectrophotometrically measured
at 595 nm (Infinite 200 PRO; TECAN, Männedorf, Switzerland).
To assess the effect of teicoplanin and of NP preparations on the
cell viability of planktonic and adherent cell subpopulations, cells
from the planktonic phase were collected and adherent cells were
recovered by scraping the wells and then suspended in 1 mL of
phosphate buffer. Cultures were diluted and CFU were estimated
by plate counting inMHAplates. Viable counts of planktonic cells
were expressed as CFU/mL and adherent cells as CFU per well
(CFU/well).
To test the effect of teicoplanin and NP preparations on
biofilm dispersal, biofilms were prepared as indicated previously
and incubated at 37◦C for 48 h before adding nanoconjugated
or non-conjugated teicoplanin (5, 25, and 50 µg/mL) and naked
IONPs or NP-APTES (40, 200, and 400 µg/mL). Following
24-h incubation at 37◦C, biofilm biomass was evaluated by CV
staining and the cell viability of adherent and planktonic cells was
estimated by applying the viable count technique, as previously
described.
Cell Cultures
Two different cell lines were used to evaluate NP-TEICO in vitro
cytotoxicity: a tumor model SKOV-3 cell line from ovarian
adenocarcinoma and a non-tumor cell line, hASCs (human
adipose-derived stem cells). SKOV-3 cells were cultured as
reported in the literature (Cappellini et al., 2015). hASCs were
isolated and cultured as previously reported (Palombella et al.,
2017).
Cytotoxicity Test
Cell cytotoxicity was determined by measuring ATP content
using the RealTime-GloTM MT Cell Viability Assay (Promega,
Milan, Italy) according to the manufacturer’s instructions.
Briefly, 500 cells were plated in 96-well plates in 200 µL of
cell medium (RPMI for SKOV-3 and DMEM/DMEM F12 1:1
for hASC). After 24 h, the cells were exposed to increasing
concentrations of nanoconjugated or non-conjugated teicoplanin
or to the corresponding concentrations of NPs (considering the
teicoplanin loaded per mg of NPs) and then a solution 2× the
substrate and NanoLuc R© Enzyme were added. The cells were
incubated at 37◦C and in 5% CO2-humidified atmosphere, and
luminescence was read every 24 h using the Infinite F200 plate
reader (Tecan Group, Männedorf, Switzerland).
Statistics
All experiments were repeated at least three times on separate
dates. Mean and standard deviation (SD) calculations were
performed using Microsoft Excel 2003 (Microsoft Corporation,
Redmond, WA, United States). Data were analyzed by means
of one-way analysis of variance (Origin_7.0 SR0; Origin lab
Corporation, Northampton, MA, United States). Significant
effects of treatments were estimated (p < 0.05, p < 0.01, and
p < 0.0001).
RESULTS
Characterization of Synthetized NPs
Numerous methods for synthesizing IONPs have been reported
in the literature (Wu et al., 2015). In this study, we used
the coprecipitation method previously optimized by Balzaretti
et al. (2017), by which IONPs with good stability and size
distribution and no tendency to aggregation could be produced.
We confirmed that the NPs obtained had a spherical shape
and an average diameter of 10.5 ± 4 nm, as shown by TEM
micrograph (Figures 1A,D). The functionalization protocol, used
to introduce amino groups on the IONPs (Figure 2), led to an
insignificant increase in the diameter of NP-APTES, which was
10.6 ± 3.6 nm (Figures 1B,E). Teicoplanin was conjugated by
following a slightly modified protocol, which was previously used
for enzyme conjugation (Armenia et al., 2017): carboxylic groups
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FIGURE 1 | TEM images and size distribution of IONPs (A,D), NP-APTES (B,E), and NP-TEICO (C,F).
FIGURE 2 | Synthetic route for teicoplanin conjugation to IONPs (not in scale). The first step is functionalization of the IONPs with APTES, followed by the conjugation
of teicoplanin by covalent bonding of the terminal carboxylic groups of the antibiotic molecules with the amino groups of NP-APTES via EDC/NHS cross-linking.
of teicoplanin molecules reacted with the amino groups on the
surface of NP-APTES after EDC/NHS antibiotic activation (see
below, Figure 2). Teicoplanin conjugation led to a more irregular
shape of the particles and a slight tendency to aggregation.
It is known that correctly conformed teicoplanin molecules
tend to dimerize back-to-back in aqueous solutions and that
dimerization plays an important role in their biological activity
(Treviño et al., 2014). However, this phenomenon was not strong
as no NP precipitation occurred. NP-TEICO had an average
diameter of 13.6 nm (Figures 1C,F).
Transmission electron microscopy observations were
complemented by measuring dynamic light scattering (DLS) of
the hydrodynamic size of IONPs (Table 1); their diameter was
estimated to be 14.2 ± 0.5 nm with an average size distribution
(PDI) of 0.127, indicating a slight polydispersity typical for the
coprecipitation synthesis (Wu et al., 2015). For NP-APTES, an
increase in the hydrodynamic diameter (26.8 ± 0.2 nm) due
to the presence of the APTES shell around the NP core was
registered. The hydrodynamic diameter of NP-TEICO was much
larger (568.2 ± 0.6 nm) (Table 1), probably due to aggregate
formation in the medium used for DLS analysis and to the effect
of the glycopeptide side chains and their tendency to dimerize,
which might slow down particle diffusion and increase their
apparent size (Szpak et al., 2013; Table 1). The difference in NP
sizes measured by DLS versus TEM is generally attributed to the
formation of extra hydrate layers in aqueous solutions (De Palma
et al., 2007; Gonçalves et al., 2017). In addition, antibiotic shells
conjugated to NPs are usually not sufficiently electron dense to
be visible under the electron microscope. The measurement of
zeta potential (Table 1) showed that the superficial charge of
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TABLE 1 | Physical parameters of synthesized IONPs, NP-APTES, and NP-TEICO.
Baseline Polydispersity Diameter (nm) Conductance (µS) Mobility Z potential (mV)
IONPs 9.9 0.127 14.2 ± 0.5 421 1.5 11.0 ± 0.8
NP-APTES 9 0.18 26.8 ± 0.2 373 1.9 22.5 ± 0.5
NP-TEICO 9 0.189 568.2 ± 0.6 400 1 12.8 ± 0.6
NP-APTES was twofold higher than for IONPs, that is, 22.5± 0.2
versus 11 ± 0.8 mV, due to the presence of the amino groups of
APTES. A reduction in the surface charge was indeed observed
after teicoplanin conjugation: NP-TEICO zeta potential was
12.8 ± 0.6 mV, indicating that NP-APTES were successfully
loaded with teicoplanin.
Preparation of NP-TEICO
Teicoplanin was conjugated to NP-APTES using standard
EDC/NHS chemistry: EDC reacted with the carboxylic group of
the antibiotic, forming an active O-acylisourea intermediate that
could be displaced by the nucleophilic attack of the amino groups
present on the NP-APTES surface (Figure 2; Hermanson, 2013).
Different reaction conditions (reactionmedium, EDC/NHS ratio,
teicoplanin concentration, time, and temperature of reaction)
were explored to improve teicoplanin conjugation onNP-APTES.
The quantity of teicoplanin bound to the surface of NP-APTES
was estimated by subtracting the unreacted teicoplanin present
in the supernatant from the added total antibiotic amount.
Teicoplanin was quantified by reverse-phase HPLC as previously
reported (Taurino et al., 2011). First trails in water, PBS, andMES
buffer indicated that the latter, at pH 6.0, was the most preferable
medium for the conjugation reaction (data not shown). As
reported inTable 2, HPLC analyses confirmed that under the best
experimental conditions tested so far, that is, 4 mg/mL of NP-
APTES in 30 mMMES buffer, pH 6.0, 13 mM EDC, 26 mMNHS,
500 µg/mL of teicoplanin, the teicoplanin conjugation yield was
TABLE 2 | Reaction conditions tested for teicoplanin conjugation to NP-APTES
via EDC/NHS chemistry in 30 mM MES, pH 6.0.
Teicoplanin
(µg/mL)
EDC
(mM)
NHS
(mM)
Temperature
(◦C)
Time
(h)
Yield (%)
100 26 13 4 2 10 ± 0.7
100 26 13 4 4 10 ± 1.5
100 26 13 4 6 12 ± 1.0
100 26 13 25 2 25 ± 0.5
100 26 13 25 4 30 ± 0.4
100 26 13 25 6 65 ± 0.8
100 13 26 25 2 70 ± 1.7
100 13 26 25 4 85 ± 1.4
50 13 26 25 6 100 ± 1.2
100 13 26 25 6 100 ± 0.7
500 13 26 25 6 90 ± 0.9
1000 13 26 25 6 50 ± 0.5
NP-APTES were used at a concentration of 4 mg/mL. Conjugation yield was
calculated by estimating the amount of residual teicoplanin in the reaction medium
by HPLC.
approximately 90%. Under these conditions, more than 100 µg
of teicoplanin was loaded per mg of NP-APTES.
NP-TEICO prepared in this way remained chemically stable
when stored at pHs ranging from 5.5 to 7.1 and temperatures
from−20 to 25◦C. Under these conditions, release of teicoplanin
from NP-TEICO was measured by HPLC analysis of incubation
buffer; 100% of the antibiotic remained fully attached to NPs
for 1 week and decreased by approximately 10% in 1 month
(data not shown). Consistently, the antimicrobial activity of NP-
TEICO – measured by the antimicrobial susceptibility test versus
S. aureus ATCC 6538P and B. subtilis ATCC 6633 (see below) –
was also maintained. After 3 weeks, NP-TEICO maintained
from 70 to 90% of its initial antimicrobial activity. Under the
same conditions, a water solution of teicoplanin (500 µg/mL)
maintained 90% of its initial antimicrobial activity.
Antimicrobial Activity of NP-TEICO
Antibacterial activity of NP-TEICO was initially investigated by
comparing the growth inhibitory effects of two commonly used
representative species of Gram-positive bacteria, that is, S. aureus
ATCC 6538P and B. subtilis ATCC 6633, and the Gram-negative
E. coli ATCC 35218, using an agar diffusion assay. Figure 3
reveals that NP-TEICO inhibited the growth of S. aureus and
FIGURE 3 | Agar diffusion assay for measuring the antimicrobial activity of
IONPs, NP-APTES, NP-TEICO, and non-conjugated teicoplanin versus the
two Gram-positive bacteria S. aureus ATCC 6538P (A) and B. subtilis ATCC
6633 (B), and versus the Gram-negative E. coli ATCC 35218 (C).
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B. subtilis, whereas no inhibition halos were observed for E. coli,
thus demonstrating that NP-TEICO maintained the typical
activity and spectrum of action of teicoplanin. Sizes of inhibition
halos for the nanoconjugated teicoplanin were not comparable
with the ones determined by the non-conjugated teicoplanin,
as expected, considering the probably slower diffusion rate of
NP-loaded antibiotic in agar medium. Conversely, IONPs and
NP-APTES did not show any inhibition halos toward either the
Gram-positive or the Gram-negative bacteria. These data indicate
that the antimicrobial activity measured by the agar diffusion
assay was conferred to NP-TEICO by the conjugation of the
antibiotic and that it was not an intrinsic feature of IONPs.
Table 3 reports the MICs of nanoconjugated and non-
conjugated teicoplanin toward clinically relevant strains of
S. aureus and E. faecalis. Although the potency of nanoconjugated
teicoplanin was slightly reduced in comparison with the
non-conjugated antibiotic, NP-TEICO maintained a valuable
antibiotic activity against MRSA and on vancomycin-resistant
E. faecalis with a VanB phenotype. MICs and MBCs, and
consequently the tolerance levels of NP-TEICO toward B. subtilis,
S. aureus, and E. faecalis, showed the same trend as those
measured for non-conjugated teicoplanin. NP-TEICO and non-
conjugated teicoplanin were inactive toward the Gram-negative
E. coli and toward the vancomycin- and teicoplanin-resistant
E. faecalis clinical isolate with a VanA phenotype (Van Bambeke,
2006; Binda et al., 2014).
Effects of NPs on Bacterial Growth
Kinetics and Cell Viability
As the antimicrobial activity of IONPs and their derivatives is
a matter of intensive debate (Auffan et al., 2008; Chatterjee
et al., 2011; Borcherding et al., 2014; Arakha et al., 2015a; Ansari
et al., 2017), we further investigated the effects of IONPs, NP-
APTES, and NP-TEICO on bacterial cell viability, by adding
our NP preparations at the log phase of the growth kinetics
of S. aureus ATCC 6538P, B. subtilis ATCC 6633, and E. coli
ATCC 35218 populations. Cultures with no added NP or to
which only teicoplanin was added were used as negative and
positive controls. Figure 4 indicates that the three bacterial
species responded differently to NP interaction. S. aureus growth
kinetics (Figure 4A) were dramatically affected by the addition
of NP preparations and, as expected, by the treatment with
teicoplanin. Albeit with a slightly different kinetics, cell density
appeared equally reduced by two-thirds on 5 h of incubation.
Indeed, NP-TEICO and non-conjugated teicoplanin drastically
reduced the population growth of B. subtilis, whereas the effects
of IONPs and NP-APTES were clearly less relevant (Figure 4B).
Finally, teicoplanin was completely inactive toward the Gram-
negative E. coli, whereas the addition of IONPs, NP-APTES, and
NP-TEICO halved the population growth in a comparable mode
(Figure 4C).
Significantly, CFU measurements at the end of the growth
kinetics reported in Figure 5 clearly indicate that exposure of
Gram-positive bacteria to teicoplanin and NP-TEICO cleared
the bacteria population, confirming the comparable antibiotic
activity of the nanoconjugated versus the non-conjugated
antibiotic (Figure 5). As expected, teicoplanin and NP-TEICO
were ineffective against E. coli cells, which conforms to the
antimicrobial spectrum of the antibiotic. In addition, exposure
to IONPs and NP-APTES was not bactericidal for any of the
tested strains as the cells survived quite well, and in some cases
(E. coli) even better than the untreated cultures. Thus, we can
conclude that NP-TEICO retained an antibiotic activity that was
comparable to that of the non-conjugated teicoplanin, whereas
IONPs and NP-APTES showed a species-specific transient
interaction with bacterial cells, which slowed down population
growth but did not kill bacterial cells. This phenomenon merits
further investigation.
Interaction Patterns of NPs With
Bacterial Cells
To shed light on the interaction pattern at the IONPs-, NP-
APTES- and NP-TEICO-bacteria interfaces, we investigated the
effect of adding NP on bacterial cell integrity by using the
TABLE 3 | Comparison of MICs, MBCs, and tolerance levels between non-conjugated and nanoconjugated teicoplanin.
MIC (µg/mL) MBC (µg/mL) Tolerance level
Non-conjugated
teicoplanin
Nanoconjugated
teicoplanin
Non-conjugated
teicoplanin
Nanoconjugated
teicoplanin
Non-conjugated
teicoplanin
Nanoconjugated
teicoplanin
B. subtilis ATCC 6633 2 2 >128 >128 >64 >64
S. aureus ATCC 6538P
(MSSA)
1 2 128 128 128 64
S. aureus ATCC 43300
(MRSA)
0.5 2 64 >128 128 >64
E. faecalis ATCC 29212 0.5 1 32 32 64 32
E. faecalis ATCC 51299
(VanB)
0.5 2 64 >128 128 >64
E. faecalis
9160188401-EF-34 (VanA)
>128 >128 >128 >128 − −
E. coli ATCC 35218 >128 >128 >128 >128 − −
The values represent the average of the data from three independent experiments.
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FIGURE 4 | Population growth kinetics of S. aureus ATCC 6538P (A),
B. subtilis ATCC 6633 (B), and E. coli ATCC 35218 (C) exposed to teicoplanin
(orange), IONPs (red), NP-APTES (green), and NP-TEICO (violet). Cultures
without any addition (blue) were used as controls. Growth was recorded for
5 h. Black arrows indicate the addition (after 1 h of growth) of NP preparations
and of teicoplanin to the bacterial populations. Triplicate experiments were
conducted for each condition: standard errors were lower than 5%.
LIVE/DEAD BacLight fluorescence assay. According to the assay
principle and as shown in Figure 6, viable cells having an intact
cell membrane were stained green by the Syto9 fluorescence
dye, whereas non-viable cells with deformed cell membranes
FIGURE 5 | Bacterial cell viability of S. aureus ATCC 6538P, B. subtilis ATCC
6633, and E. coli ATCC 35218 measured as CFUs after 5-h growth (see
Figure 4) in the presence of IONPs (black bar), NP-APTES (gray bar),
NP-TEICO (light gray bar), and teicoplanin (white bar) compared to the
untreated control populations (lined bar). Triplicate experiments were
conducted for each condition, and the error bars represent the standard
errors. One-way ANOVA analyses, ∗p < 0.05 and ∗∗∗p < 0.0001.
were stained red by propidium iodide fluorescence dye (Arakha
et al., 2015a). As shown in Figures 6A–C, untreated cells of
S. aureus ATCC 6538P, B. subtilis ATCC 6633, and E. coli ATCC
35218 exhibited green fluorescence, indicating the presence
of 99% viable cells. Figures 6D–L show that both Gram-
positive and Gram-negative bacteria tended to aggregate on NPs
when present. In the presence of IONPs and NP-APTES, the
S. aureus population exhibited almost 90% of green viable cells
(Figures 6D,G), whereas more than 50% cells turned to red
fluorescence on exposure to NP-TEICO (Figure 6J). On the other
hand, the B. subtilis population exposed to IONPs (Figures 6E,H)
exhibited the presence of 75% green viable cells, whereas the 95%
of B. subtilis cells treated with NP-TEICO were red (Figure 6K),
indicating that nanoconjugated teicoplanin caused a severe loss
of membrane integrity and cell viability. Control populations of
S. aureus and B. subtilis treated with non-conjugated teicoplanin
exhibited 98% of red non-viable cells (Figures 6M,N). In the
presence of IONPs, NP-APTES, NP-TEICO, and teicoplanin,
the fraction of red fluorescent E. coli cells was insignificant
compared to untreated cells (Figures 6F,I,L,O). Once again, these
observations confirm that the three bacterial species responded
as expected to nanoconjugated and non-conjugated teicoplanin
antibiotic action. They also suggest that naked IONPs and
NP-APTES interacted with the different bacteria in a species-
specific mode, likely depending on the diverse bacterial surface
composition, as already suggested by other authors (Huang et al.,
2010; Ebrahiminezhad et al., 2014; Arakha et al., 2015a; Dinali
et al., 2017).
Transmission electron microscopy images
(Figures 7A,D,G,J,M) indicated that the exposure of S. aureus
ATCC 6538P cells to IONPs, NP-APTES, NP-TEICO, and
teicoplanin significantly altered cell morphology in comparison
to the untreated cells. IONPs, NP-APTES, and, to a significantly
greater extent, NP-TEICO interacted with the cell wall of
this Gram-positive species. In the presence of NP-APTES,
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FIGURE 6 | Fluorescence microscopy images of live and dead cells of S. aureus ATCC 6538P [first column on the left: (A,D,G,J,M)], B. subtilis ATCC 6633 [middle
column: (B,E,H,K,N)], and E. coli ATCC 35218 [column on the right: (C,F,I,L,O)] in the absence and presence of different NP preparations and of teicoplanin. (A–C)
untreated cells; (D–F) cells treated with IONPs; (G–I) cells treated with NP-APTES; (J–L) cells treated with NP-TEICO; (M–O) cells treated with teicoplanin. Scale
bar: 12 µm.
NP-TEICO, and teicoplanin, an increasing percentage of cells
without cell walls, so-called ghost cells, became detectable
(Figures 8A,B). Lysed cells, too, which presented damage
in cell walls with cytoplasmic content leaking out, were
visible within NP-APTES- and NP-TEICO-treated cells
(Figures 8A,C). Furthermore, in the presence of NP-APTES
and NP-TEICO, intracellular spherical membrane-layered,
mesosome-like structures could be detected inside the cells
(Figures 8A,B). Mesosomes were previously described by
other authors (Shimoda et al., 1995; Hartmann et al., 2010),
as a consequence of cell membrane damage in S. aureus cells
treated with antimicrobial peptides such as defensins and
gramicidin S.
Conversely, most of the B. subtilis ATCC 6633 cells
(Figures 7B,E,H) exposed to IONPs and NP-APTES showed the
same morphology as untreated cells, with undamaged structures,
although a few dead or dying cells were detected, characterized
by a rough surface and by an interrupted cell membrane. Indeed,
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FIGURE 7 | TEM images of S. aureus ATCC 6538P [first column on the left: (A,D,G,J,M)], B. subtilis ATCC 6633 [middle column: (B,E,H,K,N)], and E. coli ATCC
35218 [column on the right: (C,F,I,L,O)] cells in the absence and presence of different NP preparations and of teicoplanin. (A–C) untreated cells; (D–F) cells treated
with IONPs; (G–I) cells exposed to NP-APTES; (J–L) cells exposed to NP-TEICO; (M–O) cells treated with teicoplanin. Scale bars: 1 µm.
the effect of NP-TEICO and teicoplanin on cell integrity was
dramatic (Figures 7K,N). Cells treated with NP-TEICO and
teicoplanin lost their envelope integrity as a consequence of the
antibiotic action (Figures 8D,E).
No specific alteration in cell morphology was observed in
NP- or antibiotic-treated cells of E. coli in comparison to the
untreated ones (Figures 7C,F,I,L,O). Interestingly, in this case,
IONPs and, to a much greater extent, NP-APTES tended to
stick to the microorganism envelope, whereas the presence of
NP-TEICO impeded this interaction. This observation seems to
confirm the occurrence of an unspecific electrostatic interaction
between positively charged NP-APTES and the negatively
charged external cell membrane of this Gram-negative strain,
which was previously suggested by other authors (Kell et al., 2008;
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FIGURE 8 | TEM images of S. aureus ATCC 6538P (A–C) exposed to NP-APTES (A), NP-TEICO (B), teicoplanin (C), and B. subtilis ATCC 6633 (D,E) exposed to
NP-TEICO (D) and teicoplanin (E). Scale bar: 500 nm. ◮indicates ghost cells; ∗ indicates lysed cells; white arrows indicate mesosome-like structures.
Huang et al., 2010; Ebrahiminezhad et al., 2014; Arakha et al.,
2015a; Dinali et al., 2017).
Effect of NPs on S. aureus Biofilm
Because of the clinical relevance of biofilm infections, the effect
of our NP preparations was tested on S. aureus ATCC 6538P
biofilm formation and eradication. As shown in Figure 9A,
non-conjugated teicoplanin and nanoconjugated teicoplanin
inhibited significantly the biofilm formation at a concentration
of 2.5 µg/mL (p = 8.03 × 10−5) and 5 µg/mL (p = 0.002),
respectively. No inhibitory effect on biofilm formation was
observed after adding IONPs or NP-APTES in comparison
to the untreated condition. In the same experimental setting,
investigating the effect of IONPs, NP-APTES, NP-TEICO, and
teicoplanin on the bacterial viability of adherent and planktonic
cell subpopulations gave further information. It was confirmed
that IONPs and NP-APTES did not influence the viability of
the two subpopulations. Conversely, nanoconjugated and non-
conjugated teicoplanin inhibited in a dose-dependent manner
the cell viability of both planktonic (Figure 9B) and adherent
(Figure 9C) cells. Teicoplanin at 5 µg/mL caused the decrease
of approximately 5 log units in the survival of planktonic
cells in comparison to the untreated control cells, whereas
the NP-TEICO addition showed a comparable antimicrobial
effect at the highest tested concentration of nanoconjugated
teicoplanin corresponding to 10 µg/mL (Figure 9B). Increasing
concentrations of non-conjugated teicoplanin caused a reduction
of 2–3 log units in the survival of adherent cells, whereas, notably,
the effect of nanoconjugated teicoplanin toward adherent cells
was more pronounced (a reduction of 5 log units) than that of
non-conjugated teicoplanin at 10 µg/mL and it was statistically
significant (p = 0.010) (Figure 9C). Conversely, neither non-
conjugated teicoplanin nor nanoconjugated teicoplanin showed
any dispersal effect on 48-h-old biofilms (data not shown), as
expected, taking into account that this glycopeptide antibiotic
inhibits cell wall synthesis in exponentially growing bacterial cells
and is not active on bacterial cells entering into the stationary
phase (Binda et al., 2014; Marcone et al., 2018).
Cytotoxicity of NP-TEICO
Cytotoxicity of NP-TEICO was evaluated using two different
human cell lines, the well-established immortalized tumor cell
line (SKOV-3) (Cappellini et al., 2015) and primarymesenchymal
stem cells extracted from human adipose tissue, which are
particularly sensitive to nanomaterials (Palombella et al., 2017).
Results shown in Figure 10 indicate that teicoplanin did not exert
any effect on the cell viability of either of the human cell lines at
any of the tested concentrations. Conversely, both SKOV-3 cells
and hASC responded to the exposure of IONPs and NP-TEICO
in a concentration-dependent manner. No significant decrease
in cell viability was observed after adding nanoconjugated
teicoplanin in the range of teicoplanin antibacterial MICs
(0.78 µg/mL) (Figures 10A,B). The corresponding amounts
of carrying NPs did not influence cell viability significantly
(Figures 10A,B). At a concentration threefold higher than the
antibacterial MICs of NP-TEICO (6 µg/mL), the effects of
nanoconjugated teicoplanin and of the carrier NPs significantly
differed from that of the free antibiotic. Naked IONPs reduced
cell viability by more than 60% (after 24 h of exposure) to 50%
(after 96 h) in SKOV-3 cells (Figure 10C), and by 50% (after 24 h)
to 70% (after 96 h) in hASC (Figure 10D). NP-TEICO were less
cytotoxic, reducing cell viability by 40% (after 24 h) to 20% (after
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FIGURE 9 | Effect of increasing concentrations of teicoplanin, NP-TEICO,
IONPs, and NP-APTES on S. aureus ATCC 6538P biofilm formation. In the
case of NP preparations, the amounts to be added were defined considering
the teicoplanin loaded on IONPs under the conditions defined in the Materials
and Methods. Effect on adherent biomass following crystal violet staining (A).
Effect on planktonic (B) and adherent (C) cells exposed to teicoplanin
(orange), IONPs (red), NP-APTES (green), and NP-TEICO (violet) on viability
assay. The values are expressed as mean ± SD of three independent
experiments. One-way ANOVA analyses, ∗p < 0.05, ∗∗p < 0.01, and
∗∗∗p < 0.0001.
96 h) in SKOV-3 cells (Figure 10C) and by less than 30% (after
24 h) to 20% (after 96 h) in hASC (Figure 10D). Interestingly,
conjugation of antibiotic molecules to IONPs surface tended to
reduce their intrinsic cytotoxicity, as already reported by other
authors who demonstrated that covering the NP surface shields
toxicity and improves biocompatibility (Javed et al., 2017; Xiang
et al., 2017; Xie et al., 2017, 2018).
DISCUSSION
In the era of antibiotic resistance, the lipoglycopeptide
teicoplanin is an extremely important antibiotic used for
the prophylaxis and treatment of serious infections caused
by Gram-positive bacteria, including MRSA and E. faecalis
(Van Bambeke, 2006; Marcone et al., 2018). It is used to
treat endocarditis, bacteremia, and bone and joint infections.
Because of its efficacy and safety, it is used in pediatrics, too.
Its spectrum of antibacterial action is similar to that of the
previously discovered glycopeptide vancomycin, but teicoplanin
has several advantages over vancomycin in the treatment
of serious infections: longer half-life, lower nephrotoxicity
and ototoxicity, and lack of requirement for serum assays in
treated patients. Because of its better stability in vivo, it can
be administered once a day or with an alternate daily dosage
and by intravenous bolus or by intramuscular injection. Oral
administration of teicoplanin has also been demonstrated to
be effective in the treatment of pseudomembranous colitis and
C. difficile-associated diarrhea. In addition, teicoplanin is active
on some of the vancomycin-resistant enterococci, which are
increasingly spreading in hospitals (Binda et al., 2014).
Notwithstanding these important features, to the best of
our knowledge, this is the first report of using teicoplanin to
functionalize NPs. The teicoplanin molecule has an addressable
functional group (the N-terminal carboxylic group of the
heptapeptide chain) that we used to covalently bind the amino-
activated IONPs. Although there are few published data on
optimizing the fabrication of nanoconjugated antibiotics onto
IONPs (Lin et al., 2005; Hussein-Al-Ali et al., 2014; Zhu et al.,
2015; Dinali et al., 2017), we succeeded in anchoring more than
100 µg of teicoplanin per mg of NP-APTES in this work. The
antimicrobial potency of nanoconjugated teicoplanin was slightly
lower than that of the non-conjugated counterpart, particularly
toward resistant clinical isolates, but NP-TEICO conserved the
teicoplanin antimicrobial spectrum of activity toward Gram-
positive bacteria and it was particularly active in controlling
S. aureus biofilm formation. The external membrane of Gram-
negative bacteria covering the peptidoglycan layer remained
highly impenetrable to both NP-TEICO and teicoplanin,
impeding their interaction with the molecular target (Binda et al.,
2014). One of the positive features of NP-TEICO prepared in
this way was that the formulation maintained chemical stability
and antimicrobial activity for at least 1 month. This aspect is
relevant, considering that one main advantage of using magnetic
antibiotic nanocarriers in vivo could be that they can be recovered
and recycled after single uses, reducing local dose administration
and potential side effects and decreasing the risk of selective
Frontiers in Microbiology | www.frontiersin.org 13 October 2018 | Volume 9 | Article 2270
Time: 19:27 # 14
Armenia et al. Nanoconjugated Glycopeptide Antibiotics: The Case of Teicoplanin
FIGURE 10 | Cell viability of SKOV 3 (A,C) and hASC (B,D) after different times of exposure to IONPs (black), NP-TEICO (gray), and teicoplanin (white). Cell viability
is expressed as a percentage of viable cells compared to the untreated sample, set as 100%. Here, 0.78 µg/mL of non-conjugated or nanoconjugated teicoplanin or
6.24 µg/mL of carrying NPs were added in (A,B); 6 µg/mL of non-conjugated or nanoconjugated teicoplanin or 48 µg/mL of carrying NPs were added in (C,D). In
the case of NP preparations, the amounts to be added were defined considering the teicoplanin loaded on IONPs under the conditions defined in the Materials and
Methods. The values are expressed as mean ± SD of three independent experiments. One-way ANOVA analyses, ∗p < 0.05 and ∗∗p < 0.01.
pressure on resistant strains. In addition, their targeted delivery
to the site of infection/biofilm by using an external magnetic field
might increase their in situ concentration, potentiating their local
efficacy. For this reason, we consider the fact that NP-TEICO
inhibited S. aureus biofilm formation, conserving the activity
of non-conjugated teicoplanin versus the planktonic cells and
improving it toward the adherent cells, to be promising. Different
non-specific interactions such as electrostatic, hydrophobic, and
van derWaal interactions are responsible for adhesion of bacteria
on anymaterial surfaces creating biofilms. Thus, it is possible that
NP-TEICO anti-biofilm activity is potentiated (in comparison to
the non-conjugated antibiotic) by intercepting these non-specific
interactions, although in our experiments IONPs and NP-APTES
had no effect on biofilm formation.
Unfortunately, S. aureus has dramatically re-emerged
as a clinically relevant pathogen due to its resistance to
antibiotics and the increased use of indwelling clinical devices.
Millions of indwelling medical devices are implanted every
year, and S. aureus is the major culprit for infections and
failure of these devices (Arciola et al., 2018). S. aureus
biofilms are also implicated in chronic wound infections
such as diabetic foot ulcers, venous stasis ulcers, and pressure
sores, which are quite resistant to antibiotic treatments.
Teicoplanin carried by magnetically driven NPs can more
easily reach deep tissue infections, which are difficult to treat
using topical antibiotics due to the poor tissue penetration,
and better penetrate the diffusion barriers that biofilms
produce.
Frontiers in Microbiology | www.frontiersin.org 14 October 2018 | Volume 9 | Article 2270
Time: 19:27 # 15
Armenia et al. Nanoconjugated Glycopeptide Antibiotics: The Case of Teicoplanin
In the last decade, a certain level of intrinsic antimicrobial
and cytotoxicity activity has been controversially attributed to
the IONPs themselves. Although IONPs and NP-APTES have
shown some antibacterial effect against diverse Gram-positive
and Gram-negative bacteria, the real extent of this phenomenon
and the underlying mechanism has hitherto not been well
understood (Baranwal et al., 2018). Ansari et al. (2017) reported
a dose-dependent antibacterial activity of IONPs against Bacillus
cereus andKlebsiella pneumoniae. In contrast, Auffan et al. (2008)
indicated that chemically stable IONPs were not toxic to E. coli
at 700 mg/L, whereas Chatterjee et al. (2011) reported a dose-
dependent effect on E. coli cells. Borcherding et al. (2014) showed
that IONPs had a positive effect in promoting the growth of
Pseudomonas aeruginosa. Arakha et al. (2015a) published an
illuminating study and demonstrated, by combining a complete
set of microbiological and biophysical methods, that IONPs did
not show any significant antimicrobial activity toward B. subtilis
and E. coli. Coating IONPs with positively charged chitosan,
instead, conferred themwith an increased so-called antimicrobial
propensity against B. subtilis and E. coli, which depends on
the interfacial interaction between NPs and bacterial surfaces
(Arakha et al., 2015a,b).
In the present work, we compared the antimicrobial activity of
NP-TEICO with that shown by IONPs and NP-APTES by using
a set of methods (agar diffusion assay, BacLight fluorescence
assay, bacterial growth kinetics, CFU measurement, and TEM
observations) comparable to those previously used by Arakha
et al. (2015a,b). Thus, we could conclude that the antibiotic
activity of nanoconjugated and non-conjugated teicoplanin
differed dramatically from the phenomenon described as
antimicrobial propensity, which is based on an electrostatic
attraction between cationic NPs and anionic bacterial cell surfaces
(Arakha et al., 2015a,b). Electrostatic attraction promotes
unspecific adhesion of NPs onto the cell wall of Gram-positive
bacteria and the external cell membrane of the Gram-negative
bacteria (Qi et al., 2013; Baranwal et al., 2018). This adhesion
likely represents the mechanism by which IONPs and, to a
greater extent, the positively charged NP-APTES impaired the
growth of S. aureus, B. subtilis, and E. coli in our experiments of
bacterial growth kinetics. This interfacial effect was transient and
reversible, differing from the specific killing activity of teicoplanin
and NP-TEICO toward the Gram-positive bacteria. Nevertheless,
TEM observations suggested that we cannot completely rule
out that cell adhesion of IONPs and of NP-APTES might
provoke cytosolic shrinkage and cell membrane detachment (and
eventually cell rupture), as observed in S. aureus and, with a lower
frequency, in B. subtilis. In any case, this phenomenon was again
sporadic, probably depending on surface composition and on the
physiological state of single bacterial cells, as indicated by Dinali
et al. (2017).
Although IONPs have been increasingly proposed for a wide
range of biomedical applications, such as drug delivery, magnetic
resonance imaging, thermal ablation therapy, and treatment of
iron-deficient anemia, our understanding of their interaction
with animal cells and animal models is still relatively limited
(Natan and Banin, 2017; Feng et al., 2018). Recent studies showed
that physicochemical properties, including particle size, PDI,
surface charge, oxidation state of iron, and different surface
coatings, greatly influence their biological effect in vitro and
in vivo (Feng et al., 2018; Wang et al., 2018). Among the
super magnetic NPs, IONPs were generally preferred because
they are less toxic than those based on nickel and cobalt
(Gornati et al., 2016). However, it was recently demonstrated
that IONPs can enter eukaryotic cells not only by endocytosis,
but also by diffusion through the plasma membrane, gaining
direct access to the cytoplasm (Zanella et al., 2017). In
addition, the intrinsic catalase-like activity of IONPs might
antagonize the accumulation of toxic reactive oxygen species
they have induced and thereby modulate the extent of cellular
oxidative stress, autophagic activity, and programmed cell
death (Wang et al., 2018). In this complex framework, a
complete evaluation of the cytocompatibility of our NP-TEICO
preparation in vitro and in vivo systems lies outside the scope
of this work, although it would represent a future interesting
extension of the study. Here, we demonstrated that at the
concentrations that encompass the teicoplanin antibacterial MIC
values, teicoplanin coating of IONPs reduced their intrinsic
cytotoxicity toward two human cell lines, thus improving their
potential biocompatibility. Further intensive in vitro and in vivo
investigations are needed to develop an NP-TEICO-based drug
formulation that could be administered systemically or topically
to treat deep tissue infections and/or cover medical devices to
prevent biofilm formation. Our results indicate that combining
synergistically the unique properties of different nanomaterials
would represent a good strategy, in this way providing a novel
route to prevent and treat bacterial infections and, at the
same time, reduce the intrinsic cytotoxicity of NPs, as already
indicated by other authors (Xiang et al., 2017; Xie et al., 2017,
2018).
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CONCLUSIONS 
In this work, IONPs were successfully synthetized through a co-precipitation 
method that was developed as a modification of methods previously reported in 
literature. The particles obtained were fully characterized with different techniques, 
i.e. TEM, DLS, electrophoretic mobility and SQUID magnetometry. Such IONPs 
shown a good r eproducibility between batches not only for shape and size 
distribution, but also for hydrodynamic diameter and electrophoretic mobility. 
The IONPs were then used as a platform for the conjugation of biomolecules, i.e. 
enzymes and glycopeptide antibiotic. 
The use of immobilized enzymes in industrial applications often presents 
advantages over their soluble counterparts, mainly in view of stability, reusability and 
simpler operational processing. In this context, nanobiocatalysis, as the combination 
of nanotechnology and biocatalysis, is rapidly emerging as a new frontier of 
biotechnology.. Because of their singular properties, such as biocompatibility, large 
and modifiable surface and easy recovery, IONPs facilitate separation of the linked 
enzymes that can be easily obtained, lowering dramatically the costs of enzymes, by 
applying an external magnetic field. To this aim, two thermophilic enzymes (AMY 
and LASPO) were conjugated to IONPs through different conjugation strategies 
obtaining efficient biocatalysts. Here, it is demonstrated the importance of the 
orientation of the enzyme active site with respect to the NP surface: the nature and the 
position of the chemical bound that links the enzyme to the NP can modify the 3D 
structure of the enzyme and this can in turn influence the enzyme activity. Taking into 
consideration the superparamagnetism of the IONPs synthetized, the NP-enzyme 
systems were successfully activated by an AMF. Nevertheless, the temperature of the 
medium increases only slightly under AMF activation. This was also confirmed by 
the activity of a thermolable free enzyme present into the reaction pot during the AMF 
application to NP-enzyme systems.  
These results also allow envisioning a future implementation of AMF-enzyme 
activation for biotechnological and biomedical applications, through a selective local 
thermo-activation of enzymes. In particular, the two enzymes used are attractive for 
biotechnological applications. Amylase is widely used in the starch industry for the 
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conversion of starch to medium-sized oligosaccharides. LASPO can be used for the 
production of D-aspartate from a racemic mixture of D,L-aspartate, a molecule 
employed in the pharmaceutical industry, for parenteral nutrition, as a food additive 
and in sweetener manufacture72. However, the industrial application of both enzymes 
is hampered by the high cost per enzymatic unit, which encourage exploring the use 
of thermophilic enzyme to improve their reusability due to their increased stability. 
Though, their use introduces the need to heat the reaction media to higher 
temperatures in order to maximize the efficiency of the reaction. As here shown that 
IONPs can generate enough local amount of thermal energy for the activation of both 
enzymes, a future implementation of AMF-enzyme activation should allow saving 
energy costs. Besides, as each enzyme was activated without raising the temperature 
of the reaction solution as a whole, it should be also feasible in a future the 
implementation of AMF-enzyme activation for the compatibility of different enzymes 
involved in multi-enzymatic processes of biotechnological interest. 
In the second part of the project, IONPs was used as a platform for the 
conjugation of teicoplanin. Classical microbiological methods, together with 
morphological analysis by fluorescence and electron microscopy, were used to assess 
the antimicrobial activity of the nano-conjugated antibiotic. As bacterial models, 
different Gram-positive bacteria (Staphylococcus aureus, Bacillus subtilis and 
Enterococcus faecalis) and a Gram-negative representative (Escherichia coli) were 
used.  
The results indicated that NP-TEICO have a high and prolonged antimicrobial activity 
toward Gram-positive bacteria. Furthermore, in comparison with IONPs and NP-
APTES, NP-TEICO showed an significant antimicrobial activity. Sensitivity of 
bacteria to NPs varied according to the surface provided by the bacteria and it was 
strain-specific. Indeed, positively charged NP-APTES tended to establish electrostatic 
interactions with negatively charged bacteria. NP-TEICO inhibited S. aureus biofilm 
formation conserving the activity of teicoplanin versus planktonic cells and improving 
it towards adherent cells.  
Although it would be worth to test NP-TEICO on a larger panel of susceptible and 
resistant Gram-positive bacteria, these initial data are encouraging and confirm that 
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the binding of teicoplanin confers to IONPs a marked and specific antimicrobial 
activity. Finally, new binding chemistries will be considered to improve the 
antimicrobial activity of the nano-system against Gram-positive bacteria and, 
possibly, to extend the activity spectrum also to Gram-negative bacteria, modulating 
the NP surface with different linkers and charges. For example, a more hydrophobic 
surface of the particles can be developed to permeate through the outer membrane 
bilayer by the self-promoting pathway, moreover it is possible to develop a nano-
system as a combination of glycopeptide antibiotic and a polymyxins that can act in a 
synergic way to attach the Gram-negative cell wall. 
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